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Summary 
 
 The thermophilic enzyme, Thermus aquaticus (Taq) DNA polymerase, is an 
essential tool in molecular biology because of its ability to synthesis DNA in vitro and its 
inherent thermal stability.  Taq DNA polymerase is widely used in the polymerase chain 
reaction (PCR), an essential technique in a broad range of different fields from academic 
research to clinical diagnostics.   The use of PCR-based tests in diagnostic testing is ever 
increasing; however, many of the samples being tested contain substances that inhibit PCR 
and prevent target amplification.  Many attempts have been made to engineer polymerases 
not only to increase resistance to overcome the problem of inhibition, but also to enhance 
other characteristics such as fidelity, processivity and thermostability.   
 Heparin, found in blood samples, and phytate, found in faecal samples, are two 
examples from a number of known PCR inhibitors.   The mode of action of most PCR 
inhibitors is not well understood, but inhibition is thought to occur by enzyme binding or 
through the chelation of Mg2+ ions essential for PCR.  In this project, a system of directed 
evolution by compartmentalised self-replication (CSR) was established and successfully 
employed to screen a mutant library for Taq DNA polymerase variants with enhanced 
resistance to the inhibitors heparin and phytate. 
 CSR is a recently-established high-throughput method for the creation of novel 
polymerases, based on a feedback loop whereby polymerase variants replicate their own 
encoding gene.  A mutant library of 106 variants was produced by random mutagenesis 
error-prone PCR, in which only the polymerase domain of Taq was mutagenised.   Firstly, 
the CSR system was established and tested by performing a screen in the presence of heparin 
to select for heparin-resistant variants.  Characterisation of selected variants revealed that a 
single round of CSR had produced a Taq variant (P550S, T588S) with a 4-fold increase in 
heparin resistance.  The IC50 was increased from 0.012U/ml heparin to 0.050U/ml heparin.   
 The study with heparin was followed by a phytate screen, in which two rounds of 
CSR were performed with an initial round of error-prone PCR followed by re-diversification 
(recombination) of the mutant library using the staggered extension process (StEP).  The two 
rounds of CSR yielded a Taq variant with a 2-fold increase in phytate-resistance compared 
to the wild-type, with IC50 increased from 360µM phytate to 700µM phytate.  The best 
phytate mutant (P685S, M761V, A814T) was further characterised and it was found that the 
catalytic activity, thermostability and fidelity of the mutant were comparable to the wild-
type enzyme.   
 The position of resistance-conferring mutations of the novel Taq variants evolved in 
this study provided some evidence for the inhibitors’ predicted modes of action in the case 
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of both phytate and heparin.  As phytate’s mode of action is poorly understood, further 
investigations were performed to elucidate its role in PCR inhibition.  A thorough 
investigation into the importance of relative phytate and Mg2+ levels on PCR was conducted 
and revealed for the first time convincing evidence that the primary mode of phytate-
mediated PCR inhibition is by chelation.  Further work led to the successful crystallisation 
of Taq in the presence of phytate, although subsequent X-ray diffraction data to 2.5Å did not 
reveal phytate bound within the enzyme structure.  Site-directed mutagenesis studies were 
used to probe cross-over between heparin and phytate-conferring mutations.  Thus, in 
addition to providing valuable information for novel Taq variants with a potential 
application in fecal-based PCR diagnostic tests, this project has begun to provide insight into 
the fundamental aspects of the mode of action of phytate as a polymerase and PCR inhibitor. 
 
 
 
Abbreviations 
 
CSR – Compartmentalised self-replication 
dNTP – Deoxynucleotide triphosphate 
DMSO – Dimethyl sulfoxide 
emPCR – Emulsion PCR 
IPTG – Isopropyl β-D-1-thiogalactopyranoside 
IVC – In vitro compartmentalisation 
Kan – Kanamycin 
LB – Luria broth 
PCR – Polymerase chain reaction 
PEI - Polyethyleneimine  
PEG - Polyethylene glycol  
Pol – Polymerase 
SAP – Shrimp alkaline phosphatase 
SDM - Site-directed mutagenesis 
SDS-PAGE – Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Taq DNA Pol – Thermus aquaticus DNA polymerase 
Wt - Wild-type (Sac7-TaqPolymerase) 
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Chapter One - Introduction 
 
Polymerase Chain Reaction (PCR) 
 
History 
 The Polymerase Chain Reaction (PCR) was first developed by Kary Mullis and 
colleagues in the 1980s.   When first introduced, PCR was a rapid and highly sensitive 
method of in vitro DNA amplification using the Klenow fragment of Escherichia coli DNA 
polymerase (Saiki et al., 1985).  It enabled for the first time the amplification of specific 
DNA sequences, producing billions of copies of the molecule in just hours.  PCR is 
comprised of 3 steps: first the double-stranded DNA is separated or denatured at 
temperatures above 90°C, second the primers anneal to the DNA template at temperatures 
around 50-60°C and lastly primer extension occurs at around 72°C.   Initially, PCR was 
hindered by the use of a polymerase that could not withstand the repeated high temperature 
incubations needed for the denaturation of the DNA duplex.  This meant that fresh enzyme 
had to be added after every cycle, which was both time consuming and costly.  Further 
investigation led to the use of the thermostable Thermus aquaticus (Taq) DNA polymerase 
in the reaction, which allowed continuous thermocycling and the development of PCR as we 
know it today (Saiki et al., 1988).  From this moment on, the use of thermostable DNA 
polymerases became key to PCR-based molecular biology techniques such as cloning and 
sequencing.   
 
Applications: PCR-based Diagnostics and DA Sequencing  
 Taq DNA polymerase (Taq DNA pol) revolutionised not only PCR but all research 
in biological sciences and medicine and has had a particularly huge impact on clinical 
diagnostics.  PCR is routinely used in the diagnosis of disease, whether it is for the detection 
of genetic mutations or microbial or viral infectious agents.  Further uses of PCR include the 
detection of antibiotic resistance genes (Dutka-Malen et al.1995) and biothreat agents 
(Makino et al., 2001), both of which are becoming more prevalent.  
 One of the first diagnostic uses of PCR was in a prenatal diagnosis test for sickle 
cell anaemia.  The use of PCR for detection of the sickle cell mutation was more rapid and 
sensitive than previous methods (Saiki et al., 1985).  More PCR-based diagnostics followed, 
including tests for the detection of low-copy number viral targets such as HIV (Guatelli et 
4 
 
al., 1989), tests for the diagnosis of pulmonary tuberculosis through the detection of 
Mycobacterium tuberculosis (D’Amato et al., 1995), and for the detection of different 
isolates of the gastrointestinal bacterium Helicobacter pylori (Akopyanz et al., 1992).  A 
selection of commercially available PCR-based diagnostic tests is listed in Table 1.1. 
Compared to traditional culture methods, PCR-based assays have shown increased speed, 
specificity and sensitivity in detection.  This is particularly important in clinical diagnostics, 
where accurate and rapid answers are often needed in such places as hospital or veterinary 
laboratories.  
 The introduction of Taq DNA polymerase to PCR also led to its use in DNA 
sequencing (Innis et al, 1988).  The thermostability of Taq DNA pol facilitated the 
automated cycling of sequencing reactions, which simplified the procedure.  It also allowed 
for higher annealing and extension temperatures which increased the specificity, yield and 
length of targets that could be amplified or sequenced (Innis et al, 1988). The traditional 
Sanger dideoxynucleotide method (Sanger et al., 1977) of DNA sequencing benefited from 
the use of Taq DNA pol because less DNA template was needed per reaction thus allowing 
the detection and sequencing of rare targets.   DNA sequencing continued to advance over 
the next decade and the increase in available sequences led to a growth in the understanding 
of structure function relationships.  In 1995 Tabor and Richardson found a single residue 
mutation that altered Taq DNA pol so that it could more efficiently incorporate the 
dideoxynucleotides needed in sequencing reactions (Tabor and Richardson, 1995).  This 
discovery came after the molecular comparison of a modified bacteriophage T7 DNA 
polymerase to Taq DNA pol.  The T7 polymerase was known to incorporate 
dideoxynucleotides more efficiently than other pol I type polymerases such as E. coli and 
Taq DNA polymerase (Tabor and Richardson, 1987).  The critical residue in T7 polymerase 
that was needed to distinguish between deoxy- and dideoxynucleotides was transferred to 
the homologous position in Taq DNA pol, thus engineering an enzyme with enhanced 
properties for DNA sequencing.  
 Due to the development of automated sequencing, the number of sequenced 
genomes is increasing significantly every year, adding to the vast sequence knowledge that 
is already available. The first genome sequence of a pathogenic bacterium was published in 
1995 and was that of Haemophilus influenza (Fleischmann et al., 1995). With improvements 
in DNA sequencing techniques, the number of known genomes of infectious pathogens and 
catalogued genes is increasing, which is key to the growth of PCR in diagnostic testing. This 
wealth of sequence data is fundamental to the design of accurate targets in clinical 
diagnostic tests, as the use of PCR relies on the availability of at least a partial sequence of 
the target DNA, in order to design specific primers.  Over the past decade, the increase in 
5 
 
available sequence data has been essential to the development of new PCR-based diagnostic 
tests.  
 
 
 
  
AME DETECTIO OF COMPAY 
Amplicor CT/NG Test 
Chlamydia trachomatis     
eisseria gonorrhoeae 
Roche 
Lightcycler Septifast 
Species ID of pathogens causing 
blood stream infections 
Roche 
COBAS Ampliscreen HBV Hepatitis B Virus (HBV) Roche 
COBAS Ampliscreen HCV Hepatitis C virus (HCV) Roche 
COBAS Ampliscreen HIV-1 
Human-immunodeficiency 
Virus type I 
Roche 
Quantifiler Human DNA 
Quantification Kit 
Quantifies human DNA in 
sample 
Applied Biosystems 
AccuPower Toxoplasma Kit Species of Toxoplasma Krypton 
AccuPower Rubella Kit Rubella virus Krypton 
Mycosensor QPCR Assay Kit 
Specific detection of most 
common Mycoplasma species 
Stratagene 
 
 
 
 Table 1.1 - Selected Commercial PCR-based Diagnostic tests.  
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Recent Developments  
 Although PCR had become widely used, it still had some limitations as an analytical 
technique because traditionally it was difficult to quantify the DNA due to the fact that only 
the end product was analysed.   This problem was solved when Higuchi et al. (1992) 
developed real-time PCR.  This enhanced method of PCR detects the amount of product 
formed during the course of the reaction through the use of fluorescent stain (e.g. SYBR 
green), which is specific for dsDNA, or by fluorescent resonance energy transfer (FRET) 
probes.  Three main FRET probes exist; 5’ nuclease probes (TaqMan), molecular beacons 
and FRET hybridization probes.  Of these TaqMan (Livak et al., 1995) is probably the most 
well known and used.  The TaqMan probe takes advantage of the 5-3’ nuclease activity of 
Taq DNA polymerase.  The TaqMan fluorescent probe binds to the target sequence 
downstream of one of the primers; it is then cleaved by the 5’ nuclease activity of Taq DNA 
polymerase as it extends along the DNA.  The cleavage of the probe causes a fluorescent 
signal which is then measured.  Real-time PCR makes it possible to calculate the starting 
amount of DNA in the reaction and the number of copies produced throughout the course of 
the PCR.  This quantitative method of PCR has become useful in gene expression analysis 
and for monitoring viral loads (Mackay, 2004).   
 Optimization of real-time PCR reagents and equipments has enabled detection in as 
little as one hour (Barken et al., 2007).  There are constant modifications being made to PCR 
in order to try to increase the speed and sensitivity of the reaction even further.  Such things 
as multiplex PCR, where multiple primer sets are used in a single reaction (Monstein and 
Ellnebo-Svedlund, 2002), and improvements to thermocyclers so that separate PCR 
reactions can be run simultaneously with different cycling conditions, are examples of some 
of the developments revolutionizing PCR and clinical diagnostics (Yang and Rothman, 
2004).  The PCR market is constantly developing; as genome databases expand the number 
of available PCR assays increases.  As PCR proves itself to be a valuable method in 
diagnostics, its use is constantly expanding, developing and taking over from more 
traditional methods of diagnosis. 
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DA Polymerases 
 
atural Function of DA Polymerases 
 In addition to being essential to PCR, in nature DNA polymerase (E.C. 2.7.7.7) has 
a fundamental role in the survival and preservation of all species.  The ability of DNA 
polymerases to replicate DNA allows genetic information to be passed from one generation 
to the next and for DNA to be repaired.  DNA polymerase catalyses the addition of a 
nucleotide onto the 3’end of a DNA primer (Figure 1.1), creating a new DNA strand 
complementary to the template strand.   A two-metal ion mechanism has been proposed for 
polymerase-catalyzed nucleotidyl transfer reactions (Beese and Steitz, 1991).  The two-metal 
ions, which are normally Mg2+, act with two conserved acidic residues, usually aspartate, 
during catalysis (Steitz, 1999).  All classes of polymerase use the same five-step scheme for 
nucleotide incorporation: (1) enzyme-nucleic acid complex binds the nucleoside 
triphosphate forming the ternary complex, (2) there is a conformational change, which 
orients the triphosphate ready for catalysis, (3) nucleotidyl transfer occurs, (4) a second 
conformational change occurs, which is followed by the final step (5) pyrophosphate release 
(Castro et al., 2007).   In addition to the catalytic polymerase domain, DNA polymerases 
often have other domains that are essential for editing, excision or interaction with other 
proteins (Alba, 2001).  
 In 1958, Lehman and colleagues were the first to report the enzymatic synthesis of 
DNA with a partially purified enzyme from E. coli.  The enzyme responsible for 
deoxyribonucleotide incorporation was then named as a ‘polymerase’ (Lehman et al., 1958). 
Since then the natural function of polymerase in DNA replication has been exploited in the 
laboratory. In vitro DNA polymerase is capable of primer-mediated enzymatic amplification 
of a target DNA sequence.  Its capacity for template-directed DNA synthesis in vitro is what 
has led DNA polymerase to become a crucial tool in molecular biology.    
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                        Figure 1.1 – Reaction catalysed by DA-dependent DA polymerase1 
DNA polymerase catalyses the addition of a nucleotide onto the 3’ OH of a growing DNA 
strand, which is followed by pyrophosphate release. 
 
 
 
 
 
 
 
 
                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
1 Reproduced from BRENDA database http://www.brenda-enzymes.info/ 
+ 
Deoxynucleoside triphosphate             +                        DNAn   
 
+ 
   =             diphosphate                        +                      DNAn+1 
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Classification and Structural Overview 
 Numerous DNA polymerases have been isolated from a range of organisms 
including Archaea, Bacteria, bacteriophage, mitochondria, Eukaryotes and viruses 
(Braithwaite and Ito, 1993). There are six different families of DNA polymerases based on 
sequence similarity: A, B, C, D, X and Y.  Thermophilic enzymes can be found in all six of 
the families.  Viral DNA polymerases belong to family A or B and those involved in 
chromosome replication belong to B, C or D (Pavlov et al., 2004).  In Bacteria there are 
three main families, A, B and C, whilst most archaeal DNA polymerases belong to family B 
(Cann and Ishino, 1999). 
 In Bacteria there are three main types of polymerase, polI (polA), polII (polB) and 
polIII (polC), which are categorized by their function and homology to the DNA 
polymerases found in E. coli (Braithwaite and Ito, 1991).  PolI represents Family A and is 
used in nucleotide excision repair and the processing of Okazaki fragments generated during 
DNA replication (Joyce et al., 1982).  Family A polymerases include E. coli polI, Thermus 
aquaticus DNA polymerase I and Thermus flavus DNA polymerase I.  Some replicative 
DNA polymerases from bacteriophages (T3, T5 and T7) are included in this family as they 
have homology to Pol I (Alba, 2001). PolII represents Family B and is involved in the 
replication of damaged DNA (including cross-links caused by UV radiation).  Family B 
includes archaeal polymerases from Pyrococcus furiosus (Pfu) and Thermococcus litoralis 
(vent).  Lastly, polIII represents Family C and is the main replicative polymerase; it is made 
up of many subunits (Alba, 2001). 
 Most family A and B Bacterial polymerases are composed of a single subunit made 
up of three domains (Figure 1.2): the 3-5’ exonuclease (proof-reading) domain, the 5-3’ 
exonuclease (nick translation) domain and the polymerase domain.  Although the 
polymerase domain is essential for catalytic activity, polymerases may also contain a 3-5’ 
and/or a 5-3’ exonuclease domain. The combination of domains will affect a polymerase’s 
proof-reading ability.  Despite differences in sequences, X-ray crystal structures have shown 
that all polymerases have a similar overall structure.  In particular, the architecture of the 
polymerase domain is said to resemble a hand with ‘thumb’, ‘finger’ and ‘palm’ sub-
domains as shown in Figure 1.2b (Steitz, 1999).   Structural studies show that each of the 
sub-domains plays a different role in the nucleotidyl-transfer reaction. The active site, which 
typically contains three acidic residues, is located in the palm domain where catalysis of the 
phosphoryl transfer reaction occurs. The palm domain is the most conserved region among 
polymerase families (Pavlov et al., 2004). The finger domain interacts with the incoming 
nucleoside triphosphate and the template base.  Lastly, the thumb domain plays a role in 
positioning the duplex DNA (Steitz, 1999).  
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Properties 
 Although DNA polymerases typically catalyse the same reaction of template 
mediated DNA extension, the properties of each polymerase can vary; some of these key 
properties are thermostability, processivity, fidelity and the rate of extension.  
Thermostability is characterised by the half-life of a DNA polymerase at a certain 
temperature.  The importance of thermostability for PCR applications has previously been 
discussed.  The fidelity of a DNA polymerase is the error rate of the enzyme and is based on 
the frequency of incorporation of incorrect nucleotides.  Fidelity is important for techniques 
such as cloning where exact copies of the DNA template are essential. Processivity is 
defined as the probability of an enzyme not to dissociate from the DNA while it translocates 
to the next position after the addition of the nucleotide.  Highly processive enzymes add 
more nucleotides in a single binding event compared to those with low processivity.  A 
similar feature is the extension rate, which is characterised by the number of nucleotides 
added per second per molecule of DNA polymerase (Pavlov et al., 2004).  Since naturally 
Figure 1.2.  Organisation of Taq DA Polymerae. 
(a) Schematic diagram of domain layout of Taq DNA polymerase. Numbers 
correspond to amino acids. (b) Taq DNA polymerase domain organisation: 5-3’ 
exonuclease domain (pink), proof-reading 3-5’ exonuclease domain (blue), which is 
inactive in Taq, and the polymerase domain, which consists of palm (green/grey), 
finger (orange) and thumb (brown) subdomains (PDB ID: 1TAQ picture produced in 
Cn3D program). 
 
(b) 
(a) 
1 289 422 831 
5’-3’ Exo Domain 
3’-5’ 
Exo Domain 
Polymerase Domain 
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occurring polymerases have different thermostability, fidelitiy and processivitiy, their 
overall properties and therefore their applications are limited (Henry and Romesberg, 2005).  
The demand for enzymes to be tailored to specific applications has lead to the rise of 
engineered polymerases with advantages over their naturally occurring equivalents.  
Methods of enzyme engineering will be discussed later in the chapter.  
 
Thermophilic DA Polymerases  
 Thermostability is a key polymerase property needed for the high temperature 
cycling involved in PCR. Thermostable enzymes are isolated from ‘thermophiles’ or 
thermophilic organisms. Thermophiles typically grow at temperatures between 55°C and 
80°C, and hyperthermophiles grow above 80°C and can exceed growth temperatures of 
110°C (Hough and Danson, 1999). The enzymes isolated from these organisms are 
extremely thermostable.  Thermophiles, fall under the larger category of ‘extremophiles’, 
which are organisms that exist in extreme environments. There are many types of 
extremophiles that live in a wide range of habitats, such as acidophiles (low pH), halophiles 
(high salt concentration) and psychrophiles (low temperature) (Demirjian, et al., 2001). In 
1974 Macelroy first coined the term ‘extremophiles’ and since then interest in extremophiles 
has grown considerably and investigations have led to the discovery of many novel 
extremophiles in all three domains of life (Rothschild and Manicinelli, 2001).  Enzymes 
isolated from extremophiles have many industrial applications as a result of their unique 
properties.  Their inherent stability and capacity to function under conditions in which their 
mesophilic (moderate) equivalents could not, makes these enzymes a key part of the 
growing biotechnology industry.   
 Thermophilic DNA polymerases have played a key role in modern biotechnology 
ever since Thermus aquaticus (Taq) DNA polymerase, the first of its kind to be 
characterised, was discovered in 1976 (Chien et al., 1976).  The use of Taq DNA pol in PCR 
led to a rise in the isolation and cloning of further thermophilic DNA polymerases from a 
range of both archaeal and bacterial species.  Discoveries are still being made to this day and 
recently a new highly thermostable DNA polymerase has been characterised from 
Thermococcus sp.NA1, a new hyperthermophilic strain isolated from a deep-sea 
hydrothermal vent (Jae et al., 2007).   Pyrococcus furiosus (Pfu) DNA polymerase (Uemori 
et al., 1993), Thermococcus litoralis (Vent) DNA polymerase (Kong et al., 1993) and 
Pyrococcus sp. strain KOD1 (KOD) DNA polymerase (Takagi et al., 1997) are examples of 
other thermostable polymerases that are now frequently used in PCR and related 
applications.  Less well known thermophilic polymerases have been isolated from the 
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archaeon Sulfolobus solfataricus (Pisani et al., 1992) as well as from numerous Geobacillus 
species including sterothomophilus and caldotenax (Sellmann et al., 1992; Burrows and 
Goward, 1992).  A list of selected thermophilic DNA polymerases and their properties can 
be seen in Table 1.2.  
 
 
 
 
 
Thermophilic 
organism 
DA 
polymerase 
Family 
5’-3’ 
exonuclease 
activity 
3’-5’ 
exonuclease 
activity 
Half -life Fidelity1 
       
Thermus 
aquaticus 
Taq A + - 9min at 97.5°CA 2.1x10-4 B 
Thermus 
aquaticus large 
fragment 
Stoffel  - - 21min at 97.5°CA  
Thermus 
aquaticus  
N-terminal 
deletion 
Klentaq  - - 
Dependent on N-
terminal deletion C 
2.0x10-4 D 
Thermus 
thermophilus HB8 
Tth A + -  3.0x10-5 E 
Thermococcus 
litoralis 
Tli or Vent B - + 8h at 95°CF 2.8x10-6 G 
Pyrococcus 
woesii 
Pwo B - + >2h at 100°CH 3.2x10-6 E 
Pyrococcus 
kodakaraensis* 
 
KOD1 B - + 12h at 95°CI 3.5x10-3 I 
Pyrococcus 
furiosus 
Pfu B - + 6h at 95°CI 1.3x10-6 G 
Rhodothermus 
marinus 
Rma A + + 2min at 90°CJ  
Rhodothermus 
marinus 
Large fragment 
  - - 11min at 90°CJ  
Thermococcus sp. 
NA1  
TNA1 B   12.5h at 95°CK 2.2x10-4 K 
Sulfolobus 
solfataricus Sso B - + 6min at 90°C
L  
 
1 errors per base duplication 
* now Thermocococcus kodakarensis (Kuroita et al., 2005). 
                                                 
A (Lawyer et al ., 1993) 
B (Keohavong and Thilly, 1989) 
C (Barnes, 1995) 
D (Barnes , 1992) 
E (Frey and Suppmann, 1995) 
F (Kong et al., 1993)  
G (Cline et  al., 1996) 
H Data derived from commercial sources (Roche) 
I (Takagi et al., 1997) 
J (Blondal  et al ., 2001) 
K (Jae et al ., 2007) 
L (Pisani et al., 1998) 
 
Table 1.2 – Selected thermophilic DA polymerases and their properties 
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Taq DA Polymerase 
 
Discovery and Characterisation 
 The thermophilic Gram-negative bacterium, Thermus aquaticus, was first isolated 
from a hot spring in Yellowstone National Park (Brock and Freeze, 1969).  Thermus 
aquaticus belongs to the Deinococcus-Thermus group (Figure 1.3) and has an optimum 
growth temperature of 70°C.   It has since been found in other similar thermal environments.  
Over the years Thermus aquaticus has become the source of many different thermostable 
enzymes with potential applications including an aldolase (Freeze and Brock, 1970), an 
RNA polymerase (Air and Harris, 1974) and most importantly Taq DNA polymerase (Chien 
et al., 1976).   
 
 
 
 
 
  
 
  
 
 
 
 
 
 Thermus aquaticus (Taq) DNA polymerase was first isolated, purified and 
characterised by Chien et al. in 1976.  It was the first thermophilic polymerase to be 
discovered and it was found to have a temperature optimum of 80°C (Chien et al., 1976).  In 
1989 the Taq DNA polymerase gene was cloned and expressed in E. coli, with the pure, 
active form of the protein having a molecular mass of 94kDa (Lawyer et al., 1989).  Taq 
DNA pol was classified as a type I pol based on its homology to E. coli polI.  
 E. coli pol I was the first polymerase to be discovered in 1956 by Arthur Kornberg 
and colleagues (Kornberg et al., 1956). Discovery of E. coli pol II and pol III followed 
shortly after, and it was then realised that Pol I was not the main replicative polymerase of 
the cell, a function performed by pol III (Kornberg and Gefter, 1971).  Friedberg (2006) 
-Bacteria (kingdom) 
   -Deinococcus-Thermus (phylum) 
      -Deinococci (class) 
        -Thermales (order) 
             -Thermaceae (family) 
                -Thermus (genus) 
                   -Thermus aquaticus (species) 
 
Figure 1.3 – Phylogeny of Taq 
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outlined the discovery of DNA polymerase and the timeline that led these three enzymes 
(pol I, II and III) to form the basis for classification of family A, B and C polymerases that 
we use today.  After the discovery of Taq DNA pol, many studies were carried out 
comparing it to E. coli pol I.  Research showed that unlike E. coli pol I, portions of Taq 
DNA pol were not essential for DNA polymerase activity and it appeared that natural 
mutations had destroyed the 3-5’ exonuclease activity leaving Taq DA pol with no proof-
reading ability (Lawyer et al., 1989).  Further studies showed that like E. coli polI, TaqDNA 
pol could be cleaved into two fragments.  In E. coli pol I the larger of the two fragments 
contains the polymerase and 3-5’ exonuclease domain and the smaller fragment is made up 
of the 5-3’ exonuclease domain (Klenow and Henningsen, 1970).  The large fragment is 
known as the Klenow fragment and retains polymerase activity. The Taq DNA polymerase 
equivalent is the 61kDa Stoffel fragment, which has its 5-3’ exonuclease domain removed 
and is the shortest form of an active Taq DNA polymerase (Lawyer et al., 1993).  An N-
terminal deletion of Taq DNA polymerase can produce a slightly larger 67kDa protein called 
KlenTaq, which retains polymerase activity but lacks the 5-3’ exonuclease domain (Barnes, 
1992).  Studies by Barnes (1992) showed that KlenTaq had a reduced tendency towards 
error compared to the full length Taq DNA polymerase.   
 
Applications 
 Taq DNA polymerase has a major advantage over its equivalent E. coli pol I as it is 
thermostable.  Whereas most Bacterial DNA polymerases are inactivated by high 
temperature, Taq DNA polymerase has the ability to withstand temperatures of up to 
~100°C (Lawyer et al., 1989), which lead to its pivotal role in PCR.  TaqDNA pol is stable 
whereas E. coli pol I is inactivated at 93-95°C, which is the temperature required to denature 
duplex DNA as required in a PCR reaction.  Taq DNA pol’s inherent thermal stability was 
crucial for its application in the repeated rounds of PCR thermocycling.   
 Over the past twenty years, the high demand for thermostable DNA polymerases in 
the biotech industry has lead to a great increase in their availability (Pavlov et al., 2004). 
Selecting the correct polymerase variant for different PCR applications is an important part 
of a successful reaction, a property that is advantageous in one situation may be 
unfavourable in another.  An example of this is the use of Taq DNA pol in error-prone PCR, 
which is used for the random mutagenesis of genes.  Leung et al. (1989) reported that adding 
Mn2+ to a PCR instead of Mg2+ increased the error-rate of Taq DNA pol and could therefore 
be used to introduce random point mutations into genes.  In this case, increasing the error 
rate of TaqDNA pol, which has been reported to be 2x10-4 mutations per base duplication 
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(Keohavong and Thilly, 1989), had its advantages.  Later on a mutant of Taq DNA pol, with 
a single amino acid substitution, was designed to incorporate dNTPs less efficiently and 
used for mutagenic PCR (Patel et al., 2001).  Mixtures of non-proof-reading (e.g. Taq) and 
proof-reading (e.g. Pfu) polymerases are often used in PCR as TaqDNA pol is beneficial 
when amplifying longer templates but Pfu DNA pol solves the problem of fidelity by 
exhibiting proofreading activity (Barnes, 1994).  Although 3-5’ exonuclease activity 
increases fidelity, it can be a disadvantage as the 3-5’ activity has been reported to attack 
unannealed primers causing a low yield in PCR (Barnes, 1992).  Taq DNA polymerase, in 
its natural form or one of its many engineered counterparts, is still currently widely used 
despite the availability of numerous alternative thermophilic polymerases. 
 
Structure 
 The crystal structure of full length Taq DNA polymerase (Kim et al., 1995) and 
Klentaq (Korolev et al., 1995) have been known for some time and have greatly increased 
our knowledge of the enzyme.   The three domains of full length Taq DNA pol form a 
strung-out arrangement as seen in Figure 1.2(b). Structural data revealed that the inactive 3-
5’ exonuclease domain of Taq DNA pol lacked 4 important carboxylate residues that are 
known to be essential for divalent metal binding and therefore 3-5’ exonuclease activity in 
the E. coli Klenow fragment (Derbyshire et al., 1988; Kim et al., 1995).  Further 
crystallisation studies demonstrated key DNA interactions in the active site (Eom et al., 
1996), and led to the discovery of conformational changes made by the enzyme that 
established the structural basis for nucleotide incorporation (Li et al., 1998).  
 Crystal structures of Klentaq bound to primer/template DNA and ddCTP revealed 
key interactions between the enzyme and its substrates.  An important conformational 
change in the enzyme during nucleotide incorporation, which affects the tip of the finger 
domain, was also discovered.  The enzyme was observed to have a closed form and an open 
form, in which a crevice was clearly visible. The transition between open and closed forms 
affects the orientation of the finger domain and specifically residue Tyr671, which is thought 
to act as a positioning device for the DNA (Li et al., 1998).  The DNA forms an S shape 
with one bend interacting with the palm domain at the active site and the second interacting 
with the thumb domain (Li et al., 1998; Doublie et al., 1998).  The incoming nucleotide 
becomes buried within the crevice in the closed form of the enzyme.  The base of the 
nucleotide stacks against Phe667 in close proximity to the three active site carboxylates 
(Asp785, Glu 786 and Asp610).  In the closed form, two Mg2+ ions are octahedrally 
coordinated by the triphosphate moiety of the incoming nucleotide and carboxylate side 
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chains in the active site.  Residues Asp610 and Asp785 are key to the metal ion 
coordination. Some of the key enzyme/substrate interactions are mentioned above; however, 
many more residues make important interactions in both the open and closed forms of the 
enzyme (Appendix A).  The determination of such substrate/enzyme interactions provided 
important information for protein engineering and fundamental studies of Taq DNA 
polymerase. 
 
Related Thermus DA Polymerases  
 A number of polymerases have been isolated from other related Thermus species 
such as Thermus thermophilus and Thermus flavus.  The isolation of various Thermus 
thermophilus strains was followed by the discovery of a thermostable polymerase in each of 
them.  The Tte DNA polymerase was isolated from strain B35, which was found in hot 
spring water (Rechkunova et al., 1998), and is very similar to the Tth DNA polymerase 
which was isolated from strain HB8 (Carballeira et al., 1990).  A third Thermus 
thermophilus strain, HB27, yielded a gene encoding Top DNA polymerase, which shares 
87% amino acid identitywith Taq DNA polymerase (Kim et al., 1998).  The polymerases 
isolated from Thermus thermophilus strains performed under similar PCR conditions to that 
of Taq DNA pol and were found to lack 3-5’ exonuclease activity (Bechtereva et al., 1989).  
Like Taq, Tth DNA polymerase has been shown to have detectable reverse transcriptase 
(RT) activity in the presence of MnCl2 and has been reported to be 100-fold more efficient in 
a coupled RT/PCR than Taq DNA pol (Jones and Foulkes, 1989; Myers and Gelfand, 1991).  
As the two enzymes have significant sequence similarity it is not known why Tth DNA pol’s 
RT ability is greater than that of Taq DNA pol’s (Shandilya et al., 2004). 
 Although the Thermus DNA polymerases share significant sequence homology and 
properties, their capacity for DNA amplification in the presence of certain PCR-inhibiting 
samples has been reported to vary.  TaqDNA pol has been shown to be very sensitive to 
blood samples, whereas Tth and Tfl from Thermus flavus (Akmetzjanov and Vakhitov, 1992) 
were less affected.  Taq and Tfl DNA polymerase were observed to be extremely sensitive to 
faecal-samples whereas Tth DNA polymerase showed a degree of resistance to faecal-
inhibitors (Al-Soud and Radstrom, 1998).  Another study reported Tth DNA polymerase to 
be more resistant to inhibitors than TaqDNA polymerase in both reverse transcription and 
PCR reactions (Poddar et al., 1998).  Despite being closely related, different thermophilic 
DNA polymerases can have subtle differences that enhance their capacity for DNA 
amplification under various conditions. 
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PCR Inhibitors 
 
 As discussed previously, PCR is widely used in diagnostic testing.  However, many 
of the samples being tested contain substances that are inhibitory and reduce the efficiency 
of the PCR.  Inhibitors can reduce the sensitivity of the PCR as well as preventing 
amplification completely.  In general, biological samples cause a problem at three key stages 
in diagnostic testing; (1) they interfere with cell lysis during DNA extraction, (2) they 
degrade the sample DNA or prevent its capture, and (3) they inhibit polymerase activity, 
which prevents target DNA amplification (e.g. binding to the polymerase or chelation of 
essential Mg2+ ions).  Many components have been reported to inhibit PCR but the mode of 
action for most is unclear (Wilson, 1997).  Common inhibitors are found in a variety of 
samples, including body fluids, food components and environmental soil samples.  Known 
PCR inhibitors include bile salts, phytic acid, haemoglobin, heparin, urea, phenolic 
compounds and humic acids (Al-Soud and Radstrom, 1998).   
 Different techniques have been developed to try to remove the inhibitors from 
samples but excess processing is not ideal.  Some disadvantages of inhibitor removal 
techniques include the fact that they are time consuming, costly, and there is the potential for 
loss of target DNA during processing, further, they are sample specific so different methods 
are needed depending on the sample type.  A better understanding of the modes of action of 
the inhibitors would allow further development of sample treatments prior to use in PCR 
(Al-Soud and Radstrom, 2001).  One inhibitor removal technique is the use of the enzyme 
heparinase, which is frequently added to samples containing heparin before DNA extraction.  
Although the enzyme successfully eliminates heparin inhibition, it represents a costly 
procedure (Taylor, 1997).  The addition of PCR facilitators or enhancers to the reaction has 
also been used as a means of overcoming inhibition.  BSA has been shown to prevent 
inhibition of PCR amplification by hemin, iron chloride, tannic acids, fulvic acids, extracts 
from feces and freshwater or marine water (Kreader, 1996).  Other PCR facilitators such as 
betaine and glycerol have also been used with mixed results (Al-Soud and Radstrom, 2000). 
Although PCR facilitators do in part solve the problem of inhibition, some optimization of 
facilitator concentration is always needed, which is time-consuming.  Many inhibitors work 
by interfering with the DNA-polymerase interaction.  There is therefore also a strong case 
for the development of inhibitor resistant polymerases as opposed to pre-treatment of 
samples or the addition of PCR facilitators. 
 Two possible modes of action for inhibitors that work by interference with the 
DNA-polymerase are either by competition with the DNA template (e.g. enzyme binding) or 
chelation of the Mg2+ ions, which are essential for polymerase activity.  A common inhibitor, 
heparin, which is found in blood samples, is suggested to compete with the DNA template 
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for binding to the polymerase (Al-Soud and Radstrom, 2001).  Studies indicate that heparin 
reversibly binds the DNA polymerases (DiCioccio and Srivastava, 1978).   Phytate, an 
inhibitor found in fecal samples, is thought to inhibit by chelation of Mg2+ ions (Thornton 
and Passen, 2004) but may also act by competition with the DNA template; the true mode of 
action of phytate is unknown.  
 Heparin and phytate are the two main PCR inhibitors focused on in this project.  
Both compounds cause a significant problem in diagnostic testing.  Heparin is an 
anticoagulant found in blood samples.  Many clinical diagnostic tests that are used to 
diagnose infectious and genetic diseases are carried out using DNA or RNA extracted from 
heparinised whole blood samples. The presence of heparin in these samples severely 
interferes with the PCR reaction (Yokota et al., 1999). The extent to which the PCR is 
affected depends on the dilution of the sample being tested, the concentration of the inhibitor 
present in the sample and the type of DNA polymerase used in the reaction.  The 
amplification capacity of some polymerases varies based on the enzyme’s sensitivity to the 
inhibitor (Al-Soud and Radstrom, 1998).   
 The same principles apply to the inhibitor phytate, which is found in fecal samples. 
Phytate is the main store of phosphorous in plants and is therefore found in most seeds.  It 
makes up a key component of animal feed, but is also highly abundant in human diets and 
human cells (Raboy, 2007).  The presence of phytate in fecal samples causes a problem in 
veterinary and medical testing.  It has been shown to inhibit PCR on bovine fecal specimens 
(Thornton and Passen, 2004).  Phytate is also likely to cause a problem in human fecal-based 
PCR testing, such as the colorectal cancer screening test from EXACT Sciences where DNA 
is amplified from a stool sample to detect mutations.  Other PCR-based fecal tests that suffer 
from the presence of inhibitors include the detection of Helicobacter pylori in humans 
(Kabir, 2004) and the detection of the enteric bacterium Lawsonia intracellularis in pigs 
(Jacobson, et al., 2004).  For efficient PCR to occur, the inhibitors have to be removed from 
the sample or treated with enzymes such as phytase (Thornton and Passen, 2004).   
 The removal of inhibitors from samples before diagnostic testing is time consuming 
and labour intensive as well as adding an extra cost to the procedure.  An alternative 
approach to solving the problem of PCR inhibition is to study the target of the inhibitors, 
which in many cases is thought to be the polymerase.  These days there are many engineered 
DNA polymerases on the market with specific advantages over naturally occurring 
polymerases. One such example is Phusion® Blood Direct, an enzyme variant based on a 
DNA polymerase from a Pyrococccus strain, with an additional dsDNA binding domain, 
which functions to enhance the processivity of the enzyme.  Phusion® DNA polymerase is 
reported to be resistant to inhibitors found in blood samples and therefore maintains its high 
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standard of activity even in blood-based PCRs (New England Biolabs2). The development of 
inhibitor-resistant polymerases like Phusion® Blood Direct, could aid in reducing the time 
spent preparing samples prior to diagnostic tests thus cutting overall costs.  The 
improvement of biological sample screening could be essential as the use and availability of 
diagnostic tests increase. 
 
Enzyme Engineering 
Approaches to Engineering 
 The growth of the biotechnology industry has meant there is always a demand for 
enzymes with specific properties. Although the list of characterised enzymes is constantly 
increasing, these days there is a need for particular properties not found in enzymes isolated 
from their natural environments.  Enzymes are used in many applications where they need to 
have high stability and catalytic activity or even display activity with non-natural substrates.  
With the increase in DNA manipulation techniques, enzyme engineering quickly becomes 
the most efficient approach to the production of enzymes with adapted characteristics.  
 Enzyme engineering can be performed in a number of ways using rational design, 
semi-rational design or directed evolution.  Rational design uses functional and structural 
knowledge of an enzyme to predict the outcome of alterations to the amino acid sequence. 
Site-directed mutagenesis is then used to introduce these specific changes to the protein 
sequence.  In addition to a comprehensive knowledge of the enzyme, this method involves 
an element of speculation and is often unsuccessful.  Despite continuous efforts of structural 
molecular biologists and other experts, it is still not possible to reliably relate protein 
sequence changes to altered properties. However, one successful application of rational 
design was in the creation of a mutant Taq DNA pol used in automated DNA sequencing.  
One amino acid change produced a modified Taq DNA pol that was able to incorporate 
ddNTPs more efficiently than the wild-type TaqDNA pol (Tabor and Richardson, 1995).  
 Another approach to enzyme engineering is directed evolution, which has become 
the most widely used method.  Directed evolution aims to mimic natural evolution through 
sequential rounds of random mutagenesis or recombination (Chen and Arnold, 1993).  In 
this technique, a mutant library with a low level of mutations is formed and mutants are 
screened for selected properties (Figure 1.4).  Mutant libraries can be formed in a number of 
ways including by combinatorial cassette mutagenesis (Black et al., 1996), error-prone PCR 
                                                 
2 Phusion DNA polymerase is developed and manufactured by Finnzymes Oy (Espoo, Finland) and distributed 
by New England Biolabs, Inc. (Hitchin, UK) http://www.neb.com/nebecomm/products/productF-547.asp 
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(Fromant et al., 1995), staggered extension process (StEP) (Zhao et al., 1998) and gene 
shuffling (Stemmer, 1994).  Two of the techniques, error-prone PCR and StEP, were used in 
this project and will thus be described in further detail below. Error-prone PCR involves the 
misincorporation of nucleotides by a polymerase to create random mutations in the target 
gene.  A number of things can be done to increase the rate of misincorporation: (1) the use of 
a polymerase without proofreading ability, (2) the use of unequal concentrations of the four 
deoxynucleoside triphosphates (dNTPs), (3) the use of Mn2+ instead of Mg2+ in the PCR and 
(4) increased PCR cycle number so that misincorporations accumulate (Fromant et al., 
1995).   StEP is a method of in vitro recombination that uses multiple primed templates that 
undergo repeated cycles of denaturation and extremely short annealing/polymerase-catalysed 
extension steps (Figure 1.5).  Multiple full-length templates are primed and then, due to 
abbreviated extension times, short fragments are created rather than full length genes.  In 
each cycle, these growing fragments can anneal to different templates based on sequence 
complementarity and extend further to create recombined genes. This ‘template switching’ 
results in the growing DNA fragment to comprise a recombined ‘hybrid’ from multiple 
parental templates. Numerous cycles occur and StEP continues until a full-length gene 
product is formed; the end result is a recombined gene (Zhao et al., 1998).   epPCR and StEP 
offer distinct but powerful techniques for the production of variants and creation of mutant 
libraries. 
 The main challenge of directed evolution comes from the high quantity of mutants 
produced during library formation, which then need to be screened.  Performing a high-
throughput method of screening and selection is a key factor in successful enzyme evolution.  
The technique of directed evolution is now routinely used to improve existing enzymes, 
change enzyme selectivity and to evolve completely new enzyme function (Tao and Cornish, 
2002).  
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Figure 1.4 – Directed Evolution. 
The gene coding for the protein of interest is selected (1) and the gene is mutated (2). A 
mutant library is formed (3). The mutants are then expressed (4), forming a library of protein 
variants (5). The protein variants are then screened based on a desired property (6).  The 
variants containing enhanced properties are selected (7) and then carried forward for further 
rounds of mutagenesis and selection (8).  
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Figure 1.5 – Staggered extension process (StEP) 
1) Primers anneal and polymerase produces short truncated products of varying 
length due to a short annealing/extension step 
2) In the next cycle, these short products are  used as primers and can anneal to 
complementary sequence in any of the templates  
3) Cycling continues until full-length ‘hybrid’ templates are formed.  The end 
result is millions of variants of recombined/ shuffled templates.  
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 A combination of rational design and directed evolution, ‘semi-rational’ design, 
forms a third approach to enzyme engineering.  In this method, structural and functional 
knowledge may be used to target a certain region of an enzyme, such as its active site (Chica 
et al., 2005).  Mutant libraries are created and screened but there is a focus on mutating 
specific residues, which have been chosen using all available knowledge of the enzyme.  
Saturation mutagenesis is often used to introduce all possible amino acid substitutions at the 
selected sites (Hayashi et al., 1994; Miyazaki and Arnold, 1999), which is not always 
achieved through random mutagenesis. Saturation mutagenesis and a semi-rational approach 
produce a more focused library of mutants and can be useful when a high-throughput screen 
is not available. 
 When larger modifications to an enzyme structure are needed to alter function, then 
‘domain swapping’ or ‘shuffling’ can be performed (Pavlov et al., 2004).  In this manner 
hybrid or chimeric DNA polymerases can be created.  Davidson (2003) combined domains 
from two different polymerases to produce an enzyme with increased processivity.  In this 
example, the T3 DNA polymerase thioredoxin-binding domain, which is known to play a 
key role in processivity, was inserted into Taq DNA polymerase to create a highly 
processive enzyme (Davidson et al., 2003). Attempts have also been made to introduce the 
3-5’ exonuclease function into Taq DNA pol by domain exchange.  Two chimeric DNA 
polymerases were made by inserting the 3-5’ exonuclease domain of E. coli pol I and 
thermophilic Thermotoga neapolitana (Tne) polymerase in place of the inactive 3-5’ 
exonuclease domain of Taq DNA pol (Villbrandt et al., 2000).   Although the 3-5’ 
exonuclease function was introduced successfully, there was a reduction in thermostability 
despite the use of the thermostable Tne polymerase to construct the chimera. This highlights 
a problem with large domain swapping, which is that protein structure and interactions are 
likely to be disturbed when large segments of a protein are altered (Villbrandt et al., 2000). 
 Two particular methods that have become popular for the in vitro selection of 
enhanced polymerases during directed evolution include phage display (Xia et al., 2002) and 
compartmentalised self-replication (Ghadessy et al., 2001).  In vitro selection is challenging, 
as the association of phenotype and genotype must be maintained by some means. Phage 
display is a technique that allows the selection of active polymerases displayed on phage 
particles.  This method has been used to evolve a variant of the Stoffel fragment of Taq 
DNA polymerase to have RNA polymerase activity and therefore incorporate ribonucleoside 
triphosphates (Xia et al., 2002).  In this example, selection of desired mutants relied on 
enzyme-catalysed labelling of the attached substrate.  The labelled substrate is attached to 
the polymerase creating a phenotype-genotype linkage that is key to the procedure and 
phage particles displaying active polymerases are then isolated. 
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 Compartmentalised self-replication (CSR) is a technique based on the 
compartmentalization of variant polymerases and a feedback loop whereby a polymerase can 
only replicate its own encoding gene.  Only the polymerases that are active under the set 
conditions are able to replicate and are therefore selected.  This method has been used to 
evolve a polymerase with an 11-fold higher thermostability than wild-type Taq DNA pol.   
The selected mutant had a half-life of 16.4 minutes at 97.5°C compared to only 1.5 minutes 
for the wild-type at the same temperature (Ghadessy et al., 2001).  This method was also 
used to screen for heparin-resistant Taq DNA pol variants, and was successfully used to 
isolate a variant that was reported to have a 130-fold increase in heparin resistance 
(Ghadessy et al., 2001).  The technique of compartmentalised self-replication is the chosen 
screening method used in the directed evolution of Taq DNA polymerase in this project. 
 
Compartmentalised Self-Replication (CSR) 
 Directed evolution by compartmentalised self-replication (CSR) combines high-
throughput screening with selection and is fast becoming a key procedure in enzyme 
engineering.  This technology works particularly well with RNA and DNA polymerases.  It 
can also be used for the evolution of other enzymes, such as nucleoside diphosphate kinases, 
although an extra step in CSR is often needed (Ghadessy et al., 2001).  CSR (Figure 1.6) is 
based on a feedback loop whereby each polymerase variant replicates its own encoding gene 
(Ghadessy et al., 2001).  After random mutagenesis to create a library, polymerase variants 
are isolated in compartments by the formation of a water-in-oil emulsion (Tawfik and 
Griffiths, 1998).  Each compartment typically contains a single expressor E. coli cell 
containing a polymerase variant and this provides the link between phenotype and genotype 
that is so key to the procedure.  PCR reagents are also contained within the compartment and 
combine with expressed polymerase enzyme when thermocycling causes cell lysis to occur.  
If the polymerase variant is expressed as active enzyme, or is active under the desired 
condition, then it will replicate its own gene, which increases the copy number of genes 
encoding an active polymerase during thermocycling (Ong et al., 2006).  Inactive 
polymerases that are incapable of self-replication will be lost from the gene pool and in this 
way the ‘sorting’ of variants becomes an inherent part of the procedure.   
 Along with the examples described above, CSR has been used to screen for DNA 
polymerases with the ability to extend mismatched bases, which therefore allows 
amplification of damaged DNA to occur (d’Abbadie et al., 2007).  A mutant library was 
created using the shuffling technique of ‘molecular breeding’ (Crameri et al., 1998) in which 
fragments of the polymerase genes from three species, Thermus aquaticus, Thermus 
thermophilus and Thermus flavus, were recombined to form chimeric polymerases.  CSR 
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was then used to screen the library of chimeric DNA polymerases and select for those 
variants that were able to extend primers with up to four mismatched bases.  The end result 
was a DNA polymerase variant that was able to outperform wild-type Taq DNA pol in the 
amplification of ancient damaged DNA (d’Abbadie et al., 2007).  CSR has also been used to 
isolate Taq DNA pol variants that are able to incorporate not only dNTPs but also 
ribonucleotides (NTPs).  In this study, short-patch CSR (spCSR) was used to diversify and 
replicate only a short region of the Taq DNA pol gene.  Two specific motifs involved in 
substrate recognition were targeted and mutagenised and following screening by CSR, Taq 
DNA pol variants with apparent dual substrate specificity were selected (Ong et al., 2006).  
These examples illustrate how directed evolution by CSR has successfully become a key 
technique in DNA polymerase engineering. 
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Figure 1.6 – A schematic diagram of compartmentalised self-replication 
1) A mutant library is produced by error-prone PCR and variants are expressed in E. coli 
2) E. coli cells are resuspended in PCR reaction buffer and PCR components, including 
primers to amplify the encoded polymerase gene, and are then separated into aqueous 
compartments by an oil-in-water emulsion. An inhibitor is also added to the compartment 
to apply a selective pressure to the evolution process. 
3) Thermocycling lyses the E. coli cell and releases the polymerase and its encoding gene, 
allowing self-replication to take place. Poorly active polymerases are unable to amplify 
their encoding genes so are lost from the gene pool. 
4) The amplified gene products are released and recloned for another cycle of CSR. 
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Aims of Project 
 
 The use of PCR-based assays in clinical diagnostics is expanding.  PCR often 
suffers because of inhibitors found in an array of biological samples used in diagnostic 
testing. One method to overcome the problem of inhibition is to engineer polymerases with 
increased resistance to known PCR inhibitors such as heparin and phytate.  The technique of 
directed evolution by compartmentalised self-replication (CSR) has recently been 
established as an efficient high-throughput method for the creation of novel polymerases. 
The aims of this project were: (1) to establish a CSR system to screen a mutant library, (2) 
use the system to select for novel heparin and phytate resistant Taq DNA polymerase 
variants, (3) to characterise the selected variants, and (4) explore the fundamental aspects of 
the inhibitors’ mode of action. 
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Chapter Two - Compartmentalised Self Replication: 
Developing a System for the Directed Evolution of Taq DA 
Polymerase 
 
Introduction 
 In order to enhance the efficiency of the directed evolution of Taq DNA polymerase 
by compartmentalised self replication (CSR), it was deemed to be advantageous to start from 
an engineered fusion enzyme with enhanced processivity.  Processivity is defined as the 
probability of an enzyme not to dissociate from the DNA while it translocates to the next 
position after the addition of a nucleotide (Pavlov et al., 2004).  Natural replicative 
polymerases often rely on accessory proteins to form stable complexes during replication 
and to achieve high processivity.  The processivity of DNA polymerases is related to their 
natural role in vivo (Davidson et al., 2003).  Taq DNA pol belongs to the Pol A family, 
which function mainly as repair enzymes.  These enzymes have evolved to fill in short 
stretches of DNA rather than to replicate entire genomes, and are therefore not very 
processive (Wang et al., 2004).   
Sac7 is a hyperthermostable, 7kDa chromatin protein from Sulfolobus 
acidocaldarius (Figure 2.1; Ko et al., 2004) that is thought to have a DNA-stabilizing 
function in vivo (McAfee et al., 1995).  The Sac7 family of proteins are the most abundant 
DNA-binding proteins found in S. acidocaldarius and have been seen to form compact 
complexes with DNA (Lurz et al., 1986).  When bound, Sac7 has been shown to bend and 
induce a kink in the DNA duplex.  Although their function is not fully understood, the Sac7 
family of proteins appear to be unique to Sulfolobus species (Bedell et al., 2005). 
 Since the discovery of these small non-specific dsDNA-binding proteins, further 
work has been carried out using Sac7 in protein engineering.  When fused to the N-terminal 
region of TaqDNA pol, Sac7 has been shown to increase the processivity of Taq DNA pol 
without altering its catalytic activity (Wang et al., 2004).  In the fusion protein, the increase 
in the processivity of the enzyme is thought to occur via stabilisation of the DNA-
polymerase complex, keeping Taq DNA polymerase tightly bound to the DNA during 
extension.  Wang et al. (2004) reported that Sac7 was shown to increase the performance of 
wild-type Taq DNA pol by enhancing its processivity from an average primer extension 
length of 22 nucleotides to 104 nucleotides.   
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 Other attempts at increasing polymerase processivity include the addition of 
thioredoxin binding domains (TBD) (Davidson et al., 2003) and helix-hairpin-helix (HhH) 
motifs (Pavlov et al., 2002).  The T3 DNA polymerase TBD was successfully inserted into 
Taq DNA polymerase in an analogous position to its location in its native T3 polymerase by 
Davidson et al. (2003). In the presence of thioredoxin, the hybrid polymerase was found to 
become tightly bound to the DNA as the thioredoxin acts as a clamp to increase processivity.   
In an alternative approach, HhH motifs have also been used to enhance polymerase 
processivity.  HhH motifs are found in many regulatory proteins and allow the proteins to 
bind to DNA in a non-sequence specific manner by interacting with the sugar-phosphate 
backbone.  The fusion of HhH motifs to a number of polymerases has been investigated with 
varying results.  While HhH motifs increased the processivity of Pfu, they were found to 
have no effect on Taq DNA polymerase (Pavlov et al., 2002).   
 Compared to the examples described in the previous paragraph, the fusion of Sac7 to 
a polymerase appears to have a broader effect as it has been shown to enhance processivity 
with both Pol A (Taq) and Pol B (Pfu) polymerases (Wang et al., 2004).  For this reason, a 
clone of the Sac7-Taq polymerase gene inserted in a pUC18-derived vector called 
pTTQ18NAK (Appendix A) for the high-level expression of the fusion protein was selected 
as the starting point for modification by directed evolution in this project.     
 Another crucial part of setting up and preparing the CSR system to be employed in 
this project was the choice of a system to select efficiently the positive clones after each 
round of CSR.  The chosen method was the use of SacB as a selectable marker as developed 
by Schweizer and Hoang (1995).  The SacB gene from Bacillus subtilis encodes the enzyme 
levan sucrase and confers sucrose lethality (Bramucci et al., 1996).  The build up of levans 
Figure 2.1 – Crystal structure of Sac7 from Sulfolobus 
acidocaldarius complexed with DA. Two DNA decamers shown 
in brown and blue. Produced using Cdn3 (Ko et al., 2004; PDB ID: 
1WD1) 
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in cells containing SacB causes cellular osmosis when cells are plated on media containing 
sucrose (Recorbet et al., 1992).  Inserting SacB into a vector in the cloning site creates a 
selection system based on sucrose lethality.  When subsequently employed to select positive 
clones during CSR, cloning the desired gene into the SacB vector and plating transformants 
on sucrose plates provides a direct screen and eliminates any colonies that still contain SacB.  
In this way, SacB is a selectable marker that can be used for screening by reducing 
background and therefore increasing mutant library size during directed evolution.  
Since the focus of this project is on the evolution of variants that are resistant to 
inhibitors of the Taq DNA polymerase enzyme, it was deemed to be preferable only to 
mutate the polymerase domain prior to CSR screening.  Therefore the SacB gene was 
designed to replace just the polymerase domain rather than the whole Sac7-Taq polymerase 
fusion.  To allow removal or exchange of just the polymerase domain to occur, site-directed 
mutagenesis was employed to introduce an extra restriction site in the appropriate site in the 
construct.  A BglII site was designed just upstream of the Taq DNA polymerase linker 
region joining the exonuclease and the polymerase domains (Figure 2.2).  The same 
restriction site was also designed into the primers for amplification of the SacB gene thus 
allowing exchange of the two fragments by digestion with BglII.  
 
 
                                                   BglII 
    1021 agggcctttctggagagatctgagtttggcagcctcctccacgagttcggccttctggaa 
            341  R  A  F  L  E  R  S  E  F  G  S  L  L  H  E  F  G  L  L  E  
                   EXONUCLEASE DOMAIN                   LINKER REGION 
         
          1081 agccccaaggccctggaggaggccccctggcccccgccggaaggggccttcgtgggcttt 
           361  S  P  K  A  L  E  E  A  P  W  P  P  P  E  G  A  F  V  G  F  
                                                                POLYMERASE DOMAIN 
 
Figure 2.2 – The Linker region between exonuclease and polymerase domains  
in Sac7-Taq polymerase. 
 
  
 In addition to the use of a processivity-enhancing domain and the SacB selection 
system described above, a number of other aspects of the CSR system had to be investigated 
to ensure that the process could be set up and conducted efficiently.  One of these was the 
optimisation of emulsion PCR for use in the system.   
The use of emPCRs or in vitro compartmentalization (IVC) has increased 
considerably over the last few years.  It is the basis of the revolutionary Roche 454 DNA 
sequencing system, in which individual DNA-capture beads are compartmentalised within a 
 
← 
→ 
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water-in-oil emulsion droplet (Margulies et al., 2005).  Each bead captures an individual 
fragment of DNA which allows parallel amplification and sequencing reactions to take place 
in millions of compartments within the emulsion.  IVC has also been widely used in the 
directed evolution of a range of different proteins.  The simplest application of IVC is use 
with DNA modifying enzymes such as DNA methyltransferase, restriction endonucleases 
and polymerases.  However, IVC has also been used to produce new ribozyme variants and 
peptides with specific antibody selectivity as reviewed by Griffiths and Tawfik (2006).    
 Although emPCR is well characterised, the use of it and the CSR system had to be 
set up and verified under the chosen conditions for this project.  Before carrying out directed 
evolution on the polymerase using CSR, several things had to be investigated and optimised: 
(1) droplet formation, (2) PCR amplification within the emulsion droplets, (3) PCR 
amplification using E. coli cells containing induced polymerase as the only source of 
enzyme in the emulsion droplets and (4) extraction of the DNA product from the emulsion 
for further use.  The investigation and optimisation of each of the steps (1)-(4) above are 
reported in this chapter.   
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Materials and Methods 
 
Standard Activity and Expression Testing  
10ml LB medium [10g/L tryptone, 5g/L yeast extract, 5g/L NaCl (all Sigma, 
Gillingham, UK)]containing Kanamycin (50µg/ml) was inoculated from a freshly streaked 
plate or an overnight starter culture and incubated at 37°C until an OD600 of  >0.6  was 
reached. The culture was induced with 0.5mM IPTG and incubated for a further 4 hours. 
Cells were harvested by centrifugation and resuspended in 500µl of TMN Lysis buffer 
[50mM Tris-HCl (pH8.5), 10mM MgCl2, 16mM (NH4)2SO4, 0.1% (v/v) Tween 20]. 
Samples were sonicated for 30 s at 15 micron and centrifuged.  200µl of lysate was then heat 
treated at 70°C for 20 min. Debris was removed by centrifugation and the heat-treated lysate 
was used as enzyme stock for an activity PCR. 
Protein samples were analysed by 10% (w/v) SDS-PAGE gels with standard buffers 
(Sambrook & Russell, 2001) and BioRad Mini Protean equipment. Samples in loading 
buffer were denatured at 95°C for 5min before loading. Proteins were visualised with 
Coomassie Brilliant Blue R 250 and molecular weights determined using the Broad Range 
Marker (BioRad, Hemel Hempstead, UK) containing: Myosin (200kDa), β-galactosidase 
(116kDa), phosphorylase b (97kDa), bovine serum albumin (66kDa), ovalbumin (45kDa), 
carbonic anahydrase (31kDa), soybean trypsin inhibitor (22kDa), lysozyme (14kDa) and 
aprotinin (7kDa). Protein concentrations were measured using the Bradford Assay (BioRad, 
Hemel Hempstead, UK). 
An M13 or 500bp Lambda activity PCR was set up with final concentrations as 
follows: 1X Taq buffer (GeneSys, Camberley, UK) containing 1.5mM MgCl2, 200µM 
dNTPs (GeneSys, Camberley, UK), M13 (or 500bp λ) forward and reverse primers at 
25pmol, 1-10ng of pTTQ18NHK Sac7-TaqPol plasmid (or λ DNA), 1µl lysate, and ddH2O 
up to 50µl. 1.25U Taq (GeneSys, Camberley, UK) was used as a control and reactions were 
run under standard M13 or 500bp λ conditions depending on the primers used. M13 
reactions were cycled as follows: 94°C for 3min, 30 cycles of 94°C for 15s, 60°C for 15s 
and 72°C 3min. 500bp λ reactions were cycled as follows: 94°C for 3min, 30 cycles of 94°C 
for 15s, 55°C for 15s and 72°C 30s.  5% DMSO was used with the M13 primers. 5µl of each 
PCR reaction was run on a 1% (w/v) agarose gel with a 1kb DNA ladder [New England 
Biolabs, Hitchin, UK (see Appendix D)]. 
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500bp λ primers: 
Common (Forward) 5’ - GAT GAG TTC GTG TCC GTA CAA CTG G 
500bp (Reverse) 5’ - GGT TAT CGA AAT CAG CCA CAG CGC C 
 
 
Plasmid Prep 
  5ml LB [10g/L tryptone, 5g/L yeast extract, 5g/L NaCl (all Sigma, Gillingham, 
UK)] containing Kan (50µg/ml) was inoculated with a single colony from a freshly streaked 
plate and incubated overnight at 37°C. The plasmid DNA was purified from the culture 
using Mini Prep kit (Promega, Southampton, UK) following the standard protocol.  The 
plasmid prep was checked by running 1µl of plasmid on a 1% (w/v) agarose gel. 
 
 
Site-Directed Mutagenesis  
An additional restriction site, BglII, needed to be added to the pSac7-TaqPol 
construct (Appendix B) and this was done using the QuikChange® Site-Directed 
Mutagenesis kit (Stratagene, Cheshire, UK).  QuikChange mutagenic primers were designed 
as per Stratagene’s guidelines.  The original Taq DNA polymerase sequence was altered 
from AGGCTT to AGATCT, which gave one amino acid change (L347S).  QuikChange 
primers were as follows:  
 
Forward primer:   
                                   Arg→Arg      Leu→Ser   
 
                                            AGG  CTT 
5’AGGGCCTTTCTGGAG AGATCTGAGTTTGGCAGCCTCCTC  
 
Reverse primer: 
 
 5’ GAGGAGGCTGCCAAACTCAGATCTCT CCAGAAAGGCCCT  
 
 
The mutagenesis reaction was set up using 1X Pfu Ultra reaction buffer (Stratagene, 
Cheshire, UK), 200µM dNTPs (GeneSys, Camberley, UK ), 125ng of each primer, 10ng 
pSac7-TaqPol vector template, 2.5U Pfu Ultra (Stratagene, Cheshire, UK) and made up to 
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50µl with water.  The reactions were run on an Eppendorf (Cambridge, UK) Mastercycler 
under QuikChange conditions as follows: 95°C for 30s, 18 cycles of 95°C for 30s, 60°C for 
1min and 68°C for 8min.  After thermocycling, the reactions were treated with DpnI before 
being transformed into XL1 Blue chemically competent cells (Stratagene, Cheshire, UK).  
1µl of DpnI treated reaction was added to 50µl XL1 Blue cells and incubated on ice for 30 
min.  The cells were heat shocked at 42°C for 30s and placed on ice for 2 min. 0.5ml of 
42°C pre-heated SOC [0.2g/L Bacto-tryptone (BD, Oxford, UK), 0.05g/L bacto-yeast extract 
(BD, Oxford, UK), 10mM NaCl, 2.5mM KCl, once autoclaved 10mM MgCl2, 10mM 
MgSO4 and 20mM glucose were added (all Sigma, Gillingham, UK)]was added to the cells 
and they were incubated at 37°C for 1h before being spread onto LB/KAN plates (50µg/ml). 
After overnight incubation at 37°C, colonies were picked and screened for the BglII site 
mutation. 
 
Screening 
 Individual colonies from the transformation plate were picked using sterile 
toothpicks and gridded onto a fresh LB/KAN plate (50µg/ml) to keep as a reference plate.  
Cells from each colony were lysed in 20µl water at 100°C for 5 min before being used as 
template in a screening PCR.  BglII screening primers were designed to amplify 500bp 
sequence around the BglII site (F-5’CACCCCGGCCTGGCTTTG and R-
5’CAGGGCCAGA ACGCTCAGGTCTT).  PCR reactions were run as follows (final 
concentrations): 1X Mastermix (GeneSys, Camberley, UK), 25pmol F’and R’primers, 1µl 
lysed template and water up to 50µl. Reactions were cycled under screening PCR 
conditions: 94°C for 3min, 30 cycles of 94°C for 10s, 55°C for 10s and 72°C or 45s. 5µl of 
PCR product was run on a 2% (w/v) agarose gel. PCR products were then digested with 
BglII to screen for correctly mutated clones.  Digests were as follows: 1X buffer 3 (New 
England Biolabs), 7µl PCR product, 10U BglII and water up to 30µl.  Digests were left at 
37°C for 1h and then the entire reaction was run on a 2% (w/v) agarose gel.  
 
SacB Cloning 
 Primers were designed to amplify the Bacillus subtilis sucrase gene (SacB) from the 
vector pDNR-LIB (Clontech, St. Germain-en Laye, France). SacB was amplified using 
Phusion polymerase (New England Biolabs, Hitchin, UK) and a 2X dilution series of the 
pDNR-LIB template vector ranging from 50ng to 1ng. The PCR was set up as follows: 1X 
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HF phusion buffer, 200µM dNTPs (GeneSys, Camberley, UK), 25pmol forward and reverse 
primer, pDNR-LIB template, 1U Phusion, and water up to 50µl. Reactions were cycled 
following Phusion guidelines.  
 All successful PCRs were treated with DpnI and purified using the Wizard SV gel 
and PCR clean-up system (Promega, Southampton, UK). SacB PCR product and pSac7-
TaqPol (BglII Mutant 8) were digested with BglII and SalI (New England Biolabs, Hitchin, 
UK) and the vector was phosphatased with 1U Shrimp Alkaline Phosphatase (SAP) (New 
England Biolabs, Hitchin, UK) per pmol of DNA. SAP was inactivated at 65°C for 15min. 
Both digests were run on a 1% (w/v) agarose gel and the large fragment of vector and the 
SacB were gel extracted and purified using Perfectprep Gel Clean up kit (Eppendorf, 
Cambridge, UK).  
 The digested pSac7-Taq and SacB were ligated using T4 Ligase (Promega, 
Southampton, UK) at room temperature for 3h. The ligation reaction was ethanol 
precipitated and 1µl was transformed into TOP 10F’ electrocompetent cells (prepared as 
below) using a standard protocol. 
 
 
Ethanol Precipitation 
 The volume of aqueous phase was measured and 0.1 volumes of 3M sodium acetate 
(pH5.2) and 2 volumes of cold ethanol were added. The sample was mixed and left to 
precipitate at   -20°C for 30 min. The sample was centrifuged at 13,000g, the ethanol was 
removed and the pellet was washed in 70% (v/v) ethanol. The pellet was left to air dry for 
approximately 10 min before being resuspended in sterile ddH20.  
 
Transformation 
 20-40µl of electrocompetent cells were thawed on ice. 1µl of ligation reaction was 
added to the cells and they were left on ice for 30 min before being transferred to a chilled 
Gene Pulser 0.1cm cuvette (BioRad, Hemel Hempstead, UK). The cells were pulsed at 
1.8kV, immediately resuspended in 1ml of SOC [0.2g/L Bacto-tryptone (BD, Oxford, UK), 
0.05g/L bacto-yeast extract (BD, Oxford, UK), 10mM NaCl, 2.5mM KCl, once autoclaved 
10mM MgCl2, 10mM MgSO4 and 20mM glucose were added (all Sigma, Gillingham, 
UK)]and were left shaking at 37°C for 1h.  Typically 50µl and 100µl aliquots of transformed 
cells were spread onto an LB/Kan plate (50µg/ml) and incubated overnight at 37°C.  
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Preparation of Electrocompetent Cells 
 10ml LB [10g/L tryptone, 5g/L yeast extract, 5g/L NaCl (all Sigma, Gillingham, 
UK)] was inoculated with a single colony of fresh TOP10F’ E. coli (F’{lacIq, Tn10(TetR)} 
mcrA (mrr-hsdRMS-mcrBC) φ80 lacZ M15 lacX74 deoR recA1 araD139 (ara-leu)7679 
galU galK rpsL(strR) endA1 nupG) and incubated overnight at 37°C with shaking.  2x 
250ml LB was inoculated with 2.5ml of the overnight culture and grown to an OD600nm ~1.0 
at 37°C.  The cultures were chilled on ice for 5min before centrifuging in pre-chilled bottles 
at 5,000g for 10min.  The supernatant was discarded and the pellets were gently resuspended 
in 25ml ice-cold ddH2O before being pooled together.  The cells were centrifuged as before, 
the supernatant was discarded and the pellet gently resuspended in 5ml ice-cold 10% (v/v) 
glycerol.  The cells were centrifuged again and supernatant discarded. The pellet was 
resuspended in ice-cold 10% (v/v) glycerol to a final volume of less than 1.5ml.  40µl 
aliquots were pipetted into chilled tubes, frozen on dry ice/methanol and stored at -80°C. 
 
Auto Induction  
 A 10ml culture of LB [10g/L tryptone, 5g/L yeast extract, 5g/L NaCl (all Sigma, 
Gillingham, UK)] containing Kan (50µg/ml) was inoculated with a single colony and grown 
with shaking at 37°C until an OD600nm of 0.5 was reached.  30ml of autoinduction Overnight 
Express medium (Novagen, Nottingham, UK) in a 250ml shake-flask was then inoculated 
with 5% (v/v) of the starter culture. The autoinduction culture was left to grow for a further 
24h before cells were harvested by centrifugation.  
 
Emulsion PCR 
2x108 induced E. coli cells expressing polymerase variants were centrifuged to 
remove media and then washed in 200µl 1X Taq buffer.  The cells were resuspended in 20µl 
1X Taq buffer before being added to the compartmentalised self replication (CSR) mix. 
200µl of CSR mix was made up as follows: 1x Taq Buffer containing 1.5mM MgCl2, 
0.25mM dNTP, 1µM of pol domain forward and reverse primer, E. coli cells expressing 
Sac7-TaqPol and water to final volume.  The oil phase was made up in light mineral oil 
(Sigma, Gillingham, UK) and consisted of 4.5% (v/v) Span 80 (Fluka), 0.4% (v/v) Tween 80 
(Sigma, Gillingham, UK), 0.05% (v/v) Triton X-100 (Sigma, Gillingham, UK), as described 
by Ghadessy et al.(2001).  A small magnetic stirrer was placed into a 5ml cryotube 
(Corning) and 0.2ml of CSR reaction (water phase) was mixed with 0.4ml of oil phase to 
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form an emulsion.  The emulsion was stirred at ~1100rpm for 5 min to create an average 
droplet size of 3-5µm as determined by light microscopy.  The emulsion PCR (emPCR) was 
aliquoted into 0.5ml thin-walled PCR tubes in volumes of less than 100µl and temperature 
cycled as follows: 94°C for 5min, 25 cycles of 94°C for 1min, 55°C for 1min and 72°C for 
5min.  
Pol domain primers:     (BglII) 
Forward 5’ AGGGCCTTTCTGGAGAGATCTGAGTTTGGCAGC CTCC   
           (SalI) 
Reverse 5’ GCCTGCAGGTCGACTCTAGAGGATCTATCACTCCTTGG 
  
 
Aqueous Phase Extraction 
The emPCRs were centrifuged at 3000g for 5 min and the top oil layer was 
removed.  0.1ml of quenching buffer [1M NaCl, 10mM Tris/HCl (pH7.4), 1mM EDTA] was 
added to each tube and the emulsion was resuspended.  The reactions were pooled together 
in a 1.5ml tube and 1ml of water-saturated ether was added. The samples were vortexed and 
centrifuged briefly. The ether (top layer) was removed leaving the aqueous layer. 1ml water-
saturated ether was added and the previous step repeated. Finally the aqueous phase was 
washed with 1ml ether, vortexed and centrifuged. The ether layer was removed and the 
aqueous phase was processed further.  The aqueous phase was ethanol precipitated to 
concentrate the DNA from the sample. The pellet was then resuspended in 30µl sterile 
water. 
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Results 
 
Expression and Activity Test of Sac7-TaqPol 
 An agar stab stock of Sac7-TaqPol (GeneSys) in TOP10F’ was used to streak a fresh 
LB Kan plate, which was incubated at 37°C overnight. A small scale expression of the clone 
was performed to check expression and activity levels. Cells were harvested from a 10ml LB 
culture with a 4h IPTG induction. The cell pellet was resuspended, sonicated and the cell 
extract was heat treated to remove the bulk of the E. coli proteins.  Protein expression was 
analysed by 10% SDS-PAGE (Figure 2.3). 25U of purified Taq was run as a size marker. 
 
 
 
  
 
 
 
 
        
 
 
The SDS-PAGE gel shows that both the uninduced sample and the induced sample 
produced protein of the correct size (99kDa).  The uninduced culture grew to a higher OD 
and also appeared to contain a higher expression of Sac7-TaqPol compared to the induced 
culture.   
To check that the expressed Sac7-TaqPol was active, a standard activity PCR with 
M13 primers was run for 30 cycles using the heat-treated cell extract in place of purified 
TaqDNA pol. A 2X dilution series of the extract was prepared and used in the PCR. 5µl of 
each PCR was run on a 1% (w/v) agarose gel (Figure 2.4).  
From a 5ml LB Kan culture of pSac7-Taq Pol in TOP10F’, plasmid was extracted 
using the Promega Mini Prep kit. To check the size of the gene, the plasmid was digested 
Figure 2.3 – Expression of Sac7-TaqPol. This SDS-PAGE gel shows 
various samples of Sac7-TaqPol solouble cell extract. (M) marker, (1) 
uninduced sample, (2) induced sample, (3) uninduced, heat treated  sample, 
(4) induced, heat treated sample, (5) 25U Taq polymerase (92kDa). Sac7-
TaqPol (99kDa) is indicated by the arrow). 
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Figure 2.4 – Activity test PCR. Varying 
levels of cell-free extract were used as 
enzyme in the 30 cycle activity PCR. (M) 
1kb DNA ladder (NEB), (1) 1µl extract, 
(2) 0.5µl extract, (3) 0.25µl extract, (4) 
blank lane, (5) 1.25U Taq control. 
with deI and SalI. When digested the plasmid should produce 3 fragments: a 212bp Sac7 
fragment (not visible in picture), a 2521bp TaqPol fragment and a large 5.4kb vector 
fragment (Figure 2.5).  
 
 
 
 
 
 
 
 
 
 
 Figure 2.4 shows that the Sac7-TaqPol clone was active in a standard PCR using 1-
0.5µl of cell-free extract.  At a lower concentration of extract the PCR failed to produce any 
visible product.  The agarose gel shows that 1µl of extract is approximately equivalent to 
1.25U of purified Taq DNA pol.  Figure 2.5 indicates that the Sac7-TaqPol clone contains 
inserts of the expected size.  Lane 3 shows the TaqPol gene band at 2521bp, with the larger 
vector fragment above it.  The small 212bp Sac7 fragment was visualised early on in the 
electrophoresis run; however, further separation of the other bands was needed and this 
meant the Sac7 band ran off the gel at the time off the photo.  The control lanes show the 
vector after single digests (1) and (2), compared to double digestion (3) and uncut circular 
plasmid (4).  As expected, the plasmid ran in a different way in all four lanes due to its 
conformational changes after single, double or no digestion.  
 
SacB Cloning 
The polymerase domain of Taq DNA pol was replaced with SacB in the 
pTTQ18NAK-Sac7-TaqPol expression vector to create a direct screen for insert-containing 
transformants.  The SacB gene was amplified from the vector pDNR-LIB (Clontech) using 
primers designed to incorporate BglII and SalI restriction sites.  To enable the cloning to 
Figure 2.5 - pSac7-TaqPol Digest. (M)1kb 
ladder, (1) deI single digest, (2) SalI single 
digest, (3) deI and SalI double digest, (4) no 
enzyme control digest, (5) 100bp ladder. 
M      1       2      3       4       5 
10kb→ 
3kb→ 
M     1      2      3     4     5 
    
 
   3kb  
   2kb 
1.5kb  
   1kb 
500bp  
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Figure 2.6 - A schematic diagram of polymerase domain replacement with the selectable 
marker SacB. (1) starting vector - pSac7-TaqPol, (2) site directed mutagenesis was used to 
incorporate a BglII site, (3) removal of the polymerase domain by digestion with BglII and SalI, 
(4) SacB was cloned and digested with BglII and SalI and then inserted in place of the 
polymerase domain (5) final vector – pSac7-TaqSacB. 
take place, a BglII site also had to be added to the Sac7-TaqPol clone, which was done using 
site directed mutagenesis (Figure 2.6).  
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Transformants produced from the site directed mutagenesis were then screened for the BglII 
site by PCR followed by a digest with BglII.  A ~570bp fragment surrounding the BglII site 
was amplified and digested.  The resulting digested PCR product produced two fragments of 
~331bp and ~241bp, demonstrating that the mutagenesis was successful. The fragments 
were visualised on an agarose gel (Figure 2.7).  
 
 
 
 
 
 
 
 
 
 
 
   
 The clones that were cut into two fragments had undergone successful mutagenesis 
and were thus demonstrated to contain the BglII site.  Since the introduction of a BglII site 
had caused one amino acid change in the original sequence, the BglII clones were carried 
forward for small scale expression and activity tests to check that the amino acid change had 
had no impact on protein function.  The heat-treated extract was analysed by SDS-PAGE 
(Figure 2.8a), and the results showed that the majority of the clones expressed protein of the 
correct size.  The extract was then used in a 500bp PCR to check that polymerase activity 
was still present.  PCRs were conducted with 1µl and 0.5µl of extract from each mutant.  
When analysed on an agarose gel, the PCRs indicated that all but one of the mutants was 
active (Figure 2.8b).  
 
 
Figure 2.7 – BglII Digest of PCR products. An agarose gel 
showing the digested PCR fragment (surrounding the BglII site). 
(M) marker, (C) negative control, (1-28) numbered lanes refer to 
colony screened. 
 
←570bp 
←331bp     
←241bp 
←570bp 
←331bp     
←241bp 
500bp→ 
275bp→ 
M   1    2     3     4     5     6     7    8     9    10   11  12   13  14   C 
M   15  16  17   18   19   20   21  22   23   24   25   26   27   28   C 
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Sac7-TaqPol BglII mutant 8 (M8) was chosen for use in all further work.  M8 and 
the SacB gene, previously amplified, were digested with BglII and SalI.  This removed the 
polymerase domain from the TaqPol gene of M8.  SacB was then ligated into Sac7-TaqPol 
M8 in place of the polymerase domain.  Transformants were plated on both Kan and 
Kan/Sucrose plates and left overnight at 37°C.  As expected no colonies grew on the 
Kan/Sucrose plates, which indicated that the ligation was successful and all transformants 
contained the SacB gene. 
The reverse cloning procedure was then performed to show that the polymerase 
domain could be successfully ligated back into Sac7-Taq(SacB).  The original Sac7-TaqPol 
and the SacB containing vector were digested with SalI and BglII.   After agarose gel 
separation, the vector and pol domain DNA were gel purified and the products were ligated. 
The transformants were plated on Kan and Kan/Sucrose, and as expected colonies were seen 
on both plates. Several transformants were picked from the Kan/Sucrose plate and were 
expressed on a small scale. The cell extracts were then tested in an M13 activity PCR. 100% 
of the clones tested were active, which showed that the SacB screening process was 
successful.  
kDa 
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Figure 2.8 – Expression and activity PCR of BglII Mutants. (a) SDS-PAGE gel 
showing the heat-treated extract of several BglII mutants (lane numbers correspond to 
mutants). First lane contains marker. Arrow indicates expression of Sac7-TaqPol. (b) 
Agarose gel showing the activity of several mutants (lane numbers correspond to 
mutants).  (M) 100bp NEB marker, (a) 1µl extract, (b) 0.5µl extract, (C) control PCR 
with 1.25U Taq. 
(b) 
M    1a   1b    2a    2b   3a    3b    4a   4b    5a    5b   7a    7b   8a    8b    C 
    1kb→ 
700bp→ 
500bp→ 
300bp→ 
M   13a  13b  14a   14b   C 
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Auto Induction 
 To increase the expression of Sac7-TaqPol, and therefore increase the yield in future 
CSR reactions, the Overnight Express (Novagen) auto-induction system was used.   A small 
scale expression test was carried out using auto-induced culture and a 4h IPTG-induced 
culture.  Cells were harvested, resuspended and processed as standard. Equivalent volumes 
of cell-lysate from the auto-induced and IPTG-induced samples were analysed by SDS-
PAGE (Figure 2.9).   The overnight express system increased the expression of Sac7-TaqPol 
and was used in all further expression.  
 
 
 
 
 
 
 
 
 
 
 
Emulsion PCR 
 The oil phase (400µl) was made according to Ghadessy et al. (2001) and mixed with 
200µl of 1X Taq Buffer to form an emulsion following the standard protocol.   The emulsion 
was viewed under a light microscope and the average size of the droplets was found to be 
5.1µm (±0.2).  In this work, the number of droplets in a typical emulsion was estimated to be 
9.7 x108 per ml, by cell-counting under a light microscope.  E. coli cells at 3.3 x108 per ml 
were then mixed with buffer and used to form an emulsion, resulting in an approximate 3-
fold excess of emulsion droplets to E. coli cells. When viewed under the light microscope, 
the E. coli cells in individual droplets could not be visualised.  
 In order to visualise the E. coli in the droplets, pGFP (Clontech), a vector carrying 
the green fluorescent protein (GFP) coding sequence, was used in the emulsion. The vector 
Figure 2.9 – Comparison of Auto and IPTG induction. This SDS-PAGE gel 
shows cell extract from auto induction and IPTG-induced cultures. (1) auto-
induced sample, (2) 4h IPTG-induced sample, (3) heat-treated auto-induced 
sample, (4) heat-treated IPTG-induced sample, (5) 25U purified Taq 
polymerase.  
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← Taq (92kD) 
M       1         2         3           4                   5      
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Figure 2.10 – A typical water-in-oil emulsion. (a) A light micrograph displaying a typical view 
of the water-in-oil emulsion with an average droplet size of 5µM (indicated by scale bar). (b) and 
(c) are two microscope images of the same section of emulsion without and with fluorescence. In 
(b) the emulsion droplets can be visualised and in (c) the E. coli cells containing GFP tagged 
vector can be visualised. 
was transformed into E. coli and then expressed. The induced cells were used in an emulsion 
and the droplets were then viewed using a fluorescence microscope. The E. coli containing 
GFP were photographed using a blue filter so the GFP could be visualised and then a second 
picture was taken of the emulsion droplets without the filter (Figure 2.10). Whilst it was 
challenging to superimpose the light microscopy and fluorescence images, the data obtained 
were consistent with the predictions that approximately one third of droplets contained an E. 
coli cell and that the vast majority of droplets that contained E. coli, contained a single cell.   
 
 
 
 
 
 
 
 
                      
 To test that amplification could be achieved within the emulsion droplets, a standard 
PCR using purified Taq DNA pol was run in the emulsion.  This proved to be successful and 
the PCR product was extracted from the emulsion.  Next the use of E. coli cells and the 
activity of Sac7-TaqPol were tested in an emPCR.  Standard Taq DNA pol was replaced by 
E. coli cells containing induced polymerase. After auto induction, the OD600 of the culture 
was measured and aliquots of ~2x108 cells (3.3 x108 per ml) were spun down and washed.  
A cell extract was made as standard from the remaining culture.  An aliquot of induced cells 
was added to the CSR mix and an emulsion made as standard.  To optimize the MgCl2 
concentration of the reaction, three emPCRs with M13 primers were run with varying 
amounts of Mg2+ ranging from 1.5mM to 2.5mM.  After thermocycling, the aqueous phase 
of the reaction was extracted.  Each emPCR was resuspended in 30µl of sterile water and 
10µl was run on a 1% (w/v) agarose gel for comparison (Figure 2.11).  The 2.7kb Sac7-
(a) (b) (c) 
5µm 
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TaqPol was amplified under all three conditions but the optimum MgCl2 concentration was 
found to be between 1.5-2mM. Standard Taq buffer contains 1.5mM MgCl2 and was used in 
all further emPCRs. 
 The product yield of an emPCR was much lower than that of a standard PCR.  To 
check that the emulsion PCR was working efficiently, a set of emulsion PCRs were run with 
varying amounts of induced E. coli cells ranging from double the stated amount of 2x108 
cells in 200µl, down to only 25% of the cells in 200µl.  The emPCRs were extracted and 
analysed on a 1% (w/v) agarose gel (Figure 2.12).  In this particular PCR, the primers used 
amplified a 1.9kb fragment of the Sac7-TaqPol gene as seen on the gel below.   
 
 
 
 
 
 
 
 
 
 
 
 An emPCR was also set up using a cell extract instead of E. coli cells as the source 
of polymerase.  It was run under emulsion conditions and extracted as standard.  When run 
on an agarose gel, the cell extract emPCR showed increased yield compared to standard E. 
coli emPCR.  This indicated that it was not the emulsion conditions that were inhibiting the 
emPCRs but rather the level of polymerase per compartment derived from the single induced 
E. coli cell. 
 
    3kb→ 
    2kb→ 
 1.5kb→ 
 
    1kb→ 
 
500bp→ 
←2.7kb product 
M       1         2        3 
Figure 2.11 – Emulsion PCR with varying 
Mg
2+
 concentrations. (M) 1kb DNA ladder 
(NEB), (1) 1.5mM MgCl2, (2)  2.0mM  
MgCl2, (3) 2.5mM MgCl2. 
    3kb→ 
    2kb→ 
 1.5kb→ 
    1kb→ 
 
500bp→ 
Figure 2.12 – Emulsion PCR with varying 
amounts of E. coli cells per 200µl reaction. 
(M) 1kb DNA ladder (NEB), (1)  2x108 
cells, (2) 1.5x108 cells, (3) 1x108 cells, (4) 
5x107 cells, (5) 4x108 cells. 
←1.9kb product 
M     1      2     3      4     5 
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Discussion 
  
 This chapter presents the work carried out in preparation for the directed evolution 
by compartmentalised self-replication of the polymerase domain of a Sac7-TaqPol fusion 
protein.  It presents the results of successful cloning experiments required to set up an 
efficient CSR system and also the results of the optimisation of the emulsion PCR (emPCR).  
Crucially, the Sac7-TaqPol protein was shown to be active in an emPCR which is essential 
for successful directed evolution by CSR that is the focus of this project. 
 The Sac7-TaqPol clone provided by GeneSys that was used as a starting point for 
this project was tested and confirmed to express the polymerase fusion protein.  A heat-
treated lysate of Sac7-TaqPol was shown to be active in a standard PCR.  The starting clone 
was then modified to help create a more efficient CSR system. 
 Site directed mutagenesis was used to incorporate a BglII site in the linker region 
between the exonuclease and the polymerase domain.  The addition of this restriction site 
allowed the removal and further manipulation of the polymerase domain.  SacB was cloned 
and inserted into Sac7-TaqPol in place of the polymerase domain.  SacB confers sucrose 
lethality and will be used as a selectable marker to reduce background and increase positive 
selection in the CSR procedure described in Chapter 1.  Sac7-TaqSacB was used as the 
starting vector in mutant library construction for directed evolution experiments which are 
described in subsequent Chapters.  The use of the SacB system ensured that cloning during 
library construction was efficient, which was crucial to the whole CSR procedure.   
 The correct set up and testing of the CSR system is essential to the success of future 
screening.  One key element was the formation of the emulsion; the stirring speed at which 
the emulsion was formed and the components in the oil phase both contribute to droplet size. 
With a stirring speed of ~1100rpm, the emulsion was shown to form droplets of an average 
size of 5µm.   The work of Tawfik and Griffiths (1998) and Ghadessy et al. (2001) were 
used as guidelines for setting up the emulsion.  In their study, Tawfik and Griffiths (1998) 
showed that droplet size varied from 0.5 to 7µm with the average droplet size being 2.5µm.  
 The droplet size of 5µm in this study was the correct size for each droplet to contain 
a single E. coli cell, which has a typical size range of 1 to 5µm (Campbell et al., 1999; 
Alberts et al., 1994)   It was estimated that a typical emulsion contained 9.7 x108 droplets per 
ml, indicating that droplet number was in excess of the number of E. coli cells in the mixture 
and therefore it would be unlikely to have a significant proportion of droplets containing 
more than one E. coli cell.   The vast majority of compartments that contained E. coli 
contained a single E. coli cell, but due to the variability of droplet size there may have been 
a low proportion of compartments that contained two E. coli cells.  This was not considered 
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to represent a serious impediment to the success of CSR because two E. coli cell-droplets are 
in such low abundance.  This point is important as it is the separation of variants into 
individual replication compartments that ensures the key phenotype-genotype linkage, which 
is imperative for a highly efficient CSR screen.  As the vast majority of compartments will 
contain only one variant, the low abundance of two-cell droplets should not have an effect 
on the screening process.  
 As well as looking at emulsion droplet formation, standard PCR was achieved 
within the droplets and the PCR product was extracted from the emulsion for further use.  
Producing a working emulsion PCR containing E. coli cells was slightly more challenging.  
Many attempts were made before emPCR with E. coli produced enough DNA amplification 
to be visualised on a gel.  It was found that the yield from an emulsion PCR containing E. 
coli cells, was lower than that of an emulsion PCR using purified Taq DNA pol, when run 
under the same conditions.  This is likely due to a suboptimal amount of polymerase 
contained within each self-replication compartment upon lysis of a single E. coli cell.  
Increasing the number of cells, above 3.3 x108 per ml used in the emulsion, did not have a 
noticeable effect on the yield.  However, decreasing the cell number did have an effect and 
when only 25% of the stated number was used then no visible product formed.  This was 
probably due to the reduced proportion of droplets containing an active polymerase-
producing cell. As increasing the cell number above 3.3 x 108 cells per ml had no effect 
there may be another limiting factor such as the concentration of PCR reagents at this level.  
An auto-induction expression system was used to increase the expression level of Sac7-
TaqPol in order to increase the yield of emPCRs.  Optimisation of the emPCR will be 
discussed further in chapter 3.   
 Having successfully established and tested the required Taq DNA pol clones and 
conditions to set up a functioning CSR process, the next step was to use the system as a 
whole to evolve polymerase variants.  This involved the creation and screening of a mutant 
library and selection of polymerases with improved properties. In the first instance, the CSR 
approach was used to evolve and screen for heparin resistant polymerase mutants, as 
described in Chapter 3.  
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Chapter Three - Testing the CSR system by Evolving Taq 
DNA polymerase Variants with Resistance to Heparin 
 
Introduction 
 
 The widespread use of PCR-based diagnostic testing has led to an increase in the 
study of PCR inhibitors, which are abundant in biological samples.  Many diagnostic tests, 
for both microbial infections and genetic disease, are carried out on blood samples, which 
often contain the inhibitor heparin.  As early as 1978, heparin was discovered to be an 
inhibitor of cellular DNA polymerases and reverse transcriptase (DiCioccio and Srivastava, 
1978).  More recently, heparin was shown to inhibit Taq DNA polymerase amplification of 
the HIV genes in a detection test (Holodniy et al., 1991).  The effect of heparin on PCR 
using white blood cells was further studied by Yokota and it was found that as little as 
0.0016 to 0.1U of heparin3 in a 50µl PCR was enough to suppress the reaction so that there 
was no visible amplification (Yokota et al., 1999). 
 Heparin has wide therapeutic use as an anticoagulant agent as it prevents the 
formation of blood clots, and it is therefore found in many blood samples. Heparin binds to 
the plasma protease inhibitor antithrombin, which leads to an increase in the rate of 
inhibition of coagulation proteases (Jordan et al., 1979).  It has been found that between 20 
and 50U of heparin per millilitre is needed to prevent coagulation in whole blood.4 Heparin 
is a highly sulphated glycosaminoglycan (GAG) or polysaccharide (Mulloy and Forster, 
2000) which falls under the broad category of polyanions (Jones et al., 2004).  It is a 
polymer made up of repeating disaccharide units (Figure 3.1) and can have a molecular 
weight ranging from 3 to 30kDa (Hirsch et al., 2001).  Heparin occurs naturally in the form 
of many different salts and can be found in vertebrate cells such as liver, lung and mast cells. 
There are many available commercial preparations of heparin with various molecular 
weights although most are around 17-19kDa (Sigma). At physiological pH, heparin is a 
highly negatively charged compound, by virtue of the multiple sulphate groups on the 
repeating sugar unit. 
 
                                                 
3 A heparin unit (U) is a measure of the anticoagulant properties of a given heparin product as it acts 
on antithrombin III (AT-III). One unit of heparin is the quantity required to keep 1ml of cat’s blood 
fluid for 24h at 0°C.  
4 Sigma technical bulletin #870. 
47 
 
Figure 3.1 – The structure of heparin. (a)  An example of the repeating disaccharide units 
that make up Heparin (PubChem SID3664) (b) The helical conformation of a heparin molecule 
(Mulloy et al., 1993; PDB-1hpn). 
 
 
 
 
 
 
 
 
 
 
 
 
 Studies suggest that heparin competitively inhibits DNA polymerase by reversibly 
binding to the enzyme and interfering with DNA template binding (DiCioccio and 
Srivastava, 1978).  Characterisation studies of heparin show that it forms a helical structure 
and that many of its protein interactions are dominated by its highly-acidic sulphate groups 
(Mulloy et al., 1993).  Although heparin in known to form high-affinity interactions with 
proteins such as the antithrombin complex, it also forms less specific interactions with many 
proteins (Mulloy et al., 1993).   The complementary electrostatic interactions between 
polyanions (e.g. heparin) and proteins have been studied, which has led to a number of 
proteins being identified and classified as ‘Heparin-binding proteins’ (Jones et al., 2004).   
These heparin binding sites have even been predicted to be ‘helical’ in structure (Cardin and 
Weintraub, 1989). All these findings suggest that heparin may inhibit DNA polymerase by 
mimicking the helical and negatively-charged structure of DNA. 
 The technique of directed evolution by compartmentalised self-replication (CSR) 
has been used to create DNA polymerase variants with increased resistance to heparin 
(Ghadessy et al., 2001).  After three rounds of CSR screening in the presence of increasing 
amounts of heparin, a variant of Taq DNA polymerase was isolated that was estimated to 
have a 130-fold increase in resistance compared to wild-type.  There were six mutated 
residues in total in the heparin-resistant Taq DNA pol variant and four of the residues are 
known through structural studies to directly contact either the template or primer strand.  
The mutations clustered in the base of the finger and thumb polymerase sub-domains.  These 
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results suggested that DNA and heparin bind in the same place in the polymerase active site 
(Ghadessy et al., 2001) and also support the view that heparin mimics and competes with the 
DNA template.   
 With the Ghadessy study in mind, it was decided that concentrating the mutations to 
the polymerase domain alone would be beneficial in the selection of inhibitor resistant 
polymerases described in this chapter.  A mutant library of polymerase variants was 
constructed using random mutagenesis but where only the polymerase domain was exposed 
to mutations.  The GeneMorph II Random Mutagenesis Kit (Stratagene) was used to 
introduce low levels of mutation into the polymerase domain of the Sac7-TaqPol clone 
resulting from the work described in Chapter 2, by error-prone PCR.   
 Once a mutant library comprising many thousands of mutants was constructed, it 
was screened by CSR in the presence of heparin, the aim being that polymerase variants that 
are able to replicate their own gene under the selective pressure of heparin inhibition would 
come through the screen.  These heparin resistant Taq DNA pol variants were then 
characterised and assayed to determine their level of heparin resistance compared to the 
wild-type Sac7-TaqPol after a single round of directed evolution.  It was deemed that setting 
up the CSR system (described in this chapter) for the evolution of Taq DNA polymerase 
variants resistant to heparin, as had been conducted previously (Ghadessy et al., 2001), 
would provide a powerful verification of the system.  
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Materials and Methods 
 
 
Random Mutagenesis 
 Random mutagenesis of the polymerase domain of Sac7-TaqPol clone (M8 Chapter 
2) was carried out using the GeneMorph II Random Mutagenesis Kit (Stratagene, Cheshire, 
UK).   Error prone PCR was performed using Mutazyme II DNA polymerase (Stratagene, 
Cheshire, UK) under conditions designed to achieve a mutation frequency of 0-4.5 
nucleotide changes per kb.  The mutagenesis reaction was set up as follows (final 
concentrations): 1X Mutazyme buffer (Stratagene, Cheshire, UK), 200µM dNTPs 
(Stratagene, Cheshire, UK), 125ng of each polymerase domain primer (GeneSys, 
Camberley, UK), ~100ng initial target template5 (480ng Sac7-TaqPol M8), 5U Mutazyme II 
(Stratagene, Cheshire, UK) and ddH2O to 50µl.  The reactions were run on an Eppendorf 
Mastercycler under Gene Morph II recommended temperature cycling conditions as follows: 
95°C for 3min, 25cycles of 95°C for 30s, 65°C for 30s, 72°C for 2min. Original Pol domain 
primers (GeneSys, Camberley, UK) were used in initial reactions (restriction sites in grey): 
Forward 5’ AGGGCCTTTCTGGAGAGATCTGAGTTTGGCAGCCTCC and Reverse 5’ 
GCCTGCAGGTCGACTCTAGAGG ATCTATCACTCC TTGG.  After cloning problems, a 
second set of primers were designed outside the original pol primers and used in further 
random mutagenesis reactions. Outer pol domain primers (MWG, Ebersberg, Germany): 
Forward 5’ ATCCTGGCCCACATGGACGA and Reverse 5’ CCGCCAGGCAAATTCT 
GTTTTATCA.  10µl of PCR product was run on a 1% (w/v) agarose gel with a 1kb DNA 
ladder (New England Biolabs) and a 1.1kb standard (Stratagene, Cheshire, UK).  PCR 
products were pooled and purified using Perfect Prep Gel Cleanup Kit (Eppendorf, 
Cambridge, UK). 
 
Vector and PCR Product Digest 
 pTTQ18NHK Sac7-TaqSacB (Chapter 2, Figure 2.6) and the mutant polymerase 
domain PCR product were digested with BglII and SalI (New England Biolabs) following 
the recommended protocol.  10µl of each digest was run on a 1% (w/v) agarose gel with 
                                                 
5 Initial target DNA refers to the amount of target DNA to be amplified, not total amount of plasmid DNA 
template to add to the reaction (as per GeneMorph II instruction manual). 
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undigested controls to check proper digestion had occurred. The vector digest (pSac7-
TaqSacB) was then treated with Shrimp Alkaline Phosphatase (New England Biolabs) as 
recommended.  Digests were purified using Perfect Prep Gel Cleanup Kit (Eppendorf, 
Cambridge, UK).  1µl of purified, digested product was run on a 1% (w/v) agarose gel with 
1kb DNA ladder (New England Biolabs).  
 When sequential digests were run, the vector and PCR product were first digested 
with BglII, followed by a clean-up step and digestion with SalI. 
 
Ligation 
 In general, ligations were set up with a 1:4 molar ratio of vector to insert.  Each 
ligation contained 1X T4 Ligase Buffer (Promega, Southampton, UK), vector (240ng), insert 
(180ng), 1µl (1-3U) T4 Ligase (Promega, Southampton, UK) and ddH2O to 10-30µl.  
Ligations were left at room temperature for 3h.  After incubation 20µl of ddH2O was added 
to the reaction and the ligase was heat killed at 70°C for 20min. The ligation product was 
precipitated either in ethanol or butanol before further use.  
 
Butanol Precipitation  
 The ligation reaction was made up to 50µl total volume with ddH2O.  500µl of 
butanol was added, the sample was vortexed briefly and then centrifuged at16,000g for 
10min. The butanol was removed and the DNA pellet was dried in a SpeedVac for 10min or 
until all residual traces of butanol had been removed. Pellets were resuspended in 5µl 
ddH2O. 
 
AKTA Plasmid Purification 
 A 2L LB [10g/L tryptone, 5g/L yeast extract, 5g/L NaCl (all Sigma, Gillingham, 
UK)] culture was inoculated from a freshly streaked plate of Sac7-TaqSacB in TOP10F’ and 
grown up overnight at 37°C.  Cells were harvested by centrifugation and the cell pellet was 
resuspended in 60ml S1 [50mM Tris-HCl (pH7.5), 10mM EDTA, no RNase added]. 60ml 
S2 (0.2M NaOH, 1% SDS) was added and the tube was gently inverted.  After 5min 60ml 
S3 (1.25M Kacetate, 14% glacial acid) was added, the tube was mixed and left on ice for a 
further 5min.  To remove cell debris the sample was centrifuged for 1h at 14,000g.  The 
lysate was removed and clarified by running through sterile filter wool.  An equal volume of 
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isopropanol was added and the sample was centrifuged for 30min. The supernatant was 
discarded and the pellet was resuspended in 10ml TE (Tris pH 8, 0.1mM EDTA).  0.5µl of 
the sample was run on a 1% (w/v) agarose gel with EcoRI/HindIII DNA ladder (GeneSys, 
Camberley, UK).    
 After clarification of the cell lysate the sample was loaded onto a Sepharose 6 Fast 
Flow column (GE Life Sciences, Little Chalfont, UK) for RNA removal and buffer 
exchange, followed by capture of the supercoiled plasmid on a PlasmidSelect column. 
Plasmid purification chromatography was performed using an AKTA (GE Life Sciences, 
Little Chalfont, UK) and following the PlasmidSelect Plasmid Purification Starter Kit 
protocol (GE Life Sciences, Little Chalfont, UK).   
 
Second Amplification of Mutant PCR Product 
 A 1/10 dilution of mutagenic pol domain PCR product (using outer pol primers) was 
used as template in a second PCR.  This PCR used the original pol domain primers (see 
random mutagenesis) which contain restriction sites.  PCR was set up as follows (final 
concentrations): 1X Taq Buffer containing 1.5mM MgCl2 (GeneSys, Camberley, UK), 
200µM dNTPs (GeneSys, Camberley, UK), 25pmol of each pol domain primer (GeneSys, 
Camberley, UK), 1µl 1/10 dilution of template, 5% (v/v) DMSO (Sigma, Gillingham, UK), 
1.25U Taq DNA polymerase (GeneSys, Camberley, UK) and ddH20 up to 50µl. Reactions 
were run on an Eppendorf Mastercycler for 10 cycles under pol domain PCR conditions: 
94°C for 3min, 25 cycles of 94°C for 15s, 60°C for 15s, 72°C for 2min.  5µl of PCR product 
was run on a 1% (w/v) agarose gel with 1kb DNA ladder (New England Biolabs).  Multiple 
PCRs were pooled and purified with the Perfect Clean Up kit (Eppendorf, Cambridge, UK) 
before further use. 
 
Screening for Pol Domain Insert 
 Colonies were picked and lysed as described in the Chapter 2 screening method.  
PCR reactions were run as follows (final concentrations): 1X MasterMix (GeneSys, 
Camberley, UK), 25pmol pol domain F and R primers, 1µl template and water up to 50µl. 
Reactions were cycled under screening PCR conditions: 94°C for 3min, 30 cycles of 94°C 
for 10s, 60°C for 10s and 72°C for 2min. Sac7-TaqPol M8 was used as control template. 5µl 
of each PCR was run on a 1% (w/v) agarose gel. 
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Glycerol Stocks of Mutant Library 
 Mutant library transformations were spread onto large LB Kan/Sucrose (5%) plates 
and left overnight at 37°C.  The colonies were then resuspended on the plate using LB and 
gentle agitation with a spreader.  The resuspended cells were pipetted and pooled into a 
cryotube and 0.5 vol of 50% (v/v) glycerol was added. The tube was gently mixed before 
being stored at -80°C.  
 
DpnI Treatment and Second Amplification of emPCR Product 
 After initial ether extraction, the aqueous phase of the emulsion PCR (emPCR) was 
treated with 20U of DpnI (New England Biolabs) for 2h at 37°C to remove parental plasmid 
DNA.  The sample was then concentrated using a SpeedVac before being purified using a 
spin column PCR Purification Kit (Qiagen,Crawley, UK) and eluted in 50µl of ddH2O. The 
DpnI treated emPCR product was then used as template in a second PCR. The PCR was run 
as follows (final concentrations): 1X HF Phusion Buffer ( New England Biolabs, Hitchin, 
UK), 200µM dNTPs (GeneSys, Camberley, UK), 25pmol of each pol domain primer, 1-5µl 
emPCR template, 5% DMSO (Sigma, Gillingham, UK), 1U Phusion (New England Biolabs, 
Hitchin, UK), and ddH2O to 50µl.  Reactions were run for 25 cycles following Phusion 
guidelines on an Eppendorf (Cambridge, UK) Mastercyler.  
 
Protein Expression and Polyethyleneimine Precipitation 
 250ml auto-induction medium Overnight Express (Novagen, Nottingham, UK) 
containing kan (50µg/ml) was inoculated from a freshly streaked plate.  The culture was left 
shaking at 37°C for 24h and then the cells were harvested by centrifugation. Cell pellets 
were weighed and resuspended in 5ml TE [50mM Tris (pH7.5), 1mM EDTA] per gram of 
cells.  Ammonium sulphate was added to a final concentration of 0.2M and samples were 
left at 80°C for 30min for lysis and precipitation to occur.  The samples were cooled to 4°C 
and 100µl aliquots of the supernatant were tested with varying concentrations of 
polyethyleneimine (PEI) ranging from 0-1%. Samples were left overnight at 4°C and 
centrifuged at 14,000g for 10min. Samples were run on a 1% (w/v) agarose gel and an 8% 
(w/v) SDS-PAGE gel.  0.4% (w/v) PEI was found to be optimal and was added to the 
remainder of the sample, which was then left at 4°C overnight.  The sample was spun at 
14,000g for 20min and the supernatant was kept for further purification. 
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Buffer Exchange and Sample Concentration 
 PEI-treated cell lysate was filtered through a 0.22µm pore filter (Millipore, Watford, 
UK) before being transferred to a 10kDa (NMWL) Amicon Ultra-15 centrifugal filter device 
(Millipore, Watford, UK).  The device was centrifuged at 6,000g until the sample was 
concentrated to about 2ml.  The sample was then resuspended in 12ml Buffer A [150mM 
KCl, 50mM Tris (pH 7.5), 0.2% (v/v) Tween 20, 0.1mM EDTA] and centrifuged again to 
concentrate the sample.  Buffer exchange and sample concentration continued until all 
ammonium sulphate and PEI were removed.  The final sample volume was approximately 
2ml.  
 
Protein Purification (Affinity Chromatography) 
 Concentrated protein in Buffer A was filtered through a 0.22µm pore filter 
(Millipore, Watford, UK) before being loaded onto a 5ml Heparin-Sepharose High 
Performance column (GE Life Sciences, Little Chalfont, UK). Protein was purified using 
affinity chromatography with a salt gradient elution from 0% - 100% Buffer B [600mM 
KCl, 50mM Tris (pH 7.5), 0.2% (v/v) Tween 20, 0.1mM EDTA] over 50min at 1ml/min 
flow rate. Protein eluted at approximately 300mM KCl. 1ml fractions were collected and 
samples were analysed on an 8% (w/v) SDS-PAGE gel.  
 
Dialysis and Protein Concentration using Polyethelene glycol 
 Dialysis tubing was prepared as follows: tubing was treated with 2% sodium 
bicarbonate and 1mM EDTA and boiled for 10min; it was then rinsed with ddH2O and either 
used immediately or stored in 20% (v/v) ethanol. Key fractions that were collected during 
protein purification were pooled together and pipetted into a sterile dialysis tube.  The 
dialysis tube was left in a beaker of Polyethylene glycol (PEG) 6000 until the volume of the 
protein sample had decreased by half.  The dialysis tubing was then transferred to a beaker 
of Taq Storage Buffer [100mM KCl, 20mM Tris (pH 8), 0.1mM EDTA, 1mM Dithiothreitol 
(DTT), 0.5% (v/v) Tween 20, 0.5% (v/v) Igepal CA630 (Sigma, Gillingham, UK)] and left 
for a 4h before being transferred to a fresh beaker of Taq Storage Buffer and left overnight at 
4°C to dialyse. Samples were removed from the dialysis tube and stored at 4°C. 
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Polymerase Activity Assay 
 1µM M13 Oligonucleotide (5’CGCCAGGGTTTTCCCAGTCACGACGTTGTA 
AAACGACGGCC) was pre-annealed to 1µg M13mp18 ssDNA template (New England 
Biolabs) in a 1X Taq Buffer (GeneSys, Camberley, UK) total volume 10µl.  Reagents were 
mixed and heated to 95°C for 2min and then cooled (slow ramp speed on PCR machine) to 
72°C for 5min to allow annealing.  Annealed oligo/template was cooled to 4°C before other 
reaction components were added.  Final reaction concentrations were as follows: 1X Taq 
Buffer (GeneSys, Camberley, UK) containing 1.5mM MgCl2, 200µM dNTPs (GeneSys, 
Camberley, UK), 1µg M13 ssDNA, 0.04µM M13 oligo and water up to 45µl.  The reaction 
was kept on ice, 5µl of enzyme was added and the reaction was split into two aliquots of 
24µl.  One aliquot was kept on ice and used as a control/time zero, the other was heated at 
72°C for 10min and then placed immediately back on ice. 75µl of TE [10mM Tris (pH 7.5), 
1mM EDTA)] was added to each aliquot and after mixing 50µl of each reaction was 
transferred to a black flat bottomed 96-well plate (Thermo Scientific, Basingstoke, UK).  A 
1:400 dilution of PicoGreen® (Invitrogen, Paisley, UK) in TE was made and 50µl was mixed 
with each reaction in the 96-well plate. The plate was incubated at room temperature for 
approximately 5min.  The amount of DNA synthesised was quantified using a PHERAstar 
fluorescent plate reader (BMG Labtech, Aylesbury, UK).  Graphical and statistical analysis 
of the data were performed using FigSys (Biosoft, Cambridge, UK). 
 Taq DNA polymerase control assays were performed with commercially available 
Taq (GeneSys, Camberley, UK) at a known Unit6/µl concentration.  These data were used 
for unit estimation of the mutant polymerases.   
 
 
General Methods 
 Standard protein expression was performed as in Chapter 2 but Overnight Express 
auto-induction medium (Novagen, Nottingham, UK) was used instead of LB and cultures 
were left for 24h.   Due to discontinuation of the original electrocompetent cell strain, 
TOP10F’ (Invitrogen, Paisley, UK), NEB 10-β strain was used in all further work. SDS-
PAGE analysis was performed as described in Chapter 2. Protein concentrations were 
measured using the Bradford Assay (BioRad, Hemel Hempstead, UK). 
                                                 
6 One Taq unit is defined as the amount of enzyme that will incorporate 10nmol of dNTP into acid-insoluble 
material in 30min at 75°C.  
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 Standard activity testing using lysate in M13 and 500bpλ PCRs was as described in 
Chapter 2. 
 All DNA sequencing used plasmid DNA as template and was carried out by 
GeneServices (Cambridge, UK). 
  
56 
 
Results 
 
Random Mutagenesis 
 Random mutagenesis was carried out on the polymerase (pol) domain of the Sac7-
TaqPol M8 clone using the GeneMorph® II Random Mutagensis Kit (Stratagene). The 
GeneMorph protocol was followed and the initial target amount of 100ng (equivalent to 
480ng plasmid template) with 25 PCR cycles was used to achieve a low mutation frequency 
(0-4.5 nucleotides/kb).  The product was analysed on an agarose gel (Figure 3.2) with 100ng 
of 1.1kb DNA standard (Stratagene).  
 
 
 
 
 
 
 
 
 
 The random mutagenesis reaction produced product of the correct size (1.7kb) and 
had a good yield.  The 1.7kb corresponds to the expected size of the Taq Pol domain PCR 
insert.  The mutant polymerase domain PCR product and the vector pTTQ18NHK Sac7-
TaqSacB were digested with SalI and BglII.  Digestion of the vector removed the SacB 
domain selective marker (as discussed in Chapter 2) and allowed insertion of the mutant Pol 
domain during cloning.  
 Following initial unsuccessful attempts to ligate and clone the mutated PCR product, 
a large scale purification of pTTQ18NHK Sac7-TaqSacB was carried out using 
PlasmidSelect to produce a good, clean sample of vector. New pol domain primers were also 
designed outside the original Pol domain primers. Investigation of the unsuccessful cloning 
attempts suggested that disruption of the restriction sites might be causing a problem. To 
Figure 3.2 – Random Mutagenesis PCR.  
This gel shows the PCR product of the 
random mutagenesis reaction. (M) 1kb DNA 
ladder, (1) 1.1kb DNA standard (100ng), (2) 
PCR product. 
←1.7kbp product 
 6kb→ 
 3kb → 
    2kb→ 
 1.5kb→ 
    1kb→ 
500bp→ 
M      1        2    
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combat this, random mutagenesis was performed using the outer pol domain primers and the 
PCR product was then subjected to a second amplification with the inner pol domain primers 
to make sure the restriction sites were intact (as they are contained in the primer sequence).  
The amplification was successful and multiple PCR reactions were pooled and purified.  
Both vector and mutant Pol domain were then sequentially digested with BglII and SalI 
before ligation and transformation into Top10F’ cells.  Colonies were screened for pol 
domain insert by PCR as displayed on the agarose gel in Figure 3.3. 
  
 
 
  
 
 
 
 
 The screening PCR showed that 10/10 of the colonies screened had the correct size 
insert and the ligation of the mutant Pol domain had been successful. The ligation was then 
repeated but on a larger scale (600ng total DNA).  Transformants were screened for insert 
and the positive clones were grown up for expression and activity testing. Although the 
majority of the clones expressed protein of the correct size, none of them were active in a 
standard control PCR. Plasmid DNA was extracted from randomly selected clones and 
sequenced.  The mutant polymerase domain sequences were aligned using CLUSTALW and 
the mutation frequency was determined.  Mutations ranged from 6-13 nucleotides per Pol 
domain with an average mutation frequency of 5.6 per kb.  This was slightly higher than 
expected which may explain the low proportion of active polymerase variants observed.  It 
was decided to adjust the mutagenesis rate before proceeding to library construction.   
 Random Mutagenesis was repeated as before with the outer pol domain primers but 
with more initial template (580ng Sac7-TaqPol M8) in order to lower the mutation 
frequency.  Once again all the colonies that were screened contained the correct size insert.  
Sequencing and alignment showed the mutation frequency to be an average of 6.5 nucleotide 
changes per Pol domain which corresponds to a mutation frequency of 3.8 nucleotides per 
kb. These mutations led to an average of 5 amino acid changes per Pol domain. Standard 
 Pol domain 
 ← 1.7kb 
Figure 3.3 – Polymerase domain screening PCR. Ten colonies were 
screened for the presence of  polymerase domain insert. (M) 1kb DNA 
ladder, colonies numbered 1-10, (11) pol domain control. 
    3kb→ 
    2kb→ 
 1.5kb→ 
    1kb→ 
 
500bp→ 
  M     1      2      3     4      5     6      7      8     9    10    11 
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expression and activity testing revealed that most of the selected clones expressed the correct 
size protein and that 20% showed some activity in standard PCR. The percent of active 
clones had increased as desired. This lower mutation frequency mutagenesis reaction was 
used to construct the polymerase variant library used in screening.  
 
Production of the Mutant Library 
 In order to create a large mutant library the transformation was extensively 
optimised to achieve the highest efficiency possible.  The voltage at which the cells were 
electroporated was investigated and 1.8kV was found to be optimal.  The concentration of 
DNA in the electroporation had an effect on the number of transformant colonies produced.  
It was found that transformations with 100ng DNA produced more colonies than if only 1ng 
of DNA was transformed.  The pre-transformation treatment of the ligation reaction was also 
found to be a critical variable.  During optimisation it was found that both ethanol- and 
butanol-precipitated samples showed an approximate 20-25% loss of DNA but that the 
butanol-precipitated ligation had a 10-fold higher efficiency than that of the ethanol-
precipitated ligation.  Butanol precipitation followed by drying of the DNA pellet using a 
SpeedVac was selected for use during library construction. 
 Multiple ligation and transformation reactions were conducted in order to construct 
the mutant library.  Colonies were counted and used to estimate total variant number or 
library size.  A single transformation produced 1x105 colonies on average. A total of 10 
transformations were carried out to produce a final library size of 1x106 variants.  The 
mutant library was then pooled, aliquoted and stored at -80°C.    
 A final characterisation of the library was performed to make sure the ligations were 
successful and the estimated mutation frequency was still accurate.  It was confirmed that 
100% of the 20 clones screened were positive for the Pol domain insert. Sequencing 
confirmed that the mutation frequency of the final library was 4.8 nucleotide changes per kb. 
There was an average of 8.2 nucleotide changes and 6 amino acid changes per pol domain.  
Details of the final library are listed in the table below (Table 3.1).  Standard activity and 
expression tests showed that, while most of the mutant library clones expressed protein of 
the correct size, less than 20% of them showed polymerase activity. 
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Table 3.1 – Characterisation of Final Mutant Library  
(Data collected from 18 mutants) 
 
Range of nucleotide changes seen in mutants  
(per pol domain) 
1-13 
Average nucleotide changes per pol domain 8.2 
Average nucleotide changes per kb 4.8 
Average amino acid changes per pol domain 6.0 
% Transitions 48 
% Transversions 53 
Ts/Tv 0.9 
% Silent Mutations 27 
% Conservative Amino Acid Changes 21 
 
 
Optimization of Emulsion PCR  
 Further optimisation of the emulsion PCR (emPCR) was conducted prior to 
screening the above generated mutant library in the system since it was expected that its 
activity would be much lower than that of wild-type polymerase expressing culture.  A series 
of emPCRs were carried out using not only the mutant library but also different percentages 
of cells expressing the wild-type polymerase. Under the same conditions it was found that no 
amplification was observed by agarose gel electrophoresis using the mutant library cells, 
whereas a high yield was observed with the wild-type cells (Figure 3.4).  The wild-type cells 
were found to still produce a good yield even when the amount of cells was considerably 
decreased (Figure 3.4). 
 
 
 
 
 
  
 M       1        2        3        4       5  
Figure 3.4 – emPCR with varying amounts of E. coli cells. 
The standard amount of cells in an emPCR is 2x108 and this was varied 
in this experiment to see the effect on amplification. (M) 1kb DNA 
Ladder, (1) 2 x108 (100%) mutant library cells, (2) 0.2 x108 (10%) wt 
cells, (3) 0.5 x108 (25%) wt cells, (4) 1 x108 (50%) wt cells, (5) 2 x108 
(100%) wt cells. 
Pol domain 
←1.7kb  
  10kb→  
 
    3kb→ 
    2kb→ 
 1.5kb→ 
    1kb→ 
500bp→ 
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 The emPCR with the mutant library produced no visible amplification.  Using as 
little as 10% of wild-type polymerase cells in an emPCR produced some amplification, 
which could indicate that less than 10% of the mutant library is made up of polymerases that 
are active under the emPCR conditions.  The above experiment indicated that the system 
required further optimisation.  Firstly, to test that the mutant library culture had expressed at 
least a low level of active polymerases, a cell lysate was made and used in a standard 
activity PCR.  The activity of the wild-type and mutant polymerases was compared by 
agarose gel (Figure 3.5).   
 
 
 
 
 
 
 
 The gel showed that the mutant library was producing some active polymerases as 
amplification could be seen in lanes 3-4 (Figure 3.5).  However, as expected the activity 
from the mutant polymerase lysate was much lower than that of the wild-type polymerase 
lysate, presumably due to the relatively low proportion of active variants in the mutant 
library.  
 Further optimisation of the emPCR was done to try to improve overall yield.  Five 
identical emPCRs were run using cells from a wild-type polymerase culture and each was 
run for a different number of PCR cycles ranging from the standard 20 up to 40.  Analysis of 
the emPCR showed that increasing the cycle number did not increase the yield of the PCR 
and in fact, 20-25 cycles was found to produce the most DNA.  This suggested that there 
may be a limiting reagent preventing further amplification beyond 25 cycles.   Several more 
emPCRs were set up and run under standard conditions but with varying either the Mg2+ or 
primer concentration to see if an increase in either improved the PCR yield.  Analysis of the 
emPCRs showed that increasing neither the Mg2+ or primer concentration had a positive 
effect on the yield of the PCR.  However, the addition of 5% DMSO to the PCR, which is 
known to aid in dissociation of the DNA strands in GC-rich templates, was found to 
decrease non-specific binding of the primers and increase overall yield of the PCR.  Next, 
Figure 3.5 – Lysate activity PCR 
Agarose gel displaying the activity PCR using lysate from a 
mutant library and a wild-type culture (M) 1kb DNA ladder 
(NEB), (1) wt, (2) wt, (3) mutant library, (4) mutant library 
  3kb→    
   2kb→ 
 1.5kb→ 
    1kb→ 
500bp→ 
M       1        2       3       4 
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varying the dNTP concentration was tested and, as dNTPs are known to chelate Mg2+, this 
too was varied alongside (Figure 3.6). 
  
  
 
 
 
 
 
 
 
 Analysis of the emPCRs showed that just doubling the dNTP concentration had little 
effect on the PCR; however, when both the dNTPs and Mg2+ were increased the yield of the 
PCR improved significantly.  From this point on it was decided that 500µM dNTPs, 2mM 
MgCl2 and 5% DMSO would be used in the standard emPCR protocol.   
 Two final aspects of the emPCR were tested and they were PCR volume and 
inhibition by oil components. A standard polymerase domain PCR was run and all the 
components of the oil phase (mineral oil, Span 80, Tween 20 and Triton X-100) were spiked 
into the PCR to see if they had an effect.  None of the components had an inhibitory effect 
on the PCR when they were used at equivalent concentrations to those used in an emPCR.   
When three different volume PCRs (50µl, 100µl and 150µl) were run, agarose gel analysis 
showed that their yields differed greatly. The Eppendorf MasterCycler PCR block was not 
designed to heat larger volumes, so a significant decrease in relative yield was seen when a 
150µl PCR was run.  The relative yield of a 100µl PCR was slightly less than that of a 
standard 50µl PCR.  In order to get optimal temperature cycling the emPCRs should be 
aliquoted into volumes less than 100µl.  This information was important because of the large 
volume of each emPCR (600µl) that is initially mixed and is required to be aliqouted prior to 
thermocycling. Despite numerous attempts at optimisation, the use of mutant library cells in 
an emPCR still gave very little, if any, visible yield.  It was decided that a second 
amplification using the emPCR product as template would be needed to produce enough 
DNA to enable cloning after a CSR screen.   
    3kb→ 
    2kb→ 
 1.5kb→ 
    1kb→ 
 
500bp→ 
Figure 3.6 – Optimisation of emPCR. 
Agarose gel displaying emPCR products under various 
dNTP and MgCl2 concentrations (M) 1kb DNA ladder 
(NEB), (1) standard 250µM dNTPs, 1.5mM MgCl2, (2) 
500µM dNTPs, 1.5mM MgCl2 (3) 250µM dNTPs, 2mM 
MgCl2, (4) 500µM dNTPs, 2mM MgCl2. 
Pol domain  
←1.7kb 
M        1        2         3       4  
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CSR Heparin Screen 
 All naturally occurring polymerases that have been characterised have different 
levels of sensitivity to heparin.  As the amount of polymerase in each E. coli cell was 
unknown it was important to calculate the sensitivity of Sac7-TaqPol to heparin in an 
emPCR in order to derive the level of heparin to be used in the CSR screen.  First, a 10x 
dilution series of heparin was tested in an emulsion PCR with wild-type polymerase 
expressing E. coli cells.  The products were analysed on an agarose gel and it was found that 
between 5U/ml and 0.5U/ml of heparin inhibited the PCR (Figure 3.7).  A 2x dilution series 
between the two values was then carried out to find the exact heparin sensitivity threshold 
(Figure 3.8).   
 
 
  
 
 
 
  
 
 
 
 Analysis of the emPCRs showed that PCR within the emulsion containing cells 
expressing wild-type Sac7-TaqPol was inhibited, to the extent that no product could be 
observed by agarose gel electrophoresis, by any concentration greater than 1.25U/ml of 
heparin. Amplification appeared to be completely inhibited at 5 and 2.5U/ml of heparin.  At 
lower concentrations of 1.25 and 0.625U/ml of heparin there was still some inhibition as the 
amplification yield was significantly decreased compared to the no heparin control.  The 
heparin sensitivity results obtained from wild-type polymerase were used as a guideline to 
pick the level of heparin in which to screen the mutant library.  It was decided that the CSR 
Pol domain 
  10kb→   
 
    3kb→ 
    2kb→ 
 1.5kb→ 
 
    1kb→ 
 
500bp→ 
Figure 3.8 – emPCR with 2x dilution series of 
heparin. (M) 1kb DNA ladder (NEB), (1) 
emPCR with 5U/ml heparin, (2) emPCR with 
2.5U/ml heparin, (3) emPCR with 1.25U/ml 
heparin, (4) emPCR with 0.625U/ml heparin, 
(5) no heparin control. 
Pol domain 
←1.7kb 
M      1       2       3       4       5 
  10kb→   
    3kb→           
    2kb→ 
 1.5kb→ 
 
    1kb→ 
 
500bp→ 
Figure 3.7 – emPCRs with 10x dilution 
series of heparin. Agarose gel displaying the 
emPCRs at different levels of heparin.  (M) 
1kb DNA ladder (NEB), (1) emPCR with 
5U/ml heparin, (2) emPCR with 0.5U/ml 
heparin, (3) emPCR with 0.005U/ml heparin, 
(4) no heparin control. 
M         1        2         3        4   
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heparin screen using cells expressing mutant polymerase variants would be run under two 
different concentrations of heparin: 2.5U/ml and 1.25U/ml.  
 Despite the optimisation carried out in the previous section, the yield of an emPCR 
containing the mutant library was very low and the addition of heparin to the emPCR 
produced even further inhibition and reduction in yield of the PCR. A second amplification 
of the emPCR product was needed to produce enough DNA to enable cloning.  Multiple 
emPCRs for each heparin concentration (2.5 and 1.25U/ml) were set up using the mutant 
library and the Outer Pol domain primers.  After thermocycling and extraction, the reactions 
were concentrated and treated with DpnI to make sure any parental DNA was removed.  The 
emPCRs were pooled together and purified but, even after combining multiple emPCRs, no 
product was visible when the samples were run on an agarose gel.  The purified emPCR 
product was concentrated to prepare template for a second standard Phusion PCR using the 
original Pol domain primers.  The PCR products from this second amplification were 
analysed on an agarose gel (Figure 3.9). 
 
 
 
 
 
 
 
 
 
 Product was only observed on the gel in the1.25U/ml heparin emPCR.  In multiple 
attempts, no amplification could be obtained using the 2.5U/ml heparin emPCR as template. 
The second amplification Phusion PCR was repeated with the 1.25U/ml heparin emPCR 
template to produce enough DNA for cloning.   
 
 
 
Figure 3.9 – Second amplification of the heparin emPCR. 
Different amounts of the two concentrated heparin emPCR were used 
as template to re-amplify the polymerase domain.  (M) 1kb marker, 
(1) 5µl of 2.5U/ml template, (2) 1µl of 2.5U/ml template, (3) 5µl of 
1.25U/ml, (4) 1µl of 1.25U/ml, (5) control template. 
M       1      2       3       4      5 
Pol domain 
← 1.7kb 
    3kb→    
    2kb→ 
 1.5kb→ 
    1kb→ 
 
500bp→ 
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Selecting Heparin Resistant Polymerase Variants 
 The mutant polymerase domains that were amplified during the CSR heparin screen 
belonged to those polymerases that were still active under the inhibitory heparin conditions 
of the screen.  In order to further select for the polymerase with the highest resistance to 
heparin, the polymerase domain had to be inserted into a full-length Sac7-TaqPol clone so 
that the whole protein variant could be expressed.  The amplified mutant polymerase domain 
PCR product (from 1.25U/ml of heparin reaction) was cloned into the BglII and SalI site of 
the pTTQ18NHK Sac7-TaqSacB vector following excision of the SacB domain as described 
in Chapter 2.  Subsequent transformation into NEB10-β cells produced the first round 
heparin resistant mutants.     
 A standard expression and activity test was done using 25 of the first round mutants.  
A cell extract was prepared using heat precipitation as standard.  SDS-PAGE gel analysis of 
the heat-treated cell extracts revealed that 80% of the mutants showed strong expression of 
the correct size protein while the remaining 20% showed very little expression of 
polymerase. Standard 500bp λ activity PCRs with the extract revealed that 80% of the 
mutants had polymerase activity, which correlated with the expression results.  The activity 
level observed was significantly higher than that of the starting mutant library, which 
indicated that the screen had successfully selected for active mutants.  
 Next the heparin sensitivity of these mutants was tested in a PCR alongside the 
wild-type.   A cell extract of Sac7-TaqPol was prepared using heat treatment to provide a 
wild-type control.  The extract was then used in an activity PCR using Pol domain primers 
and a range of heparin concentrations.  The PCR reactions were analysed and it was found 
that under standard activity PCR conditions, the reaction was slightly inhibited by 
0.625U/ml of heparin and was completely inhibited by 1.25U/ml of heparin.  The sensitivity 
of the polymerase first round mutants was then tested at similar heparin levels.  A 
comparable level of mutant polymerase extract was used in an activity PCR with four 
different levels of heparin: 0, 0.3125U/ml, 0.625U/ml and 1.25U/ml.  Sac7-TaqPol extract 
was used as a control so that the activity of the mutants could be compared to wild-type.  
The activity of selected mutants in the presence of heparin is shown on the agarose gel 
below (Figure 3.10). 
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Figure 3.10 – Heparin mutant activity in PCR with different concentrations of heparin compared 
to wt. This agarose gel shows a 500bpλ activity PCR with different levels of heparin (a) 1.25U/ml (b) 
0.625U/ml  (c)  0.3125U/ml (d) 0 control. The results from various Heparin resistant mutants are 
displayed alongside wild-type controls. 
    Hep14                Hep19                 Wt        
M   a   b    c   d          a    b   c    d          a   b   c   d 
 
 
  
 
 
 
 
 
 
Figure 3.10 shows that mutants 6, 7, 21 and 22 demonstrate clearly an increased 
resistance to heparin.  These four mutants were able to produce amplification at levels of 
heparin that completely inhibited the wild-type polymerase. Although the remaining mutants 
in the above gel (Figure 3.10) showed polymerase activity in the no heparin control, they did 
not seem to have any increased resistance to heparin compared to the wild-type.   
 A total of forty polymerase variants were tested for activity and increased resistance 
to heparin.  Ten of the active variants were selected for sequencing (GeneServices).  Table 
3.2 shows the amino acid changes of selected hepain resistant mutants isolated in this study 
as well as changes seen in the heparin resistant mutants isolated by Ghadessy et al. (2001). 
Using CLUSTALW 10 sequences were aligned (Figure 3.11) and it was found that the 
mutants contained from 1 to 10 amino acid changes, with an average of two amino acid 
changes per mutant.   
 
 
 
 
 
 
 
 
 
    3kb→    
     
    1kb→ 
500bp→ 
Hep21              Hep22              Hep23 
Hep 6               Hep7               Hep11 
M   a   b    c   d         a   b   c   d         a   b   c   d 
M   a    b   c    d         a   b   c   d         a   b   c   d 
    Hep24                Hep25                 Wt 
M   a   b    c   d          a    b   c    d          a   b   c   d 
    3kb→    
    1kb→ 
500bp→ 
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(Taq DA polymerase numbering7) 
Mutant Amino Acid Changes 
Total Amino Acid 
Changes 
Rounds of CSR 
Hep 7 R630L 1 1 
Hep11 V529A 1 1 
Hep21 
D355G, Y430N, V453T, Y456*, 
F482L, L490Q, L519M, K540M, 
S612I, E713G 
10 1 
Hep22 P550S, T588S 2 1 
Hep35 S409T, G809A 2 1 
Ghaddesy H32 
K340E, Q534R, T539A, V703A, 
R778K 
5 1 
Ghaddesy H948 
K225E, L294P, A454S, L461R, 
D578G, N583S 
6 2 
Ghaddesy H159 
K225E, E388V, K540R, D578G, 
N583S, M747R 
6 3 
* stop codon 
 
                                                 
7 See AppendixC for Sac7-TaqPol and Taq alignment 
8 Patent application WO 2002/022869 A2 
9 Patent application WO 2002/022869 A2 
Table 3.2 – The amino acid changes of selected heparin resistant mutants. 
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TaqPol    270 RAFSERLEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEARGLLAKD 
Hep6  RAFSERLEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEARGLLAKD 
Hep7  RAFSERLEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEARGLLAKD 
Hep11  RAFSERLEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEARGLLAKD 
Hep14  RAFSERLEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEARGLLAKD 
Hep19  RAFSERLEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEAWGLLAKD 
Hep21  RAFSERLEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEARGLLAKG 
Hep22  RAFSERLEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEARGLLAKD 
Hep32  RAFSERLEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEARGLLAKD 
Hep34  RAFSERLEFGSLLHELGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEARGLLAKD 
Hep35  RAFSERLEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEARGLLAKD 
  ***************:*************************************************************** *****. 
 
TaqPol    356 LSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLSAVL 
Hep6  LSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLSAVL 
Hep7  LSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLSAVL 
Hep11  LSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLSAVL 
Hep14  LSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAGERAALSGRLFANLWGRLEGEERLLWLYREVERPLSAVL 
Hep19  LSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLSAVL 
Hep21  LSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLNREVERPLSAVL 
Hep22  LSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLSAVL 
Hep32  LSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLSAVL 
Hep34  LSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLSAVL 
Hep35  LSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAGERAALTERLFANLWGRLEGEERLLWLYREVERPLSAVL 
  *****************************************************: ******************* *********** 
 
TaqPol    442 AHMEATGVRLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKTGKRSTSAAVLEALREAHP 
Hep6  AHMEATGVRLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKTGKRSTSAAVLEALREAHP 
Hep7  AHMEATGVRLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKTGKRSTSAAVLEALREAHP 
Hep11  AHMEATGVRLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKTGKRSTSAAVLEALREAHP 
Hep14  AHMEATGVRLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERILFDELGLPAIGKTEKTGKRSTSAAVLEALREAHP 
Hep19  AHMEATGVRLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKTGKRSTSAAVLEALREAHP 
Hep21  AHMEATGVRLDTA-LRALSLEVAEEIARLEAEVFRLAGHPLNLNSRDQQERVLFDELGLPAIGKTEKTGKRSTSAAVMEALREAHP 
Hep22  AHMEATGVRLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKTGKRSTSAAVLEALREAHP 
Hep32  AHMEATGVRLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKTGKRSTSAAVLEALREAHP 
Hep34  AHMEATGVRLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKTGKRSTSAAVLEALREAHP 
Hep35  AHMEATGVRLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKTGKRSTSAAVLEALREAHP 
  ***********.* **************************:******* **:*************************:******** 
 
TaqPol    528 IVEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQ 
Hep6  IVEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQ 
Hep7  IVEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQ 
Hep11  IAEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQ 
Hep14  IVEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQ 
Hep19  IVEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQ 
Hep21  IVEKILQYRELTMLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYIQ 
Hep22  IVEKILQYRELTKLKSTYIDSLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRSPLGQRIRRAFIAEEGWLLVALDYSQ 
Hep32  IVEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQ 
Hep34  IVEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQ 
Hep35  IVEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQ 
  *.********** *******.***************************************:*********************** * 
 
TaqPol    614 IELRVLAHLSGDENLIRVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQS 
Hep6  IELRVLAHLSGDENLIRVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQS 
Hep7  IELRVLAHLSGDENLILVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQS 
Hep11  IELRVLAHLSGDENLIRVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQS 
Hep14  IELRVLAHLSGDENLIRVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQS 
Hep19  IELRVLAHLSGDENLIRVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQS 
Hep21  IELRVLAHLSGDENLIRVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQS 
Hep22  IELRVLAHLSGDENLIRVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQS 
Hep32  IELRVLAHLSGDENLIRVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQS 
Hep34  IELRVLAHLSGDENLIRVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQS 
Hep35  IELRVLAHLSGDENLIRVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQS 
  ************************************************************************************** 
 
TaqPol    700 FPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAADLMKLAMVKLFPRLEEMGARMLLQVHD 
Hep6  FPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAADLMKLAMVKLFPRLEEMGARMLLQVHD 
Hep7  FPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAADLMKLAMVKLFPRLEEMGARMLLQVHD 
Hep11  FPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAADLMKLAMVKLFPRLEEMGARMLLQVHD 
Hep14  FPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAADLMKLAMVKLFPRLEEMGARMLLQVHD 
Hep19  FPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAADLMKLAMVKLFPRLEEMGARMLLQVHD 
Hep21  FPKVRAWIEKTLEGGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAADLMKLAMVKLFPRLEEMGARMLLQVHD 
Hep22  FPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAADLMKLAMVKLFPRLEEMGARMLLQVHD 
Hep32  FPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAADLMKLAMVKLFPRLEEMGARMLLQVHD 
Hep34  FPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAADLMKLAMVKLFPRLEEMGARMLLQVHD 
Hep35  FPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAADLMKLAMVKLFPRLEEMGARMLLQVHD 
  ************* ************************************************************************ 
 
TaqPol    786 ELVLEAPKERAEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLSAKE----- 
Hep6  ELVLEAPKERAEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLSAKE----- 
Hep7  ELVLEAPKERAEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLSAKE----- 
Hep11  ELVLEAPKERAEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLSAKE----- 
Hep14  ELVLEAPKERAEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLSAKE----- 
Hep19  ELVLEAPKEGAEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLSAKE----- 
Hep21  ELVLEAPKERAEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLSAKE----- 
Hep22  ELVLEAPKERAEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLSAKE----- 
Hep32  ELVLEAPKERAEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLSAKE----- 
Hep34  ELVLEAPKERAEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLSAKE----- 
Hep35  ELVLEAPKERAEAVARLAKEVMEAVYPLAVPLEVEVGIGEDWLSAKE----- 
        ********* *************.***********************          
← Palm 
Palm → ← Thumb 
Thumb → ← Palm            Palm → ← Thumb → ← Palm → 
← Fingers 
Fingers → ← Palm 
Palm → 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.11 – Alignment of the polymerase domain of wild-type Taq and selected  
heparin mutants. Alignment of Taq and 10 selected 1st round heparin mutants was 
performed using ClustalW. Mutations are highlighted in red. * = single fully conserved 
residue, : = conservation of strong groups, . = conservation of weak groups. Thumb, 
finger and palm sub-domains are labelled. 
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Purification of Selected Heparin Resistant Mutants 
The five polymerase mutants, which displayed the most heparin resistance in initial 
PCR tests were grown up, expressed and purified alongside wild-type Sac7-TaqPol.   
An ammonium sulphate precipitation and heat lysis step were performed on the cell lysate to 
remove unwanted E. coli proteins and a PEI precipitation was performed to remove nucleic 
acid from the protein preparation. 100µl aliquots of extract were tested with various 
concentrations of PEI to determine the optimum level for complete removal of the nucleic 
acids while still leaving the protein in solution.  Following this study, 0.4% (w/v) PEI was 
chosen as the optimal level for further PEI treatment.   
 After PEI precipitation, the protein sample underwent buffer exchange to remove the 
PEI and ammonium sulphate that had been previously added during the first steps of 
purification.  The existing buffer was replaced with Buffer A (p.51), which meant that the 
protein sample was ready to be loaded onto a Heparin Sepharose column (GE LifeSciences) 
pre-equilibrated with Buffer A.   All protein samples were purified using affinity 
chromatography with a salt gradient (150-600mM KCl).  Samples that were collected during 
protein purification were analysed on an 8% SDS-PAGE gel.  The purification of heparin 
mutant number 7 is shown in Figure 3.12.   
 
 
 
 
 
 
  
 
 
Analysis of protein fraction showed that the protein eluted off the Heparin 
Sepharose column over a wide range of salt concentrations but yielded very pure protein at 
the expected molecular weight of 99kDa.  Mutant Heparin 7 eluted at approximately 270-
315mM KCl, which can be seen in Figure 3.12 lanes 14-23.  The wild- type Sac7-
TaqPolymerase and all the mutants that were purified eluted at around 300mM KCl.  The 
peak fraction (containing the most protein) from each purification was run on an 8% SDS-
kDa 
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   31 
 
 
   22 
 
 
Figure 3.12 – SDS-PAGE gel of the protein purification of first round heparin mutant 7. (M) 
marker, (1) after (NH4)2SO4/PEI treatment, (2) unfiltered sample, (3) sample loaded on column, (5) 
buffer exchange flow through (FT) 1, (6) buffer exchange FT 2, (7) purification FT 1, (8) 
purification FT 2, (9)-(27) fractions collected sequentially over increasing salt gradient, (28) 
sample loaded on column. 
M    1     2     3    4     5    6    7    8    9   10   11  12  13   14 M  15  16   17   18   19   20   21  22  23  24  25   26   27  28 
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PAGE gel with whole cell extract and the sample that was loaded onto the column for 
purification (Figure 3.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 The protein samples that were loaded onto the Heparin Sepharose column did not 
have a very high concentration of protein as seen in Figure 3.13.  However, after 
purification, the eluted fractions showed concentrated protein of the correct size which was 
estimated to be over 90% pure.  The protein-containing fractions from each polymerase 
variant were pooled together, concentrated and dialysed.  Hep21 had an extremely low yield 
and could not be visualised by SDS-PAGE gel.  
 
Characterisation of Heparin Resistant Variants 
 Following protein purification, the protein concentration of the polymerase variants 
was estimated using a Bradford Assay (Table 3.3). The first-round heparin variants were 
then characterised using a standard polymerase assay and the specific activity of the wild-
type Sac7-TaqPol and the selected heparin mutants was determined (Table 3.3).  No activity 
was detectable with Heparin mutant 21.  
 
 
Figure 3.13 – SDS-PAGE gel of the purification of all polymerase variants and wt. 
Protein samples from key steps in the purification and the final peak fraction of purified protein were 
analysed by 8% SDS-PAGE. Wt Sac7-TaqPol and each variant is labelled above the gel.  The 
samples from each purification are: (1) whole cell extract, (2) loaded sample, (3) peak fraction, 
except in the case of Hep21 where the pure fraction could not be visualised by SDS-PAGE. (M) 
marker.  (T) Pure Taq (no Sac7). 
 
←Taq 
M    1    2   3      1    2   3    M   1    2    3    1   2   M   T 
 WT            Hep7             Hep11    Hep 21 
M    1   2    3     1    2    3   M   T  
Hep22        Hep35 
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Table 3.4 – Percent activity of heparin mutants compared to wild-type. 
(Assays were carried out in 0.01U/ml heparin). 
Table 3.3 – Calculated activity, protein concentration and specific activity 
of wild-type Sac7-TaqPol and first-round heparin variants. 
 
 Activity (U/ml) 
Protein 
Concentration 
(mg/ml) 
Specific Activity 
(U/mg) 
Wild-Type 1310 0.066 19,850±580 
Hep7 2270 0.212 10,700±1250 
Hep11 7100 0.394 18,010±270 
Hep22 7450 0.502 14,870±620 
Hep35 2670 0.450 5,940±1890 
 
 
 Further characterisation was performed and the polymerase activity of the variants 
was compared to that of wild-type Sac7-TaqPol in the presence of the inhibitor heparin.  
Initially, different dilutions of the enzymes were assayed in order to determine the optimal 
concentration for the fluorescent signal to be in range and to ensure that doubling the amount 
of enzyme in the assay gave double the activity.  Once the optimal enzyme concentration 
was established, each variant polymerase was assayed in the presence of heparin.  The 
percent activity with heparin was then calculated based on the 100% activity control10.  
Preliminary data were collected for each mutant at 0.01U/ml heparin (Table 3.4). 
 
 
ame % Activity at 0.01U/ml heparin 
Wild-type 50% 
Hep7 89% 
Hep11 74% 
Hep22 90% 
Hep35 100% 
 
 The initial assays revealed that all the polymerase variants that were tested showed 
increased resistance to heparin compared to wild-type Sac7-TaqPol.  Mutants Hep7, Hep22 
and Hep35 all showed very little inhibition at 0.01U/ml heparin, which was sufficient to 
inhibit wild-type enzyme by 50%.  Due to its specific activity and the results of the earlier 
                                                 
10 100% activity refers to each enzyme in the assay without the presence of inhibitor (zero heparin control). 
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PCR experiments (Figure 3.10), mutant Heparin22 was selected for more extensive 
characterisation. 
 A full characterisation of Heparin22 using the polymerase assay over a range of 
heparin concentrations was carried out alongside the wild-type.  Graphical analysis of the 
assay data was used to determine the level of heparin resistance of each polymerase (Figure 
3.14).  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 Graphical analysis of the polymerase assay data over a range of heparin 
concentrations shows that there is a significant difference in the sensitivity to heparin of the 
wild-type compared to mutant 22.  The IC50 (inhibitory concentration at 50% activity) for 
Mutant 22 was 0.050 U/ml, which is approximately four times higher than that of the wild-
type IC50 of 0.012 U/ml, indicating a substantial increase in resistance to heparin.    
 As well as using PicoGreen to analyse activity, the polymerase assays were run on 
an agarose gel to see if the change in ssDNA to dsDNA could be visualised, thus confirming 
DNA extension and polymerase activity. An assay using the Heparin 22 variant over a range 
of heparin concentrations was run as standard. Instead of mixing the assay with PicoGreen, 
it was loaded straight onto a 0.7% (w/v) agarose gel and the DNA was visualised. Figure 
Figure 3.14 – A graph showing the polymerase activity of wild-type Sac7-TaqPol compared to 
Heparin Mutant 22 in the presence of heparin. 
Wt IC50 – 0.012 U/ml 
Mut 22 IC50 – 0.050 U/ml 
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3.15 shows the expected change in DNA conformation during the polymerase assay.  An 
assay with commercially available Taq DNA polymerase (GeneSys) was also run on the gel; 
the assay was run as standard for 10 min with various concentrations of Taq.   
 
 
 
 
 
  
 
 
 
 
 Analysis of the polymerase assay on an agarose gel showed that there was a shift in 
migration in the DNA as it went from single stranded to double stranded.  In the Taq DNA 
polymerase assay the effect of a higher concentration of enzyme can be seen; as more 
enzyme is added, more double stranded DNA is produced over the 10min time period. In the 
Heparin 22 assay, the affect of heparin can be seen; as the heparin concentration increases 
the amount of dsDNA produced decreases.  At 0.2U/ml of heparin there is almost complete 
polymerase inhibition.  There is only a slight shift in the band in lane 9 (0.2U/ml heparin) 
compared to the time zero control (M13 ssDNA) in lane 10.  These data correspond to that 
found using fluorescent readings of the assay, where only approximately 10% activity was 
seen at 0.2U/ml heparin, and presents a powerful verification of the fluorescence-based 
assay system used.  
 Further characterisation was done by analysing the amino acid changes in each of 
the mutants using the sequencing data previously obtained.  There was a low mutation 
frequency in all the mutants that came through the first-round heparin screen; most only had 
1 or 2 amino acid changes (Table 3.2).  The exception was Heparin21, which showed 
activity in initial PCR tests but had a low yield in purification, showed no detectable activity, 
and had a total of 10 amino acid mutations.  One of the mutations in Hep21 (K540M) was 
very interesting as it had also been mutated in the Ghadessy heparin resistant mutant and is 
found in the DNA binding pocket.  In general, when compared to Heparin resistant mutants 
← dsDNA 
← ssDNA 
Figure 3.15 – Agarose gel of polymerase assay. 
10 min polymerase assays with Heparin 22 over a range of heparin 
concentrations and purified Taq over a range of enzyme concentrations. (M) 
1kb marker, Hep22 with heparin at the following concentrations (U/ml): (1) 0, 
(2) 0.005, (3) 0.01, (4) 0.05, (5) 0.075, (6) 0.1, (7) 0.15, (8) 0.2. (9) Hep22 time 
0 control. (10) Taq time 0 control, (11) 0.125U Taq, (12) 0.25U Taq, (13) 
0.35U Taq, (14) 0.4U Taq.  
 
  10kb→ 
    6kb→ 
    3kb→ 
    2kb→ 
 1.5kb→ 
    1kb→ 
500bp→ 
M      1      2      3      4      5      6      7      8     9     10    11    12     13   14    M 
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that were evolved by Ghadessy (2001) over three rounds of CSR, the first round mutants in 
this study had fewer amino acid changes and no identical mutations were seen amongst the 
mutants.   
 The mutated residues were modelled onto the published structure of Taq DNA 
polymerase (Li et al., 1998: PDB ID-2KTQ), using the Cn3D program, to see if any of them 
came into contact with the DNA or potentially influenced heparin/DNA binding in the DNA 
binding pocket.  The mutated residues are highlighted in Figure 3.16. To follow up the 
extensive polymerase assays carried out with Heparin 22, a closer look at one of the amino 
acid changes in this mutant was performed.   In order to do this, the Taq DNA polymerase 
structure (Li et al., 1998: PDB ID-2KTQ) was visualised using the Cn3D program.  Heparin 
mutant 22 had a residue change (T588S) that was very close to the DNA binding pocket.  
Although T588 is not predicted to bond directly with the DNA template based upon X-ray 
crystallographic structures, it is possible that Heparin has a slightly different binding site 
compared to DNA.  Its location with respect to the location of bound DNA can be seen in 
Figure 3.17.   
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
                                    
R630 
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Figure 3.17 – Taq Polymerase structure showing the location of T588S (one of the 
mutated residues of Heparin 22) (a) The whole Taq Polymerase structure with the 
mutated residue highlighted in yellow and the DNA shown in pink.   The image shows that 
the residue is located in the DNA binding pocket. (b) A close up of the residue highlights 
its close proximity to the DNA strand.   
 
 
 
 
 
 
 
 
 
T588 
75 
 
Discussion 
 
 The data presented in this chapter demonstrate that a system of directed evolution by 
compartmentalised self-replication has been successfully established and employed to 
produce heparin resistant DNA polymerases.  The CSR system, set up in Chapter 2, was 
used to screen a mutant library to demonstrate that it was capable of selecting active heparin 
resistant variants from a pool of mainly inactive polymerases. The process was verified by 
the characterisation of selected Taq DNA pol variants in the presence of heparin to reveal 
the extent of resistance achieved by just a single round of directed evolution.  
 The GeneMorph® II Random Mutagensis Kit (Stratagene) was used to create Taq 
DNA polymerase mutants by error-prone PCR.  A low mutation frequency was decided on 
based on the fact that most directed evolution experiments are carried out to produce 1-4 
amino acid changes per polypeptide (You and Arnold, 1994 and Vichier-Guerre et al., 
2006), although libraries have been screened containing mutants with as many as 20 
mutations per gene (Daugherty et al., 1999).  In general, a low error rate is expected to 
accumulate mostly adaptive mutations, as opposed to a high error rate which will generate 
deleterious mutations (Arnold et al., 2001). A final mutant library was produced containing 
approximately 1x106 mutants with an average of 6 amino acid changes (8.2 nucleotide 
changes) per polymerase molecule.  Analysis of the final library showed that almost 100% 
of the mutant library clones were expressing polymerase but that less than 20% of them were 
active.   These final figures are comparable to the work carried out by Ghadessy (2001) 
where a 107 mutant clone library had an average of 4-5 amino acid mutations per polymerase 
variant and only 1-5% of the resulting mutants were said to be active.   
 In directed evolution, the size of the library to be screened is ultimately limited by 
the screen itself.  In high-throughput in vitro screens such as CSR and phage display, 
libraries of 107 or 108 can be screened successfully (Holmberg et al., 2005).  Genetic 
complementation screening or screens that require 96-well plate activity assays are limited 
to library sizes of 104 or 105 (Henry and Romesberg, 2005). In this project, optimisation of 
ligation and transformation reactions was performed to increase efficiency and aid in library 
construction. Through numerous transformations a library size of 106 was achieved.  The use 
of the CSR high-throughput screen allowed for the relatively easy screening of such a large 
library.   
 Before screening of the library could occur, the emPCR was optimised to account 
for the low level of active polymerases that would be present when the CSR was run with 
the mutant library and in the presence of heparin.  Despite extensive optimisation, a 
secondary amplification of the emPCR was needed to produce enough DNA for cloning. 
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Another key step in the screening of the mutant library was to determine the level of heparin 
to be used in CSR.  It was necessary to use a level of heparin that did not completely inhibit 
the reaction but still allowed some amplification to occur otherwise nothing would come 
through the screen.  E. coli cells containing wild-type Sac7-TaqPol were used in an emPCR 
with various concentrations of heparin to determine the level of heparin inhibition.  It was 
important to run this test in the emPCR with 2x108 cells, exactly as in a CSR screen, because 
different conditions and levels of enzyme may affect the heparin sensitivity.  It was 
concluded that wild-type enzyme was slightly inhibited by 1.25U/ml of heparin and 
completely inhibited by 2.5U/ml of heparin under emPCR conditions.   The first-round CSR 
screen using the mutant library was run in the presence of 1.25U/ml of heparin.  If further 
rounds of directed evolution and CSR were to be undertaken then the level of heparin used 
in the screen would increase each round.  
 The polymerases that were able to replicate their polymerase domain in the presence 
of 1.25U/ml of heparin came through the first round of screening.  Standard activity testing 
of the first-round heparin mutants showed that the percent active clones had increased to 
80% compared to less than 20% in the original mutant library.  This was a good indication 
that the CSR screen was able to pull out the active polymerases from the pool of largely 
inactive polymerases that made up the mutant library.   
 The next step in the verification of the CSR screen came from the characterisation of 
the first-round mutants.  Forty mutants were tested in a set of PCRs over a range of heparin 
concentrations.  The mutants’ sensitivity to heparin was compared to that of wild-type Sac7-
TaqPol and the mutants with the highest heparin resistance were chosen for further 
characterisation.  After scale-up, expression and purification using ammonium sulphate 
precipitation, heat precipitation and PEI precipitation followed by Heparin Sepharose 
affinity chromatography, preliminary polymerase assays were used to investigate the activity 
of each mutant in the presence of 0.01U/ml of heparin. All the mutants tested out-performed 
the wild-type enzyme at 0.01U/ml of heparin, indicating that the CSR screen had been 
successful.   
 Heparin mutant 22 was then taken forward for further study with assays over a range 
of heparin concentrations to determine the percent activity compared to the wild-type.  
Graphical analysis of the data revealed that Heparin22 had a 4-fold increase in resistance to 
heparin compared to the wild-type.  This is a substantial change to observe in a single round 
of directed evolution.  In the similar experiment performed by Ghadessy (2001), it was said 
that an 8-fold increase in resistance had been achieved after one round of CSR, a comparable 
change (Patent application WO 2002/022869).  Had further rounds of CSR been carried out, 
then the 4-fold increase in resistance of the first round mutants would have been built on and 
even more significant changes could have been achieved.  Ghadessy observed further 
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changes of 4-fold in round two and a further 4-fold in round three, leading to a final mutant 
with 130-fold increased resistance to Heparin.   
 When the specific mutations found in the first-round heparin mutants were studied 
further, a large proportion of them were seen to cluster around the DNA binding pocket 
(Figure 3.16), as was also seen with the Ghadessy heparin resistant mutants (Ghadessy et al., 
2001).   In particular, the position of the amino acid change (T588S) in the most well 
characterized mutant, Heparin22, was of interest as it was in the DNA binding pocket of 
TaqDNA pol and is therefore likely to have some influence on Heparin binding in the DNA 
binding site.   Whilst the substitution of Threonine 588 with Serine is a conservative 
substitution, it is envisaged that this alteration in such close vicinity of the predicted heparin 
binding site could have a significant effect on the relative binding of heparin and DNA.  
Although residue T588 has not been shown to have direct interactions with the DNA, its 
close proximity to other residues that do interact with the DNA may have led to a small 
change, which caused a regional affect on DNA/heparin binding.  Although there were no 
identical residue changes in any of the mutants, K540 was mutated in both Heparin21 from 
this study and Ghadessy15 (Table 3.2); it is also situated in the DNA binding pocket, which 
suggests it may be an important residue in conferring heparin resistance.  
 The work presented in this chapter provides clear evidence that the CSR system is 
successfully functioning as a screen for improved Taq DNA pol variants. Starting from a 
mutant library containing a low proportion of active variants, CSR enabled the screening and 
selection of a TaqDNA pol variant with a 4-fold increase in resistance to heparin.  The 
optimisation and verification of the CSR system described in this chapter provide the 
groundwork for the technique to be applied to a novel inhibitor of Taq DNA pol.  The 
inhibitor selected for this work is phytate and the next Chapter describes the attempts to 
evolve phytate resistant mutants of Taq DNA pol by CSR.   
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Chapter Four – Engineering Taq DA polymerase 
resistance to Phytate by CSR 
 
 
Introduction 
 
 Fecal-based PCR assays for the detection of bacterial infection and disease are 
commonly used on veterinary samples (Rajeev et al., 2005) and are becoming more 
widespread in human clinical analysis (Al Amri et al., 2007).  Traditional methods of 
detection require culture-based techniques, which are labour-intensive and far less rapid than 
PCR-based detection.  Although PCR-based diagnostics have obvious advantages, there is 
one key difficulty in fecal-based PCR that stems from the problematic and time-consuming 
removal of PCR inhibitors with the use of phytase or sample processing kits.   
 Phytic acid, also known as inositol hexakisphosphate (IP6), or phytate in its salt 
form, is the main PCR inhibitor found in fecal samples. It is the main store of phosphorus in 
many plant tissues, especially seeds, and is thus highly abundant in soil and animal manure 
(Graf, 1983).  Phytic acid makes up a key component of animal feed and is also highly 
abundant in human diets and human cells (Raboy, 2007); it therefore causes a problem in 
both veterinary and medical fecal-based diagnostics.  
 Phytic acid is a small molecule that contains a 6-C ring with one phosphate group 
attached to each carbon atom.  Each of the 6 phosphate groups has 2 replaceable hydrogens, 
which leads to interactions with various metal ions in the environment and the formation of 
phytate salts (He et al., 2006), which are typically found to form amorphous powders with 
non-stiochiometric atomic ratios (Evans and Pierce, 1982).  An example of a phytate sodium 
salt can be seen in Figure 4.1 along with the most well accepted structure of phytic acid, 
which was proposed by Anderson in 1914.  As a result of its structure and the ionisable 
nature of its six phosphate groups, phytic acid is known to be a highly potent chelator of 
divalent and trivalent metal ions, including Cu2+,  Zn2+, Ni2+, Co2+, Mn2+, Ca2+, Mg2+, Fe2+ 
and Fe3+ (Cheryan, 1980; Maenz et al., 1999).  The binding affinity of phytate with the 
different ions and chemical properties of the resulting phytate-metal chelates vary 
significantly and are influenced by a number of factors including pH (Cheryan et al., 1983; 
Crea et al., 2006).  Various researchers have studied the formation of phytate complexes.  
For example, Luttrell (1993) reported a binding affinity of phytate for Ca2+ under 
physiological conditions of 1.9 x 105 liters/mol.  In a comprehensive study Crea et al. (2006) 
compared the binding characteristics of phytate- Ca2+ and phytate-Mg2+ complexes and 
found them to have broadly similar binding parameters.  In each case they observed 10 
different stable species to form. 
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 In nature, as well as its role as a phosphate store in plants, phytate (IP6) is a regulator 
of many cellular functions in eukaryotes (Shears, 2001).  For example, IP6 plays a role in 
regulating endocytosis by binding to the α subunit of the tetrameric clatherin assembly 
protein AP-2 complex (Beck and Keen, 1991) and has also been observed to bind other 
proteins involved in protein trafficking (Shears, 2001).  Furthermore, it is an activator of 
enzymes conducting DNA repair, is a cellular antioxidant and has been reported to have 
anticancer activity (Vucenik et al., 2004).  It is thought that phytate may have therapeutic 
effects because of its ability to inhibit proteins through metal ion chelation and its 
antioxidant properties.  Among other properties, phytate’s potent chelation of Fe3+ is thought 
to decrease iron absorption in humans and protect against free radical formation (Hawkins et 
al., 1993 and Reddy et al., 1996).   
 The conformation of IP6 has been suggested to mimic the pyranose ring structure of 
heparin and therefore to cause inhibition of heparin-binding proteins through competitive 
inhibition (Vucenik et al., 2004).  Given that heparin is known to bind to polymerases and 
interfere with template/primer interaction (DiCioccio and Srivastava, 1978), it is reasonable 
to hypothesise that phytate may also inhibit in this way, particularly as phytate is known to 
bind a range of other proteins as mentioned above.  
 Although phytate has many important cellular functions, its presence in the human 
diet and its potential negative effects have been open to debate.  Phytate has been shown to 
have an inhibitory effect on the iron absorption or bioavailability of key minerals in the body 
due to its chelating potential (Layrisse et al., 2000, Glahn and Wortley, 2002).  Phytate has 
Figure 4.1 – The structure of phytic acid. (a)  Dodecasodium phytate salt (Pub Chem:CID 
66391). (b) One of the first published structures of phytic acid by Anderson, 1914 (Johnson 
and Tate, 1969) 
 
(a) (b) 
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been said to exacerbate mineral deficiency in developing countries where diets are cereal 
and legume based; this has led to the development of low-phytate crops as some scientists 
believe that a reduction in phytate content of grains could be beneficial (Raboy, 2007).  
However, others argue that in most diets phytate does not cause a significant problem and its 
health benefits out-weigh any negative effects (Shamsuddin, 2008). 
 Although much is known about phytate and its natural role in vivo, its mode of 
action as a PCR inhibitor is still not clear.  The affect of phytate on PCR amplification of 
fecal samples has been studied by Thornton and Passen (2004).  It was found that at levels 
above 0.3mM phytate, PCR was completely inhibited and at lower levels phytate could 
cause non-specific amplification in the PCR.  Although processing samples with phytase 
(50U/ml) prior to PCR was found to reduce inhibition, this did not represent a very 
economic solution to the problem.  Thorton and Passen proposed two ways in which phytate 
may inhibit PCR (1) removing Mg2+ by chelation and (2) changing the ionic composition of 
the PCR through the addition of potentially inhibitory counter-ions from the phytate salts.  
Based on their investigations with different counter-ions, they concluded that phytate 
inhibition was produced by chelation, which means that phytate, not its counter-ions, causes 
inhibition (Thorton and Passen, 2004), although no direct evidence was presented.  As other 
PCR inhibitors such as heparin (DiCioccio and Srivastava, 1978) and components of soil 
(Watson and Blackwell, 2000) are known to inhibit polymerase by binding and competing 
with the DNA template, it is a possibility that phytate may also inhibit in this way.  
 One thing that is certain is that phytate interferes with amplification and causes a 
problem in PCR-based diagnostics.  This chapter will present the results of attempts to 
evolve resistance to PCR inhibition by phytate.  Using the technique of directed evolution by 
compartmentalised self-replication, which has previously been used to evolve polymerase 
resistance to heparin, it was hoped that phyate resistant variants may be evolved to combat 
the problem of phytate inhibition in PCR.   
 Following on from the work in Chapter 3, a mutant library was screened by CSR in 
the presence of the novel PCR inhibitor phytate, the aim being that polymerase variants that 
are able to replicate their own gene under the selective pressure of phytate inhibition come 
through the screen.  A total of two rounds of CSR were carried out with the use of a 
recombination technique called staggered extension process (StEP), described in Chapter 1, 
employed to rediversify the library in between rounds of screening. After two rounds of 
CSR, the phytate resistant Taq DNA pol variants were then characterised and assayed to 
determine the level of phytate resistance compared to the wild-type Sac7-TaqPol.   
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Material and Methods 
 
Emulsion PCR 
 emPCRs were performed as described in Chapter 2, except for the following 
changes to the final concentrations of some of the PCR reagents: 0.5mM dNTPs, 1µM of 
outer pol domain forward and reverse primers (Chapter 3),  and 5% (v/v) DMSO.  emPCRs 
were extracted as standard (Chapter 2).   
 
General Methods   
 DpnI treatment and amplification of emPCR products were as standard (Chapter 3). 
Ligation reactions were performed as standard and butanol precipitated (Chapter 3).  
Screening for pol domain insert was conducted as standard (Chapter 3). 
Standard expression and activity tests were carried out as described in Chapter 2, but with 
the following changes: 30ml of Overnight Express auto-induction medium (Novagen, 
Nottingham, UK) containing kan (50µg/ml) was inoculated and left shaking at 37°C for 24h. 
10ml pellets were harvested by centrifugation and a cell lysate was prepared as standard.  
Glycerol stocks of the 2nd mutant library were made as in Chapter 3. 
Purification and dialysis was carried out as in Chapter 3. 
 
Staggered Extension Process (StEP) 
 StEP was carried out using first-round round phytate mutants as template. 50ng of 
each of 9 mutants were combined to give 450ng total template. The StEP reaction was set up 
with the following final concentrations: 1x Taq Buffer (GeneSys, Camberley, UK) 
containing 1.5mM MgCl2, 200µM dNTPs (GeneSys, Camberley, UK), 25pmol of Pol 
domain forward and reverse primers (Chapter 3), 500ng template, 2.5U Taq DNA 
polymerase (GeneSys, Camberley, UK) and ddH2O to 100µl.  The reaction was 
thermocycled as follows: 94°C for 5min, and 80 cycles of 94°C for 30s and 60°C 5s.  5µl of 
the reaction was removed for agarose gel electrophoresis analysis after 20, 40, 60 and 80 
cycles of the StEP.  
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DpnI Digestion and Secondary Amplification of StEP  
 PCR products from the StEP reaction were treated with 10U of DpnI for 1 h at 37°C 
and then used as template in a secondary PCR.  A Phusion PCR was set up with the 
following final concentrations: 1x Phusion HF Buffer (New England Biolabs, Hitchin, UK), 
200µM dNTPs (GeneSys, Camberley, UK), 25pmol of original pol forward and reverse 
primer (Chapter 3), 1-5µl StEP PCR product template, 5% (v/v) DMSO (New England 
Biolabs, Hitchin, UK), 1U Phusion (New England Biolabs, Hitchin, UK) and ddH2O up to 
50µl.  Reactions were thermocycled as follows: 98°C for 30s, followed by 25 cycles of 98°C 
for 30s, 60°C for 15s, and 72°C for 45s.  5µl of the PCR was analysed on a 1% (w/v) 
agarose gel. 
 
Secondary Amplification of 2
nd
 Round CSR emPCR Product 
 The emPCR product was DpnI treated as standard.  New polymerase domain 
primers were designed: Forward 5’ GCCCCTGGAGGTGGACTTC and Reverse 5’ 
GGATGTGCTGCAAGGCG ATTA.  A PCR using the 2nd round emPCR as template was 
set up with final concentrations as follows:  1x Phusion HF Buffer (New England Biolabs, 
Hitchin, UK), 400µM dNTPs (GeneSys, Camberley, UK), 25pmol of forward and reverse 
primers (GeneSys, Camberley, UK), 1µl template, 5% (v/v) DMSO (New England Biolabs, 
Hitchin, UK), 1U Phusion (New England Biolabs, Hitchin, UK), 1.5mM MgCl2 and ddH2O 
up to 50µl.  Reactions were run following the recommended protocol for 30 cycles.  
 
Polymerase Assay 
 M13 oligonucleotide was pre-annealed to M13mp18ssDNA template (New England 
Biolabs, Hitchin, UK) as described in Chapter 3.  Annealed oligo/template was cooled to 
4°C before other reaction components were added.  Final reaction concentrations were as 
described in Chapter 3.  5µl of enzyme was added to the 45µl of final reaction mixture. After 
mixing, the reaction was divided into 3 aliquots of 15µl.  One aliquot was kept on ice and 
used as a control/time zero, the other two replicates were heated at 72°C for 10min and then 
placed immediately back on ice.  35µl of TE [10mM Tris (pH7.5), 1mM EDTA] was added 
to each aliquot and they were transferred to a black flat-bottomed 96-well plate (Thermo 
Scientific, Basingstoke, UK).  50µl of a 1:400 dilution of Quant-iT PicoGreen® dsDNA 
reagent (Invitrogen/Molecular Probes, Paisley, UK) in TE was then added to each well and 
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mixed with the reaction. The plate was incubated at room temperature for approximately 
5min and the amount of DNA synthesized was quantified and analysed as in Chapter 3.  
 
Thermal Inactivation Assay 
 20µl aliquots of enzyme in 1x Taq Buffer (GeneSys, Camberley, UK) were heated 
on a PCR block at 90°C for set time intervals (0 to 90min) and quenched by immediate 
transfer to ice.  10µl of each aliquot was added to a standard polymerase assay (as above) to 
a final volume of 50µl.  The reaction was split into 3 aliquots of 15µl and polymerase assays 
were run as standard for 10min at 72°C.  Reactions were treated and quantified as in the 
polymerase assay (as above).  
 
Fidelity Assay 
 pFidelity plasmid (based on pUCIQ17 from Frey and Suppmann, 1995) pre-
linearised by digestion with DraII was supplied by GeneSys (Camberley, UK).  A fidelity 
PCR was set up with the following final concentrations: 1x Taq Buffer (GeneSys, 
Camberley, UK) with 1.5mM MgCl2, 200µM dNTPs, 25pmol forward and reverse Cla 
primers (Cla Forward 5’ AGCTTATCG ATGGCACTTTTCG GGGAA ATGTGCG, Cla 
Reverese 5’ AGCTTATCGATAAGCG ATGCCGGGAGCAGACAAGC), 10ng linearised 
pUCIQ17, 1µl of mutant or wild-type Sac7-TaqPol enzyme and ddH2O up to 50µl.  
Reactions were thermocycled as follows: 94°C for 3min, followed by 25 cycles of 94°C for 
10s, 55°C for 30s and 72°C for 5min.  5µl of the fidelity PCR was analysed on a 1% (w/v) 
agarose gel. After pooling multiple PCRs, an aliquot was run on a 1% (w/v) agarose gel next 
to a 3.6kb PCR product Marker (GeneSys, Camberley, UK) to estimate DNA concentration. 
Fidelity PCR products were digested with ClaI (New England Biolabs, Hitchin, UK) as 
recommended and then gel purified using the NucleoSpin Extract II kit (Machery-Nagel). 
Purified products were checked on a 1% (w/v) agarose gel before approximately 100ng of 
the ClaI digested product was ligated (to form circular plasmid) with T4 ligase (Promega, 
Southampton, UK) as recommended.  Ligations were ethanol precipitated, resuspended in 
5µl, and 1µl was transformed into NEB 5α electrocompetent cells (New England Biolabs, 
Hitchin, UK) as described in Chapter 2.  Tranformations were spread onto Met:Amp:Xgal 
(40ug/ml) LB agar plates and incubated overnight at 37°C before blue and white colonies 
were counted.  The error rate was calculated using the following formulae (Frey and 
Suppmann, 1995):  
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• Duplication = log10(yield/template)/log10(2) 
• Fraction white = white colonies/total 
• Calculated error rate = -ln (fraction white)/(duplications x 34911) 
 
 
                                                 
11 LacI gene is 1080bp so there are 349bp phenotypically identified (by blue-white screening) single-base 
substitutions possible within the LacI gene. 
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Results 
 
 
CSR Phytate Screen 
 An initial test to gauge polymerase sensitivity to phytate was performed using a 
standard 500bp λ PCR with Taq DNA polymerase (GeneSys) and purified Sac7-TaqPol 
(from Chapter 3) over a range of phytate concentrations.  The sensitivity to phytate in the 
PCRs was analysed by gel electrophoresis (Figure 4.2).  
 
 
 
 
 
 
 
 
 
 Analysis revealed that in this PCR, Taq DNA pol appeared significantly inhibited by 
250µM phytate and completely inhibited by 500µM.  Although the Sac7-TaqPol PCR yield 
was lower than that of Taq DNA pol, it was only slightly inhibited by 500µM whereas no 
amplification could be seen at this level in the Taq DNA pol PCR.  The results of this PCR 
were used as an initial guideline to select appropriate concentrations for testing phytate 
levels in emPCR.  Four levels of phytate, 500, 250, 100 and 50µM, were selected and used 
in a standard emPCR with E. coli cells.  After extraction of the emPCR, products were 
analysed on an agarose gel alongside a zero phytate control (Figure 4.3). 
 
 
 
Figure 4.2 – A Phytate dilution series with Taq and Sac7-TaqPol. An 
agarose gel showing the results of a 500bp PCR with Taq and Sac7-TaqPol 
over a range of phytate concentrations.  (M) 1kb DNA ladder (NEB), 1 to 9 
indicate phytate concentrations: (1) 2.5mM, (2) 1mM, (3) 500µM, (4) 
250µM, (5) 100µM, (6) 50µM, (7) 10µM, (8) 5µM, (9) zero phytate control.  
    3kb→ 
    2kb→ 
 1.5kb→ 
    1kb→ 
500bp→ 
M   1    2    3   4   5   6    7   8    9    1   2   3   4   5   6   7   8   9  
  Taq                               Sac7-TaqPol 
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 Analysis of the emPCRs over a range of phytate concentrations showed a slight 
inhibition and a decrease in product yield at 500µM phytate.  Although further inhibition 
would have been seen at higher concentrations, 500µM phytate was chosen as the starting 
concentration for the CSR screen due to the fact that producing amplification in the emPCR 
with the mutant library and inhibitor had been difficult during the previous heparin CSR 
(Chapter 3).  It was decided that 500µM phytate was a good level at which to start the CSR 
screen and still achieve some amplification.   
 The mutant library that was produced in Chapter 3 and initially screened for heparin 
resistant Taq DNA pol variants was now used to screen for phytate resistant variants.  To run 
the CSR screen, two sets of emPCRs using cells from the mutant library were run in the 
presence of 500µM phytate.  The first contained 1.5mM MgCl2, which is standard in Taq 
Buffer, and the second contained 2mM MgCl2, as this was seen to improve the PCR yield in 
previous tests (Chapter 3).  After extraction and DpnI treatment, the emPCR was analysed 
on an agarose gel (Figure 4.4). 
 
 
 
 
 
 
 
Figure 4.3 – emPCRs over a range of phytate 
concentrations. (M) 1kb Marker (NEB), (1) 500µM phytate, 
(2) 250µM phytate, (3) 100µM phytate, (4) 50µM phytate, 
(5) zero phytate control.  
M          1           2          3         4          5  
   
    3kb→ 
    2kb→ 
 1.5kb→ 
    1kb→ 
500bp→ 
Pol domain  
←1.7kb 
   
    3kb→ 
    2kb→ 
 1.5kb→ 
    1kb→ 
500bp→ 
Figure 4.4 – emPCR CSR screen with 500µM phytate. An 
agarose gel displaying the resuts of a CSR screen at 500µM 
phytate with the mutant library. The resulting emPCR, with 
outer pol domain primers, produced a 2.1kb product.  (M) 1kb 
DNA ladder, (1) 500µM emPCR with 1.5mM MgCl2, (2) 
500µM emPCR with 2mM MgCl2. 
M            1             2  
←2.1kb product  
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 Gel electrophoresis of the emPCR revealed that a small amount of product at 2.1kb 
was visible in lane 1 (Figure 4.4).  This result was unexpected as all previous attempts using 
the mutant library in an emPCR had produced no visible product (as described in Chapter 3).  
Although the 1.5mM MgCl2 emPCR had yielded visible product, the level of DNA was still 
too low for cloning purposes so a secondary amplification of the emPCR was performed.  
The resulting pol domain PCR product was processed and digested as standard and cloned 
into the SalI and BglII site of the pTTQ18NHK Sac7-TaqSacB vector (as described in 
Chapter 2).  Transformation into NEB 10-β cells produced the first-round phytate resistant 
mutants. 
 
Selecting Phytate Resistant Polymerase Variants  
 The mutant polymerase domains that were amplified during the CSR phytate screen 
belonged to those polymerases that were the most active under the inhibitory phytate 
conditions of the screen.  Once the pol domain was inserted into the full length Sac7-TaqPol 
clone, the whole protein was expressed and further selection of the first-round mutants was 
performed.  
 A standard expression test using 45 mutants revealed that 60% of the mutants 
showed strong expression of the correct size protein with the remainder displaying poor or 
zero expression; some mutants appeared to produce a truncated protein product.  A standard 
activity test revealed similar results, with 50% of the mutants showing polymerase activity, 
which was an increase on the 20% activity seen in the original mutant library.  Further 
selection was performed by PCR to select mutants to progress to the second round of 
directed evolution.  Active mutants were tested in a PCR in the presence of phytate.  The 
sensitivity of the mutants to phytate was compared to that of the wild-type Sac7-TaqPol.  
One mutant that performed well in the PCRs was Phytate10, which is shown in Figure 4.5 
alongside wild-type.  
 
 
 
 
 
M       1        2        3       4       5       1        2       3       4        5  
Figure 4.5 – Phytate PCR comparing sensitivity of wild-type to mutant Phytate 
10. A 500bp λ activity PCR with wt and Phytate 10 over a range of phytate 
concentrations.  (M) 1kb DNA ladder, (1) zero phytate control, (2) 500µM phytate, 
(3) 550µM phytate, (4) 600µM phytate, (5) 650µM phytate.  
   Wild-type                              Phytate10 
    3kb→ 
    2kb→ 
 1.5kb→ 
     1kb→ 
500bp→ 
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Table 4.1 – Residue changes of first-round phytate mutants 
(Taq DNA Polymerase numbering. Coloured boxes indicate 
residues mutated in more than one mutant. * = stop codon) 
 
 Analysis of the phytate activity PCRs revealed that whilst wild-type was still active 
over all four of the phytate concentrations tested, it was seen to be inhibited by all levels of 
phytate compared to the no phytate control.  Phytate 10, however, performed strongly at all 
phytate concentrations and only showed signs of slight inhibition at the highest 
concentration of 650µM.   
 Mutants that performed well in the phytate PCRs were selected for sequencing and 
further study.  Sequencing revealed that mutations ranged from 4-14 nucleotides per pol 
domain with an average of 6.3 changes.  This led to an average of 4.8 amino acid changes 
per mutant.  A few of the residues were mutated in more than one mutant, and these same 
residue changes are highlighted in Table 4.1.  In particular, K540 was mutated in two of the 
selected mutants and had previously been found to be mutated in one of the heparin first-
round mutants as well as the Ghadessy heparin resistant mutant (Table 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               
 
Mutant 
t 
changes 
AA 
changes 
Residue Changes 
Phy1 14 8 
W299C, K 314M, L365R, L459F, 
E473V, L477Q, K508*, K767T 
Phy3 5 4 R476L, L733Q, L781P, V810E 
Phy5 5 5 
L288M, W318*, M444T, E524G, 
I594V 
Phy9 6 6 
W299R, F482L, K540E, E734V, 
K804M, V821A 
Phy10 4 3 K340I, M761V, A814T 
Phy11 6 4 R425W, S575C, R636W, M658T 
Phy26 4 4 P373S, A454V, R492T, S515I, 
Phy36 9 8 
L324M, D371E, K540M, T557R,  
A675P, E721G, A748S, L781V 
Phy42 4 2 P685S, A791T 
Average 6.3 nt 4.8 AA  
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M        1        2       3       4 
Re-diversification and Production of Mutant Library Two 
 After initial selection of mutants from the first-round phytate CSR screen, the 
selected clones were rediversified by the staggered extension process (StEP), a PCR 
shuffling technique.  Rediversification of the pol domain was performed so that a new 
mutant library could be constructed and screened in a second round of CSR. 
 The 9 mutants (Table 4.1) were combined and used as template in a StEP PCR.  
Aliquots of the StEP PCR were analysed on an agarose gel to determine if the full-length 
gene product had been produced (Figure 4.6). 
 
 
 
 
 
 
 
 
 Analysis of the StEP PCR by gel electrophoresis showed that full-length pol domain 
product could be visualized after 40 cycles.  DNA smears can be seen in lanes 2-4 due to the 
large amount of short fragments that were being produced during each cycle.  The yield 
from StEP was low as the process requires multiple cycles to fully extend the gene product 
and therefore growth is not exponential as in standard PCR. 
 Although the StEP had successfully produced full-length product, the yield from the 
StEP PCR was low so a secondary amplification of the product was performed after DpnI 
digestion to remove parental plasmid DNA.  The recombined pol domain StEP PCR product 
was then cloned into the SalI and BglII site of the pTTQ18NHK Sac7-TaqSacB vector (as 
described in Chapter 2).  A large ligation and multiple transformations into NEB 10-β cells 
were performed.  The resulting transformant colonies produced mutant library two, just as 
the original mutant library was produced in Chapter 3.  The second mutant library produced 
from the re-diversification of first-round phytate mutants had a final library size of 5 x104.  
 Mutants from the library were screened for the pol domain insert and it was found 
that not all the colonies tested contained the correct size insert.  Despite multiple gel 
purifications of the pol domain PCR product following StEP and during the cloning 
Figure 4.6 – StEP PCR over 80 cycles. 
An agarose gel displaying aliquots of the StEP PCR after 20 
cycle increments. The production of full-length gene product can 
be visualised. (M) 2-log ladder (NEB), (1) after 20 cycles, (2) 
after 40 cycles, (3) after 60 cycles, (4) after 80 cycles. 
 
    3kb→ 
    2kb→ 
 1.5kb→ 
1.2kb→ 
     1kb→ 
500bp→ 
 
Pol domain  
←1.7kb 
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procedure, it appeared that some fragments of the wrong size had been cloned.  This was due 
to the fact that the StEP PCR would have produced many different recombination fragments 
which may not all have been a full-length polymerase domain.  The process of purification 
and cloning of the StEP pol domain was repeated but 100% insertion of the correct size pol 
domain could not be achieved.  It was decided that the small percentage of clones that 
contained the wrong size insert would not cause a significant problem as they would most 
likely not produce active polymerases and would therefore be lost during the next round of 
CSR.   
 Characterisation of the second mutant library using standard expression and activity 
tests of 15 mutants revealed that 75% of the mutants expressed protein of the correct size 
and 50% showed polymerase activity.  Sequencing data confirmed that the StEP PCR 
reaction had successfully recombined first-round phytate mutants.  All the mutants that were 
sequenced contained combinations of the amino acid changes that were seen in the phytate 
mutants selected for StEP (Table 4.1).   A small number of new mutations were also 
introduced possibly because of DNA template switching.  There was an average of 4.6 
nucleotide changes and 3.4 amino acid changes per mutant in the recombined library (Table 
4.2). It was concluded that a second mutant library had been successfully produced by re-
diversification of selected phytate mutants from the first-round CSR screen. 
 
 
Mutant t changes AA changes 
ML2 (1) 6 3 
ML2 (2) 4 3 
ML2 (3) 3 3 
ML2 (4) 4 2 
ML2 (5) 6 6 
Average  4.6 nt 3.4 AA 
 
 
2nd Round CSR – Screening and Selection  
 A second round of CSR was performed to screen the re-diversified mutant library.  
In this round, the level of phytate was increased from that used in the first round screen.  
Two concentrations, 600µM and 750µM, of phytate were tested in an emPCR; neither 
Table 4.2 – Mutation frequency of selected clones from 
Mutant Library Two produced by StEP 
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produced visible amplification when analysed by gel electrophoresis, so a secondary 
amplification was carried out.  The secondary amplification had to be optimised to achieve 
any visible yield.  New primers around the polymerase domain were designed, the dNTP 
concentration was increased and extra MgCl2 was also added.  After these changes were 
made, the secondary amplification of the emPCR was performed and analysed on an agarose 
gel (Figure 4.7) 
  
 
 
 
 
 
 
  
  
 
 
 Following optimisation, the secondary amplification produced enough product to be 
visualised by gel electrophoresis but only when the 600µM emPCR screen was used as 
template.  750µM phytate proved too high a concentration to use in the CSR screen.  The 
yield of the 600µM PCR was still quite low, so multiple PCRs were run and pooled together 
to produce enough DNA for cloning.  The pol domain was then cloned into the SalI and 
BglII site of the pTTQ18NHK Sac7-TaqSacB vector.  Following cloning and transformation, 
the resulting colonies were screened for the pol domain insert. Approximately 1000 
transformant colonies were produced and 30 of these were screened for insert; 100% of the 
selected colonies had the correct size insert.  These clones represented the second-round 
CSR mutants that had come through the 600µM phytate screen.  
Standard activity and expression tests on the second-round CSR mutants revealed 
that 80% of the mutants that were tested expressed the correct size protein and showed 
polymerase activity.  Next the mutants’ sensitivity to phytate was compared to that of wild-
type in a range of standard 500bp λ PCRs (Figure 4.8). 
 10kb →  
    6kb→  
    4kb→ 
    3kb→ 
    2kb→ 
 1.5kb→ 
     1kb→ 
500bp→ 
Figure 4.7 – Secondary amplification of emPCR 
products during the 2
nd
 round of CSR. 600µM and 
750µM emPCR product was used as template in a 
secondary PCR.  (M) 1kb DNA ladder (NEB), (1) 750µM 
PCR, (2) 600µM PCR product.  
 
M          1           2  
← pol domain 
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Analysis of phytate PCRs revealed that whilst wild-type was almost completely 
inhibited at 800-1000µM, the selected mutants shown in Figure 4.8 were all able to produce 
amplification at all the phytate levels tested.  These initial PCRs demonstrated that selected 
second-round mutants had an increased resistance to phytate compared to the wild-type 
Sac7-TaqPol.  
A total of 50 mutants from the second-round CSR screen were tested for activity and 
increased resistance to phytate.   Fifteen of the second-round mutants were selected for 
sequencing and it was found that there was an average of 5.2 nucleotide and 3.6 amino acid 
changes per mutant.  Two of the mutants were identical to the first-round phytate mutants 
used in the StEP re-diversification procedure; however, as expected, the majority of the 
mutants that were sequenced contained combinations of amino acid changes that were found 
in the first-round mutants that were used to create the second StEP re-diversified library.  
Following phytate PCRs and sequencing, five mutants (Table 4.3) were selected for further 
characterisation.  Figure 4.9 shows the alignment of the polymerase domain of selected 
mutants and wild-type Sac7-TaqPol.  
 
 
 
Figure 4.8 – Selected Round Two mutant PCRs with Phytate. 
Agarose gels displaying the results of PCRs with round two mutants run over a 
range of phytate concentrations. (M) 1kb DNA ladder (NEB), (a) zero phytate 
control, (b) 400µM phytate, (c) 600µM phytate, (d) 800µM phytate, (e) 1000µM 
phytate.  The mutant number is indicated above each set of phytate PCRs.  
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Mutant t changes AA changes Residue changes 
Phy2(2) 5 2 P685S, M761V 
Phy2(19) 6 6 R405Q, R469C, S475F, F495Y, T557R, P792Q 
Phy2(28) 6 5 K340R, P382T, P685S, M761V, A814T 
Phy2(30) 5 3 P685S, M761V, A814T 
Phy2(45) 5 4 K340I, E694D, M761V, A814T 
 
 
The mutated residues from the 5 selected mutants were modelled onto the Taq DNA 
polymerase structure (Li et al., 1998; PDB ID 2KTQ) using Molscript to see if any of them 
came into contact with the DNA or potentially influenced DNA binding.  The mutations did 
not appear to cluster at any one particular location on the Taq DNA polymerase structure 
(Figure 4.10). 
 
Table 4.3 – Residue changes of selected second-round mutants (Taq numbering). 
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Taq                270   RAFLERSEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARG 
Phy2(45)        RAFLERSEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARG 
Phy2(28)        RAFLERSEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARG 
Phy2(30)        RAFLERSEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARG 
Phy2(2)        RAFLERSEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARG 
Phy2(19)        RAFLERSEFGSLLHEFGLLESPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARG 
                         ************************************************************ 
 
Taq                330   GRVHRAPEPYKALRDLKEARGLLAKDLSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEG 
Phy(2)45        GRVHRAPEPYIALRDLKEARGLLAKDLSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEG 
Phy2(28)        GRVHRAPEPYIALRDLKEARGLLAKDLSVLALREGLGLPPGDDPMLLAYLLDTSNTTPEG 
Phy2(30)        GRVHRAPEPYKALRDLKEARGLLAKDLSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEG 
Phy2(2)        GRVHRAPEPYKALRDLKEARGLLAKDLSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEG 
Phy2(19)        GRVHRAPEPYKALRDLKEARGLLAKDLSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEG 
                         ********** *****************************************.******* 
 
Taq                390   VARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLSAVLAHMEATGV 
Phy2(45)        VARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLSAVLAHMEATGV 
Phy2(28)        VARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLSAVLAHMEATGV 
Phy2(30)        VARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLSAVLAHMEATGV 
Phy2(2)        VARRYGGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLSAVLAHMEATGV 
Phy2(19)        VARRYGGEWTEEAGEQAALSERLFANLWGRLEGEERLLWLYREVERPLSAVLAHMEATGV 
                         ***************:******************************************** 
 
Taq                450   RLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKT  
Phy2(45)        RLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKT 
Phy2(28)        RLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKT 
Phy2(30)        RLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKT 
Phy2(2)        RLDVAYLRALSLEVAEEIARLEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKT 
Phy2(19)        RLDVAYLRALSLEVAEEIACLEAEVSRLAGHPFNLNSRDQLERVLYDELGLPAIGKTEKT 
                         ******************* ***** *******************:**************  
 
Taq                510   GKRSTSAAVLEALREAHPIVEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTAT 
Phy2(45)        GKRSTSAAVLEALREAHPIVEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTAT 
Phy2(28)        GKRSTSAAVLEALREAHPIVEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTAT 
Phy2(30)        GKRSTSAAVLEALREAHPIVEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTAT 
Phy2(2)        GKRSTSAAVLEALREAHPIVEKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTAT 
Phy2(19)        GKRSTSAAVLEALREAHPIVEKILQYRELTKLKSTYIDPLPDLIHPRRGRLHTRFNQTAT 
                         *********************************************** ************ 
 
Taq                570   ATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQIELRVLAHLSGDENLI 
Phy2(45)        ATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQIELRVLAHLSGDENLI 
Phy2(28)        ATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQIELRVLAHLSGDENLI 
Phy2(30)        ATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQIELRVLAHLSGDENLI 
Phy2(2)        ATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQIELRVLAHLSGDENLI 
Phy2(19)        ATGRLSSSDPNLQNIPVRTPLGQRIRRAFIAEEGWLLVALDYSQIELRVLAHLSGDENLI 
                         ************************************************************ 
 
Taq                630   RVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEA 
Phy2(45)        RVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEA 
Phy2(28)        RVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAISYEEA 
Phy2(30)        RVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAISYEEA 
Phy2(2)        RVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAISYEEA 
Phy2(19)        RVFQEGRDIHTETASWMFGVPREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEA 
                         *******************************************************.**** 
 
Taq                690   QAFIERYFQSFPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAF 
Phy2(45)        QAFIDRYFQSFPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAF 
Phy2(28)        QAFIERYFQSFPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAF 
Phy2(30)        QAFIERYFQSFPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAF 
Phy2(2)        QAFIERYFQSFPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAF 
Phy2(19)        QAFIERYFQSFPKVRAWIEKTLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAF 
                         ****:******************************************************* 
 
Taq                750   NMPVQGTAADLMKLAMVKLFPRLEEMGARMLLQVHDELVLEAPKERAEAVARLAKEVMEG 
Phy2(45)        NMPVQGTAADLVKLAMVKLFPRLEEMGARMLLQVHDELVLEAPKERAEAVARLAKEVMEG 
Phy2(28)        NMPVQGTAADLVKLAMVKLFPRLEEMGARMLLQVHDELVLEAPKERAEAVARLAKEVMEG 
Phy2(30)        NMPVQGTAADLVKLAMVKLFPRLEEMGARMLLQVHDELVLEAPKERAEAVARLAKEVMEG 
Phy2(2)        NMPVQGTAADLVKLAMVKLFPRLEEMGARMLLQVHDELVLEAPKERAEAVARLAKEVMEG 
Phy2(19)        NMPVQGTAADLMKLAMVKLFPRLEEMGARMLLQVHDELVLEAQKERAEAVARLAKEVMEG 
                         ***********:****************************** ***************** 
 
Taq                810   VYPLAVPLEVEVGIGEDWLSAKE 
Phy2(45)        VYPLTVPLEVEVGIGEDWLSAKE 
Phy2(28)        VYPLTVPLEVEVGIGEDWLSAKE 
Phy2(30)        VYPLTVPLEVEVGIGEDWLSAKE 
Phy2(2)        VYPLAVPLEVEVGIGEDWLSAKE 
Phy2(19)        VYPLAVPLEVEVGIGEDWLSAKE 
                         ****:****************** 
 
← Palm                     Palm → 
← Thumb  
Thumb → ← Palm 
Palm → ← Thumb → ← Palm → ← Fingers 
Fingers → ← Palm 
Palm → 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 – Alignment of the polymerase domain of wild-type Taq and selected 
phytate round 2 mutants.  Alignment of Taq, Phy2(2), Phy2(19), Phy2(28), Phy2(30) and 
Phy2(45) were performed using ClustalW. Mutations are highlighted in red. * = single fully 
conserved residue, : = conservation of strong groups, . = conservation of weak groups. 
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Characterisation of Phytate Resistant Variants 
Five second-round polymerase mutants selected for further analysis were purified 
and further characterised alongside the wild-type Sac7-TaqPol.  A few mutants from the 
first-round screen were also selected for purification; they had not been characterised 
initially but were important as they made up the basis of the StEP re-diversified second 
library as their amino acid changes were carried through to second-round mutants.   
Mutants were purified following the standard procedure used during Heparin mutant 
purification as described in Chapter 3.  Following initial treatment and buffer exchange, the 
protein samples were purified using Heparin Sepharose affinity chromatography, with 
elution over a salt gradient (100-600mM KCl).  Samples collected during the protein 
Figure 4.10 – A structural diagram of the polymerase domain of Taq DA polymerase 
complexed with DA.  Mutated residues from selected second-round variants are labelled. 
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purification were analysed by SDS-PAGE to determine which fractions contained pure 
protein of the correct size.  The purification of Phy2(30) is shown in Figure 4.11 as an 
example. 
 
  
 
 
 
 
 
 
 
 
Analysis of the protein fractions by SDS-PAGE revealed that the peak fraction for 
this particular purification was 15 (Figure 4.11) and the mutant eluted off the Heparin 
column at around 270mM KCl.   All mutants that were purified eluted at around 270-
300mM KCl.  The peak fraction from each purification, along with the whole cell extract 
and the sample that was loaded onto the column for purification, were analysed by SDS-
PAGE (Figure 4.12). 
 
 
 
  
 
 
 
 
M   1   2   3  1   2  3   1  2   3  1   2   3         M  1   2   3   1  2   3   1  2  3    1   2   3          M   1  2  3   
Figure 4.11 – SDS-PAGE gel of the purification of Phy2(30) round two mutant. 
This gel shows the samples collected over the course of  the purification starting 
from the initial sample (1) to the pure polymerase mutant peak fraction (15).  (1)-
(2) sample after initial heat lysis and PEI precipitation, (4) -(6) initial wash/ flow 
through before salt elution gradient, (7)-(18) fractions from elution gradient. 
 
      kDa 
 
      116 
       97 
        66 
 
 
        45 
 
 
        31 
 
 
        22 
 
M    1    2    3    4    5    6    7    8   9   10   11  12   13  14            M   15  16   17   18 
Figure 4.12 – SDS-PAGE gel of the purification of wt polymerase and variants from rounds 
1 and 2 of CSR. Protein samples from key steps in the purification and the final peak fraction of 
purified protein were analysed by 8% SDS-PAGE. Each variant is labelled above the gel; numbers 
1 and 2 indicate the round of CSR in which the mutant was obtained followed by the individual 
mutant number.  The samples from each purification are: (1) whole cell extract, (2) loaded sample, 
(3) peak fraction. (M) marker.  Sac7-TaqPolymerase is indicated by the arrow.  
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Following purification, the concentration of the protein samples was determined 
using the Bradford Assay.  Then, using the standard polymerase assay and samples of a 
known activity, the specific activities of the mutants were determined (Table 4.4).  No 
detectable activity was found in mutants Phy1(9) and Phy2(19).  Two of the second-round 
mutants were selected, based on their performance in preliminary assays, and they were 
characterised further in the presence of phytate.  After initial polymerase assays were 
performed to determine the optimal enzyme level and fluorescent signal, assays were run 
over a range of phytate concentrations.  The percent activity at each phytate concentration 
was then calculated based on 100% activity controls.  Graphical analysis of the data, 
performed as in Chapter 3 for the Heparin mutant Hep22, was used to determine the level of 
phytate resistance of Phy2(30) and Phy2(45) (Figure 4.13). 
 
 
 Activity (U/ml) Protein Concentration (mg/ml) Specific Activity (U/mg) 
Wild-type 2380 0.120 19,850±580 
Phy10 5670 0.343 16,530±1900 
Phy42 1700 0.122 13,970±1400 
Phy2(2) 4350 0.204 21,340±2300 
Phy2(28) 3840 0.130 29,560±2000 
Phy2(30) 3610 0.153 23,620±2000 
Phy2(45) 2800 0.132 21,180±3100 
 
 
 
 
 
 
 
 
 
Table 4.4 – Calculated activity, protein concentration and specific activity of the purified 
polymerase variants. 
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(b) 
Wt IC50 – 360µM 
Phy2(45) IC50 – 750µM 
(a) 
Wt IC50  – 360µM 
Phy2(30) IC50  – 700µM  
Figure 4.13 Graphs showing the polymerase activity of (a) mutant Phy2(30) and  (b) 
Phy2(45) at varying concentrations of phytate.  A polynomial regression curve fit of 
the data was performed. 
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 Graphical analysis of the polymerase assay data over a range of phytate 
concentrations revealed a significant difference in the sensitivity to phytate of the wild-type 
compared to the both Phy2(30) and Phy2(45).  The IC50 (inhibitory concentration at 50% 
activity) for Phy2(30) was 700µM and Phy2(45) was 750µM, both of  which are 
approximately 2 times higher than that of the wild-type enzyme (IC50= 360µM), indicating a 
substantial 2-fold increase in resistance to phytate.  The increased resistance of Phy2(30) to 
phytate was also demonstrated in a 500bp λ PCR over a range of phytate concentrations 
(Figure 4.14). 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 clearly demonstrates that Phy2(30) was able to amplify a 500bp DNA 
template in the presence of phytate at concentrations up to 1250µM, whereas the wild-type 
was inhibited at levels above 750µM.  Increased levels of phytate may even have had an 
enhancing effect on the Phy2(30) mutant PCRs, as seen in lanes 4 and 5 (Figure 4.14).  
These PCRs were repeated numerous times and the same effects were seen in all cases.   
To characterise mutant Phy2(30) further, a thermal inactivation assay was 
performed.  Enzyme aliquots were heated at 90°C for set time periods and the enzyme was 
then tested in a standard polymerase assay.  The percent activity after heating at each time 
point was then calculated; graphical analysis of the data can be seen in Figure 4.15.  The 
wild-type enzyme was slightly more thermostable than the mutant with a t1/2 of 37 min 
compared to a t1/2 of 30 min for mutant Phy2(30).  This indicated that the mutations in 
Phy2(30) did not significantly affect the thermostability of the enzyme. 
 
Figure 4.14 – Wt and Mutant Phy2(30) in a phytate PCR. 
Agarose gels displaying the ability of wt and Phy2(30) to amplify DNA in the presence of 
phytate. PCRs were run over a range of phytate concentrations: (1) zero phytate control, (2) 
250µM, (3) 500µM, (4) 750µM, (5) 1000µM, (6) 1250µM, (7) 1500µM, (8) 1750µM, (9) 
2000µM, (10) 2250µM, (11) 2500µM.  (M) 1kb DNA ladder (NEB). 
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 Lastly, a fidelity assay was run comparing the wild-type Sac7-TaqPol and mutant 
Phy2(30).  In the LacI PCR-based fidelity assay (Frey and Suppmann, 1995), a linearised 
fidelity plasmid was amplified by both enzymes.  Following re-ligation of the plasmid and 
transformation, the number of blue and white colonies were counted and used to estimate 
error rate.  Disruption of the LacI gene, caused by errors introduced during PCR, led to the 
LacI- phenotype (blue colonies) on X-gal plates.   Error rates (Table 4.5) were calculated 
using the formulae provided in the methods section.  It was found that the error rates of the 
two enzymes differed slightly; the mutant was found to be more error prone than the wild-
type enzyme.     
 
 
Enzyme 
Amount of 
template(ng) 
Yield 
(ng) 
Duplications 
White 
colonies 
Total 
Colonies 
Fraction 
of white 
colonies 
Calculated 
error rate 
Wt 20 3000 7.23 727 1027 0.7079 1.37x10-4 
Phy2(30) 20 300 3.91 2300 3423 0.6719 2.92x10-4 
 
 Following characterisation of mutant Phy2(30), the positions of its 3 amino acid 
residue changes (P685S, M761V, A814T) were modelled onto the Taq DNA polymerase 
structure (Li et al., 1998) which was viewed using Cn3D (PDB ID: 3KTQ).  Unlike with the 
mutations seen in the heparin resistant mutants, none of the 3 amino acid changes were close 
Table 4. 5 – Fidelity assay data and calculated error rates of wild-type and Phy2(30). 
Figure 4.15 – Thermal inactivation of wild-type and Phy2(30). 
t½ of wild-type was 36 min compared to t½ of 30 min for mutant Phy2(30) . 
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to the DNA binding pocket of Taq DNA polymerase, although M761V was in close 
proximity to one of the Mg2+ binding sites of the enzyme (Figure 4.16).   
 
Figure 4.16 – M761V the mutated residue of Phy2(30) shown on the Taq 
Polymerase structure (PDB ID: 2KTQ). (a) The large fragment of  Taq 
with the mutated residue highlighted in yellow, the DNA shown in pink and 
grey spheres representing the Mg2+.  (b) A close up of the highlighted 
residue and the Mg2+.  
  
(a) 
(b) 
M761 
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Discussion 
 
 In this chapter, two rounds of directed evolution by compartmentalised self-
replication (CSR) were performed to produce phytate resistant DNA polymerases.  The CSR 
system, which was set up and verified in the previous two chapters, was used with the 
inhibitor, phytate.  After one round of screening against the error-prone PCR library 
produced in Chapter 3, a re-diversified mutant library was produced using staggered 
extension process (StEP), followed by a second round of CSR.  Selected mutants were 
characterised and the extent of phytate resistance achieved after two rounds of CSR was 
determined using polymerase assays. 
 The mutant library that was produced in Chapter 3 was used and screened again in 
this chapter.  Instead of performing CSR in the presence of heparin, as in Chapter 3, the CSR 
screen was run with the addition of phytate.  Initial emPCR experiments testing the 
sensitivity of wild-type Sac7-TaqPol to phytate revealed that 500µM phytate caused slight 
inhibition in the PCR and this was selected as an appropriate concentration to use in the first 
round of CSR.  
 The CSR screen was run with the mutant library in the presence of 500µM phytate.  
The polymerases able to replicate their polymerase domain under the set conditions came 
through the screen and were known as the first-round mutants.   Standard activity testing of 
the first-round mutants showed that the percentage of active clones had increased to 50% 
compared to less than 20% in the original mutant library.  This figure of 50% active clones 
was slightly lower than expected, as in the first round of heparin screening the percent of 
active clones increased to 80%. Nevertheless, the screen had increased the level of active 
clones compared to the pool of largely inactive polymerases that made up the original 
mutant library and thus demonstrated that active variants had been enriched by the process. 
 Sequencing of selected first-round mutants revealed that there was an average of 4.8 
amino acid changes per mutant.  It was found that one amino acid, K540, had been mutated 
in two of the mutants and had previously been found to be mutated in one of the first-round 
heparin mutants as well as a heparin-resistant mutant described by Ghaddessy et al. (2001) 
(Table 3.2).  K540 can be found in the DNA binding pocket of Taq DNA Polymerase and 
has been shown to interact with the DNA template (Li et al., 1998).  It was interesting that 
this residue appeared mutated in a number of selected mutants in independent experiments, 
which suggests that it may be an important residue in conferring inhibitor resistance.   
 Forty-five mutants were tested in PCRs over a range of phytate concentrations and 
their sensitivity to phytate was compared to that of the wild-type.  The mutants that 
performed well in initial PCR screens in the presence of phytate were selected to be taken 
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forward and used in StEP.   The PCR shuffling technique, StEP, was performed to re-
diversify the mutant library through the recombination of the first-round selected clones.  
Shuffling of the first-round selected clones combined multiple mutations that were thought 
to confer phytate resistance and also allowed for different combinations of these positive 
mutations to be explored.  In directed evolution, selection from a random mutagenesis 
library followed by recombination is often employed, as recombination allows for the rapid 
accumulation of beneficial mutations as well as the removal of deleterious mutations from 
the population (Moore et al., 1997: Arnold et al., 2001).   
 A new library of re-diversified mutants was constructed with a final size of 5x104.  
The size of the second library was smaller than that of the original mutant library. The use of 
the re-diversification technique rather than random mutagenesis limited the number of 
possible mutant outcomes so it was therefore deemed not necessary to make such a large 
library. Sequencing of the mutant library revealed that the clones contained mutations from 
the first-round phytate mutants as expected, which verified that StEP had been performed 
successfully.  Activity testing revealed that the new library contained 50% of active mutants. 
 Following re-diversification of the library, a second round of CSR was performed 
using the new library and a higher level of phytate.  The concentration of phytate was 
increased from 500µM to 600µM.  Although the higher level of 750µM phytate was tried in 
the screen, no amplification was achieved as the inhibition must have been too strong for 
any significant portion of the mutant library to withstand and to come through the screen.  
After the 600µM CSR screen, 80% of the second-round mutants showed polymerase 
activity, which was an increase on the 50% activity seen in the second library.  Sequencing 
of 15 mutants revealed there to be an average of 3.6 amino acid changes per mutant. 
 Second-round mutants were tested by PCR over a range of phytate concentrations.  
The mutants’ sensitivity to phytate was compared to that of wild-type by PCR and the 
mutants with the highest phytate resistance were chosen for further characterisation.   After 
purification using Heparin Sepharose affinity chromatography, preliminary polymerase 
assays were performed and the specific activities of the mutants were determined; no 
significant changes to the specific activities were observed. Two mutants, Phy2(30) and 
Phy2(45), were characterised further using polymerase assays over a range of phytate 
concentrations.  Graphical analysis of the assay data revealed that both mutants had a 2-fold 
increase in resistance to phytate compared to the wild-type.  Although a substantial increase 
in resistance was seen, it was not as significant an increase as was seen previously in the 
heparin screen (Chapter 3) after one round of CSR.  In this chapter, two rounds of CSR were 
performed, which was anticipated to produce even more substantial changes in resistance.    
  PCR experiments confirmed the results of the polymerase assays by demonstrating 
that Phy2(30) could withstand phytate concentrations 2-fold higher than wild-type enzyme 
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before amplification was inhibited.  Phy2(30) was able to amplify 500bp DNA at 
concentrations up to 1250µM phytate whereas the wild-type was inhibited at levels above 
750µM.  Increased levels of phytate may even have had an enhancing effect on the Phy2(30) 
mutant PCRs; this could be the result of evolution performed under the selective pressure of 
phytate.  Mutants may have evolved not only to withstand the inhibitory effects of phytate 
but also to require it for efficient PCR.  Phy2(30) was characterised further using thermal 
inactivation and fidelity assays.   
 Thermal inactivation assays under PCR buffer conditions at 90°C revealed the wild-
type to be slightly more thermostable with a t1/2 of 36.8 min compared to a t1/2 of 30.3 min 
for the mutant Phy2(30).  As a comparison, standard published figures for the activity half-
life of Taq DNA pol is 9 min at 97.5°C (Lawyer et al., 1993).  The fusion of the Sac7 
protein onto Taq DNA pol has been shown not to alter the stability of the enzyme (Wang et 
al., 2004).  Given that the CSR selection was performed at high temperatures, it would not 
be anticipated that thermostability would be selected against.  However, thermal assays were 
an important verification to ensure that the unnatural amino acid changes of the mutant had 
not affected this crucial enzyme property.  CSR has been used for the evolution of increased 
thermostability in Taq DNA polymerase simply by increasing the duration of the initial 
denaturation step in the PCR reaction, which allowed for the selection of thermostable 
variants (Ghadessy et al., 2001).  A Taq DNA pol variant was isolated with an 11-fold 
longer half life (t1/2 16.5min) at 97.5°C compared to the wild-type (t1/2 1.5min).  
  Fidelity is another property that could affect the potential utility of the mutant 
enzyme.  Fidelity assays showed the error rate of the mutant to be higher than that of the 
wild-type Sac7-TaqPol enzyme. This can be expected when mutations are introduced into an 
enzyme; however, the fidelity of the mutant enzyme was found to be only slightly higher 
than that of standard Taq DNA polymerase, which has a stated error rate of 2x10-4 (Saiki et 
al., 1988).  The slight increase in the error rate observed is not likely to cause a problem with 
further use of this mutant.  Subsequent rounds of mutagenesis and screening may serve to 
decrease the error rate again.  
Wild-type Sac7-TaqPol was found to have a lower error rate than that reported for 
standard Taq DNA pol, which was not predicted.  Fidelity assays with a Sac7-Pfu 
polymerase fusion protein have shown that Sac7-Pfu maintains the same fidelity as the 
standard Pfu enzyme in PCR (Wang et al., 2004).  Similar assays have not previously been 
conducted using Sac7-Taq, but it has been reported that processivity, which is known to be 
enhanced by the Sac7 protein, may be inversely correlated with its accuracy in nucleotide 
incorporation (Barnes, 1992).  
 Sequencing results revealed Phy2(30) to contain 3 amino acid changes. When these 
mutations were mapped onto the Taq DNA polymerase structure (Figure 4.10) none of them 
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fell in the DNA binding pocket, as had been the case with the Heparin mutations (Chapter 
3).  It was thus not immediately possible to rationalise how the observed mutations had 
affected the enzyme or to make further conclusions regarding the mechanism of phytate 
inhibition.  However, M761V was in close proximity to the Mg2+ binding site of the enzyme 
(Figure 4.16) so it is possible that this mutation may have had an effect on the Mg2+ binding 
of the enzyme by subtly changing the environment in the vicinity of the ion binding site 
instead of affecting phytate-enzyme binding . 
 The structural location of mutation M761V, along with the fact that two rounds of 
CSR only yielded polymerase variants with a 2-fold increase in phytate resistance, may 
indicate that phytate inhibits by metal ion chelation and not competitive inhibition with the 
DNA template.  If this is the case, then in directed evolution by CSR one would expect to 
produce an enzyme with increased metal binding affinity, therefore giving increased 
resistance to metal chelators such as phytate.  The 2-fold increase in phytate resistance 
achieved during two rounds of CSR may have been due to the fact that it is difficult to 
evolve increased metal binding as the residues that have direct contact with metal ions are 
highly conserved (Ador et al., 2004).   
 The work presented in this chapter provides some evidence that the CSR system can 
be used to screen for phytate resistant Taq DNA pol variants. CSR enabled the screening and 
selection of active variants with a 2-fold increase in resistance to phytate.  Whilst the screen 
was able to select active variants, only a two-fold increase in resistance was observed after 
two rounds of CSR.   Despite this result it is possible that the final characterised mutant 
enzyme Phy2(30) (P685S, M761V, A814T) may have potential application in PCR 
amplification in natural phytate-containing samples, such as faecal samples. The actual level 
of phytate in faecal samples is hard to predict as it is dependent on both diet and the 
digestion process.  Ruminant animals, such as cows and sheep, do not completely digest 
phytate (He and Honeycutt, 2001) and animals such as pigs and chickens cannot digest 
phytate at all (Wodzinski and Ullah, 1996); therefore the level of phytate in faecal samples is 
very variable but given its abundance in most animal and human diets its presence in fecal 
samples is certain. 
 In light of the results described in this chapter, the small improvement in resistance 
achieved may have been due in part to the mode of action of the phytate; however, further 
rounds of CSR would need to be carried out before firm conclusions could be made.  Work 
in the next chapter investigates the possible enzyme binding sites of phytate and its chelating 
potential in an attempt to further elucidate the role of phytate in PCR inhibition. 
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Chapter Five – Investigation of the Mechanism of phytate 
Inhibition of PCR 
 
Introduction 
 As previously discussed in Chapter 4, the mechanism of phytate inhibition of PCR is 
not clearly understood.  Although phytate as a compound has been well known and studied 
for years, investigations into its role as a PCR inhibitor have been limited.  One study of 
phytate inhibition in PCR led to the proposal that inhibition occurs through the chelation of 
Mg2+ ions (Thorton and Passen, 2004), which are essential for the polymerase-catalysed 
nucleotidyl transfer reaction (Steitz, 1999).  As phytate is known to be a potent chelator of 
metal ions (Maenz et al., 1999), then chelation is definitely one possible mode of inhibition; 
however, other facts suggest that phytate may inhibit by binding to the enzyme, which must 
be considered as an alternative mode of action.  
 In solution at physiological pH, phytate will carry a strong negative charge due to 
multiple phosphate groups.  As well as forming complexes with metal ions, phytate is able to 
bind directly to proteins through electrostatic charges (Angel et al., 2002).  Although phytate 
is a small molecule, it can self-aggregate into multivalent, macromolecular complexes that 
are proposed to have higher apparent binding affinity to proteins than individual phytate 
molecules (Shears, 2001).  These facts may imply a potential similarity in the mode of action 
between phytate and heparin, the PCR inhibitor discussed in Chapter 3.   We know that 
heparin is negatively charged, forms a helical structure and can form interactions with many 
proteins (Mulloy et al., 1993).  Therefore, it is thought that heparin may inhibit DNA 
polymerase by mimicking the helical and negatively-charged structure of DNA.  The 
conformation of phytate has been suggested to mimic the pyranose ring structure of heparin 
and therefore to cause inhibition of heparin-binding proteins through competitive inhibition 
(Vucenik et al., 2004).  The reverse situation has also been reported, where heparin inhibits 
binding of inositol phosphates causing the inactivation of Ca2+ channels and signal 
transduction events (Tones et al., 1989).  In conclusion, both phytate and heparin may 
inhibit DNA polymerase activity and therefore PCR through competitive binding at the 
DNA primer/template binding site.   
 In work by Ghadessy and collegues (2001), a Taq DNA pol variant was produced 
that had a 130-fold increase in resistance to heparin compared to the wild-type.  This 
heparin-resistant variant had 6 residue changes that clustered in the base of the finger and 
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thumb subdomains, which are regions involved in binding the primer-template duplex. Four 
of the mutated residues actually come in contact with either the primer or template strand in 
the open and closed ternary polymerase-template-primer complex (Li et al., 1998).   As 
heparin is thought to compete with the DNA for binding to the polymerase, the results of this 
study suggest that the heparin-resistance conferring mutations reduced affinity for heparin 
whilst not altering the polymerases binding of DNA (Ghadessy et al., 2001).  The potential 
similarity in the mode of action between phytate and heparin suggests that heparin-
conferring mutations may also confer phytate resistance.  
  Another PCR inhibitor that has been recently investigated is humic acid, which is 
found in soil.  Humic acid is a poorly characterised heterogeneous mixture of phenolic 
compounds, which like phytate, has the ability to complex with metal ions (Zipper et al., 
2003).  A recent investigation by Kermekchiev and colleagues (2009) not only involved an 
investigation into the mode of action of humic acid but also the production of a Taq DNA 
polymerase mutant with resistance to humic acid.  It was proposed that soil could exhibit 
two modes of inhibition, one by affecting the catalytic activity of the DNA polymerase, and 
two by reducing enzyme processivity/speed either directly or by blocking the DNA template.  
In the above study the humic acid resistant mutants showed a stronger affinity to DNA than 
the wild-type Taq DNA pol, which suggests the mutants had a stronger interaction with the 
template and an increased ability to overcome competitive inhibition caused by inhibitors 
(Kermekchiev et al., 2009).  In research of other soil components, inhibitors have been 
observed to bind the DNA polymerase, therefore suggesting polymerase to be the target for 
inhibition (Watson and Blackwell, 2000).  These studies indicate further that binding to the 
DNA polymerase is a key mechanism of inhibition for many naturally occurring PCR 
inhibitory compounds.   
 Kermekchiev and colleagues (2009) showed that the effect of inhibitors, found in 
soil and blood samples, was primarily on the Taq DNA polymerase as inhibition could be 
overcome by the introduction of mutations into the polymerase.  The key residue 708, which 
was mutated to confer resistance, is located on the surface of the protein 40 residues from 
the finger domain which interacts with the incoming template and dNTPs (Li et al., 1998).  
This key residue falls in a ‘hinge’ region that allows movement of the finger domain during 
conformational changes of the enzyme.  Kermekchiev proposes that some PCR inhibitors 
may interact with the surface of the enzyme and slow down the movement of the fingers and 
by mutating residue 708 the effect of the inhibitor can be reduced.   
 Although there are many published crystal structures of KlenTaq and Taq DNA 
polymerase (Korolev et al., 1995; Kim et al., 1995), to date no structures have been 
published with a PCR inhibitor bound, which leaves us to speculate on their apparent 
binding sites.  The crystal structures of the open and closed forms of the large fragment of 
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Taq DNA pol provide crucial information regarding the residues that contact the 
primer/template and dNTP polymerase substrates (Eom et al., 1996; Li et al., 1998).   The 
crystal structures of a phytase-phytate complex (Lim et al., 2000) and the antithrombin-
thrombin-heparin complex (Li et al., 2004), present the natural binding interactions of these 
compounds with their associated enzymes.  Figure 5.1 shows a phytate molecule in the 
active site of E. coli Phytase (Lim et al., 2000).  The available Taq DNA polymerase crystal 
structures, along with the structures of PCR inhibitors, allow some speculation as to inhibitor 
modes of action or possible enzyme binding sites; however, docking studies with inhibitory 
compounds such as heparin and phytate would provide valuable information and further our 
understanding of the mode of action of PCR inhibitors.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 This chapter presents the results of some experiments that attempted to elucidate 
further the potential mode of action of phytate’s inhibition of PCR.  Three possible 
hypotheses were considered: (1) chelation of Mg2+, (2) competitive inhibition by enzyme 
binding, or (3) a combination of (1) and (2).  Mg2+ titration PCRs were carried out to 
investigate phytate chelation in PCR and X-ray crystallography studies were performed in an 
attempt to determine whether phytate binds the DNA polymerase.  Furthermore, as phytate 
also shows some similarities to heparin, site-directed mutagenesis was used to investigate 
whether mutations known to confer heparin-resistance could also confer phytate resistance.  
 
 
Figure 5.1 – Crystal structure of E. coli Phytase complexed with phytate. 
This picture shows a phytate molecule in the active site of the Phytase 
enzyme (PDB ID: 1DKM). Phytate molecule shown in grey, red and green. 
Phytase residues are shown in blue. Hg2+ depicted by white sphere.  
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Methods 
 
Magnesium Titration Phytate PCRs 
 Five sets of 500bp λ PCRs were set up with 0, 100, 250, 500 and 1000µM phytate 
(phytic acid dodecasodium salt hydrate supplied by Sigma, Gillingham, UK).  Each set of 
PCRs was run over a range of Mg2+ concentrations from 0 to 6mM increasing in 0.5mM 
increments.  Final PCR concentration were as follows:  1x Taq Buffer (GeneSys, 
Camberley, UK) with no added MgCl2, 200µM dNTPs, 25pmol of forward and reverse 
500bp λ primers, 1ng λ DNA, 1µl Sac7-TaqPol enzyme (purified in Chapter 4), XmM 
MgCl2, YµM phytate and ddH20 up to 50µl.  Cycling conditions: 94°C for 3min, followed 
by 30 cycles of 94°C for 15s, 55°C for 15s and 72°C for 45s.  5µl was analysed on a 1% 
(w/v) agarose gel.  
 
Buffer Exchange and Analysis of KlenTaq Sample 
 For crystallisation, pure KlenTaq protein sample was supplied by GeneSys 
(Camberley, UK).  The purity of the sample was analysed by 8% SDS-PAGE as standard 
(Chapter 2).  To remove glycerol from the original enzyme storage buffer, a Microcon 
30kDa filter device (Millipore, Watford, UK) was used to perform buffer exchange and also 
protein concentration. The final protein buffer was 50mM KCl, 20mM Tris (pH 8), 0.1mM 
EDTA, 1mM DTT, 0.5% (v/v) Tween 20, and 0.5% (v/v) Nonidet 40.  The Bradford assay 
(BioRad, Hemel Hempstead, UK) was used to estimate the protein concentration of the 
sample. 
 
Crystallisation  
 The Hampton Research pre-crystallisation test was used as recommended with 
~20mg/ml KlenTaq sample to check correct protein concentration and sample homogeneity.   
A crystallisation screen was set up using the hanging drop method with 1µl of protein to 1µl 
of well/reservoir buffer solution; crystals were grown at 16°C. Final crystallisation 
conditions were as follows: 13% (w/v) polyethylene glycol (PEG) 4000, 100mM Tris (pH 
8.5), 200mM MgCl2, and 1mM phytic acid dodecasodium salt hydrate (Sigma, Gillingham, 
UK).  Standard crystallisation buffer for initial crystal growth was as above but without the 
addition of phytate.  Crystals were seeded using seed bead (Hampton Research, Aliso Viejo, 
CA, USA) in order to produce larger single crystals.  
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Crystal Data Collection and Structural Analysis 
 The selected crystal was frozen in a beam of nitrogen at 100K before x-ray diffraction, 
which took place at the Diamond Light Source synchrotron, Oxfordshire, using a 3 Giga 
electron volt light beam.  180 images were taken while rotating the crystal by 1° for each 
image collected.  The data collection was performed by Dr.Susan Crennell.  The structure 
was resolved to 2.45Å and refined to 2.5Å. All structural determination was performed by 
Dr.Susan Crennell and Lisette Meerstein at the University of Bath.  
 
Site-Directed Mutagenesis 
 Site-directed mutagenesis was performed using the QuikChange® Multi Site-
Directed Mutagenesis kit (Stratagene, Cheshire, UK) to introduce multiple residue changes 
into Sac7-TaqPol.  The following mutants of Sac7-TaqPol were created: (1) Ghadessy, 
K611R, D649G, N654S and M781R, (2) Heparin, V600A, T659S, R701L. QuikChange 
mutageneic primers were designed as per Stratagene’s guidelines. 
Heparin mutant primers (Bioneer, Alameda, CA, USA): 
HepV600A - 5’ GAGGCCCACCCCATCGCGGAGAAGATC 
Hep T659S – 5’ AACATCCCCGTCCGCAGCCCGCTTGGG 
Hep R701L – 5’ GAACCTGATCCTGGTCTTCCAGGAGGG 
Ghadessy Mutant primers (Bioneer, Alameda, CA, USA): 
Ghad K611R – 5’ CGGGAGCTCACCAGGCTGAAGAGCACCTAC 
Ghad D649G and N654S – 5’ 
AGTAGCTCCGGTCCCAACCTCCAGAGCATCCCCGTCC 
Ghad M781R – 5’ GCCGAGCGCAGGGCCTTCAACATGCC 
 
 The mutagenesis reactions were performed following the recommended protocol.  
After thermocycling, the reactions were treated with 10U DpnI (Stratagene, Cheshire, UK) 
before being transformed into XL10 gold cells (Stratagene, Cheshire, UK) following the 
Stratagene guidelines. Transformation reactions were spread onto LB/Kan (50µg/ml) agar 
plates and incubated at 37°C overnight.  Ten colonies were selected for culture and plasmid 
prep, and were then sent for sequencing as standard.  If all mutations were not present 
following sequencing, the mutagenised plasmid was used in another mutagenesis reaction 
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with the appropriate primers until all mutations were added.  Mutations from each sequential 
mutagenesis reaction were confirmed by sequencing. 
 
Purification of Site Directed Mutants 
 Protein expression, PEI precipitation and buffer exchange to prepare the protein 
samples for purification were performed as in Chapter 3.  Affinity chromatography using a 
heparin Sepharose column (GE Life Sciences, Little Chalfont, UK) was performed followed 
by dialysis into Taq storage buffer, as described in Chapter 3. 
 
Polymerase Activity Assay 
 The DNA polymerase assays were run and analysed as described in Chapter 4. 
Graphical analysis was performed using the program FigSys (BioSoft, Cambridge, UK). 
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Results 
 
Investigation of Mg
2+
 Chelation in Phytate PCRs 
 As phytate is known to be a potent chelator of divalent metal ions, a set of phytate 
PCRs were performed with the aim to investigate whether phytate chelation of Mg2+ leads to 
inhibition in PCR and to see if this inhibition could be overcome with the addition of extra 
Mg2+.  Five different phytate concentrations were tested, including a zero phytate control, 
over a range of Mg2+ concentrations.  The wild-type Sac7-TaqPol, purified in Chapter 4, was 
used in a range of PCRs as described above and each set of phytate PCRs was analysed by 
gel electrophoresis (Figure 5.2).  
 Analysis of the Mg2+/phytate PCRs revealed that in the zero phytate control PCR, 
amplification could be visualised at all levels of Mg2+ (1-6mM) and as expected no 
amplification was seen when zero Mg2+ was added as it is essential for DNA polymerase 
activity.   In the remaining 4 PCRs there was a general trend, as the level of phytate 
increased so did the level of Mg2+ needed in order to get visible amplification. 
Unexpectedly, at all levels of phytate, amplification could only be visualised over a certain 
range of Mg2+ concentrations.  At 100µM phytate, amplification was seen at 1-2.5mM Mg2+ 
but above this level of Mg2+ it appeared that the PCR was inhibited.  Similar results were 
obtained in the 250µM phytate PCRs where amplification was only visualised between 1-
3.5mM Mg2+, and in the 500µM phytate PCRs where amplification was only visualised at 
1.5-4mM Mg2+.   
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Figure 5.2 – Phytate PCRs over a range of Mg
2+
 concentrations. 
500bp λ PCRs were run with Sac7-TaqPol with 5 different levels of 
phytate: (a) zero, (b) 100µM, (c) 250µM, (d) 500µM, (e) 1000µM.  
Each level of phytate was tested over a range of Mg2+ concentrations 
(the amount in mM is marked above each lane). 
 (a) 
0 Phytate 
(b) 
100µM 
Phytate 
(c) 
250µM 
Phytate 
(d) 
500µM 
Phytate 
(e) 
1000µM 
Phytate 
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Investigation of Phytate/Enzyme Binding by X-ray Crystallography 
 Crystallisation studies were performed in order to investigate whether phytate 
inhibition of PCR was caused by phytate binding to the DNA polymerase.  The enzyme 
polymerase domain, in the form of Klentaq, was crystallised in the presence of phytate to 
attempt to dock the molecule into any binding site(s) within the enzyme structure prior to X-
ray diffraction and polymerase structure determination.   
 A purified KlenTaq DNA polymerase (62.5kDa) sample was provided by GeneSys 
(Appendix C). To check the sample purity and homogeneity, a dilution series of the protein 
was analysed by SDS PAGE (Figure 5.3).   
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 The KlenTaq sample was estimated to be >95% pure when it was analysed by SDS 
PAGE.  A Bradford assay was performed to check the concentration of the sample which 
was calculated as 16mg/ml.  Additives, such as glycerol, that are present in storage buffers 
can hinder crystallisation trials so were removed from the protein sample.  The KlenTaq 
sample was transferred to a glycerol-free storage buffer through buffer exchange to prepare 
it for crystallisation. 
 The Hampton Research pre-crystallisation test was carried out on the KlenTaq 
sample to check for homogeneity and that the sample was in the correct protein 
concentration range needed for crystallisation.  The test indicated that the protein 
concentration may be too low so the sample was concentrated slightly from 16mg/ml to 
20mg/ml. The pre-crystallisation test was repeated and this time crystals started to form after 
a couple of days, which indicated that the protein sample was at a good concentration for 
Figure 5.3 – Purified KlenTaq DA polymerase 
A dilution series of the protein sample was analysed 
by SDS-PAGE.  (M) Marker, (1) ~0.5µg, (2) ~1µg, 
(3) ~2µg, (4) ~3µg. 62.5kDa KlenTaq indicated by 
arrow.  
 
 M                1      2       3       4   
   kDa 
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     97 
     66 
 
 
     45 
 
 
     31 
 
 
     22 
← 
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Figure 5.4 – (a) Photograph of a crystallisation screen plate with hanging drops and (b) 
Klentaq crystal grown in the presence of phytate. 
crystallisation.  As crystals had grown in the pre-crystallisation test buffer B2, it was decided 
to start crystal trials under similar buffer conditions: 0.1M Tris (pH8.5), 0.2M MgCl2, 15% 
(w/v) PEG 4K.  Crystallisation screens (Figure 5.4a) were set up using the hanging drop 
method and through the course of the crystal trials many aspects of the buffer such as pH, % 
PEG and concentration of MgCl2 were adjusted to promote crystal growth. 
 Once the optimal buffer conditions for crystal growth had been established, phytate 
was then added to the buffer and a new set of crystals were grown in the presence of 1mM 
phytate.  Precipitation was observed to occur readily in certain samples. The crystals that 
formed were fairly thin and flat and were either rectangular or leaf shaped.  A few needle 
clusters were also seen.  It was decided to try to seed the crystals to promote the growth of 
larger crystals.  The results of the seeding experiments were very positive with more well-
defined and larger crystal formations.  The final crystals used in X-ray diffraction were thin 
and rectangular in shape with an approximate size of 2.1µm by 5.0µm (Figure 5.4b). 
  
     
   
 
 
 
 
 
 
 
 
 A crystal grown in the presence of phytate was selected for X-ray diffraction. 
During diffraction, 180 images were taken while rotating the crystal by 1° each image.  
Diffraction images, such as the one in Figure 5.5a, were processed using the position and 
intensity of each spot, or reflection from the crystal.  The final structure of Klentaq DNA 
polymerase, crystallised in the presence of phytate, was resolved to 2.5Å and can be seen in 
Figure 5.5b.  Unfortunately, no phytate was visible in the structural data which suggested 
that phytate had not bound to the enzyme. 
(b) (a) 
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Investigation of Phytate Inhibition by Site-Directed Mutagenesis 
 In an attempt to figure out whether the mutations that conferred heparin-resistance 
could also confer phytate-resistance, a set of mutants were produced using  the QuikChange® 
Multi Site-Directed Mutagenesis kit.  The first of these was the Ghadessy mutant (K540R, 
Figure 5.5 – Diffraction images and final Klentaq structure. 
(a) Examples of images obtained from X-ray diffraction. Black dots or Spots 
were produced by reflections from the crystal during diffraction and were used 
in preliminary data analysis. 
(b) The structure of Klentaq DNA polymerase determined by X-ray 
crystallography and resolved to 2.5Å.  Grey spheres indicate Mg2+ ions. 
 
(a) 
(b) 
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D578G, N583S, M747R), which was based on a heparin-resistant Taq DNA polymerase 
variant that Ghadessy and colleagues (2001) produced and which incorporated four amino 
acid changes into the polymerase domain.   The original variant produced by Ghadessy and 
colleagues contained 6 mutations but only those in the polymerase domain were selected for 
use in this project.  The second mutant was created using a combination of amino acid 
changes from heparin mutants in chapter 3 that were located close to the DNA binding 
pocket.  The triple heparin mutant (V529A, T588S, R630L) combined mutations found in 
Hep7, Hep11 and Hep22 (Chapter 3).   
 The site-directed mutants (SDM) were expressed and purified as standard (Chapter 
3) using a Heparin-Sepharose column and affinity chromatography.  Purification samples 
were analysed by SDS-PAGE and it was found that the mutants eluted off the column, as 
expected, at around 300mM KCl.  Key stages in the purification, including the peak elution 
fraction, are shown in Figure 5.6. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 From SDS-PAGE analysis, the protein was estimated to be over 90% pure. 
Following purification, the protein concentration of the site-directed mutants was determined 
using a Bradford assay.  The two mutants were then characterised further using the 
polymerase assay.   The specific activities of the mutants were determined using the standard 
polymerase assay and samples of a known activity (Table 5.1). 
 
M   1    2   3    1    2   3 
Ghad SDM   Hep SDM 
← 
Figure 5.6 – SDS-PAGE gel of key stages in the purification of 
site-directed mutants. Protein samples from key steps in the 
purification and the final peak fraction of purified protein were 
analysed by 8% SDS-PAGE. The samples from each purification 
are: (1) whole cell extract, (2) loaded sample, (3) peak fraction. (M) 
markers.  Sac7-TaqPolymerase is indicated by the arrow. 
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       97 
       66 
 
       45 
 
 
       31 
 
 
       22 
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 Activity (U/ml) Protein Concentration (mg/ml) Specific Activity (U/mg) 
Ghadessy SDM 2563 0.142 18,050 
Heparin SDM 4815 0.159 30,290 
 
  
 After initial polymerase assays were performed to determine the optimal enzyme 
level and fluorescent signal, assays were run over a range of phytate concentrations to 
determine if these mutants, despite being evolved for heparin-resistance, may also exhibit 
phytate-resistance.  The percent activity at each phytate concentration was calculated based 
on 100% activity controls.  Graphical analysis of the data, performed as in Chapters 3 and 4 
for the previous mutants, was used to determine the level of phytate resistance of the 
Ghadessy (Figure 5.7a) and Heparin site-directed mutants (Figure 5.7b).  The wild-type data 
from Chapter 4 were used as a comparison.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1 – The calculated specific activities of site-directed mutants. 
Wt IC50 – 360µM 
 Mutant IC50 – 950µM 
(a) 
Figure 5.7(a) – Graph showing the polymerase activity of Ghadessy site-directed mutant at 
varying concentrations of phytate. A polynomial regression curve fit was performed on the 
data. 
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 Graphical analysis of the polymerase assays over a range of phytate concentrations 
revealed that there was a difference in the sensitivity to phytate of the wild-type compared to 
the Ghadessy mutant.  The IC50 (inhibitory concentration at 50% activity) for Ghadessy was 
950µM, which was almost 3 times higher than that of the wild-type (IC50 of 360µM), 
indicating a substantial 2.6-fold increase in resistance to phytate.  These data indicated that 
the Ghadessy mutations, which had previously been shown to confer heparin-resistance, also 
confers phytate-resistance to some extent.   Analysis of the Heparin site-directed mutant 
revealed that there was a slight difference in its sensitivity to phytate compared to the wild-
type, albeit not statistically significant.  Both the wild-type and the heparin mutant had a 
similar IC50; 360µM and 420µM, respectively.  This revealed that the combination of amino 
acid changes, which were selected from different heparin-resistant Taq DNA polymerase 
variants produced in Chapter 3, did not confer a significant increase in phytate resistance.  
The mutants’ relative sensitivity to phytate was also demonstrated in a 500bp λ PCR over a 
range of phytate concentrations with standard 1.5mM Mg2+ (Figure 5.8). 
 
 
 
Figure 5.7(b) – Graphs showing the polymerase activity of Heparin site-directed mutant at 
varying concentrations of phytate. A polynomial regression curve fit was performed on the 
data. 
Wt IC50 – 360µM 
Mutant IC50 – 420µM 
 
(b) 
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 Figure 5.8 clearly demonstrates that the Ghaddesy mutant was able amplify 500bp 
DNA at phytate concentrations up to 2250µM whereas the wild-type was inhibited at levels 
above 750µM.  These results corresponded to the polymerase assay data, where a 3-fold 
increase in phytate-resistance was observed with the Ghadessy mutant.  The Heparin mutant 
was able to amplify 500bp DNA in concentrations up to 1000µM phytate, which was a slight 
improvement on the wild-type, but no substantial change in resistance was observed, which 
once again corresponded to polymerase assay data. 
 To characterise the Heparin site-directed mutant further, a series of heparin 
polymerase assays was performed to see if the 3 mutations (V600A, T659S, R701L) selected 
from different heparin-resistant Taq DNA pol variants (Chapter 3) demonstrated increased 
heparin-resistance when all the amino acid changes were combined in one mutant.  Although 
the mutant had been previously tested with phytate and only demonstrated a minor increase 
in phytate-resistance, the mutations were originally selected based on their ability to confer 
heparin-resistance and therefore the mutant’s sensitivity to heparin was tested.  Polymerase 
assays were run as standard over a range of heparin concentrations and graphical analysis of 
the data was performed as in Chapter 3 (Figure 5.9). 
Figure 5.8 – Wt and site-directed Heparin and Ghadessy mutants in a phytate PCR. 
Agarose gel displaying the ability of the wt and the mutants to amplify DNA in the presence of 
phytate.  PCRs were run with a standard 1.5mM Mg2+ over a range of phytate concentrations: (1) 
zero phytate, (2) 250µM, (3) 500µM, (4) 750µM, (5) 1000µM, (6) 1250µM, (7) 1500µM, (8) 
1750µM, (9) 2000µM, (10) 2250µM, (11) 2500µM.  (M) 1kb DNA ladder (NEB). 
M    1     2     3     4     5     6     7     8     9    10   11 M     1      2     3    4     5     6     7     8     9   10   11 
1000µM 2250µM 
Heparin Mutant Ghadessy Mutant 
M    1      2     3    4     5     6    7     8     9    10    11 
Wild-type  
750µM 
    3kb→ 
    2kb→ 
 1.5kb→ 
    1kb→ 
500bp→ 
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 Graphical analysis of the polymerase assay data over a range of heparin 
concentrations revealed that there was a difference in the sensitivity to heparin of the wild-
type compared to the Heparin mutant.  The IC50 of the heparin mutant, 0.026U/ml, was 
double that of the wild-type IC50 of 0.012U/ml.  This revealed that the combination of amino 
acid changes selected from different heparin-resistant Taq DNA pol variants, conferred a 2-
fold increase in heparin resistance; however, the increase in resistance was not as significant 
as the 4-fold resistance achieved in Heparin mutant 22 (Chapter 3). 
Figure 5.9 – A graph showing the polymerase activity of wild-type Sac7-Taq Polymerase 
and the site-directed Heparin mutant over a range of heparin concentrations. A first-order 
decay with residual curve fit was performed on both sets of data. 
Wt IC50 – 0.012U/ml 
Mut IC50 – 0.026U/ml 
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Discussion 
 
 In this chapter a number of experiments are described which attempted to elucidate 
the mode of action of phytate inhibition of PCR, which was initially hypothesised to occur in 
three ways: (1) chelation of Mg2+, (2) competitive inhibition by enzyme binding, or (3) a 
combination of (1) and (2).  Experiments were performed in three areas to investigate 
phytate inhibition: (a) the chelation of Mg2+ ions, which are essential for Taq DNA 
polymerase activity, (b) binding of phytate to the polymerase as evidence of competitive 
and/or non competitive inhibition, and (c) the ability of heparin-conferring mutations to also 
confer phytate resistance. 
 Mg2+ titration experiments over a range of phytate concentrations revealed some 
important findings.  They provided strong evidence that chelation of Mg2+ ions by phytate 
leads to a decrease in the availability of Mg2+ to the extent that polymerase activity and thus 
PCR amplification are inhibited.  It was found that at each level of phytate tested, addition of 
Mg2+ to a certain critical level was able to overcome inhibition and thus to permit 
amplification.  As the level of phytate increased, so did the level of Mg2+ needed in order to 
achieve PCR amplification.  PCRs at all different levels of phytate tested, started working at 
a critical point (Figure 5.2), where the relative level of Mg2+ was in excess of  the predicted 
number of ion binding sites within each phytate molecule, assuming that approximately 5-6 
Mg2+  ions bind to each phytate molecule.  The ability of phytate to inhibit the PCRs below 
the critical level of Mg2+ provides strong evidence that the phytate-Mg2+ binding affinity is 
stronger than that of the enzyme-Mg2+ binding affinity, therefore allowing phytate to bind 
Mg2+ preferentially over the enzyme.   
 Thorton and Passen (2004) speculated that phytate’s mode of inhibition was 
primarily by chelation of Mg2+; however, the investigation reported herein presents the first 
experimental evidence that this is the case.  The findings imply that the problem of phytate 
inhibition in experimental samples (e.g. for diagnostic applications) can be overcome to 
some extent by addition of Mg2+ at a level in excess of the critical point, at least over the 
range of phytate concentrations tested (0-1mM). 
 Unexpectedly, it was found that as the Mg2+ level was increased significantly above 
the relative number of phytate ion binding sites the PCRs were again inhibited.  This 
contrasted with the zero phytate control PCRs which worked over all the Mg2+ levels tested, 
with an optimal concentration of 1.5-3mM.  At 100µM phytate, amplification could be seen 
at 1-2.5mM Mg2+ but above this level of Mg2+ PCR was inhibited (Figure 5.2b).  As Mg2+-
phytate complexes are known to exist in a complex mix of up to ten different chelate species 
in solution (Crea et al., 2006), it is possible that one or more of these species may be a 
123 
 
potent inhibitor of the enzyme and at a certain ratio of Mg2+ to phytate. If this is the case at 
this point, the mode of inhibition moves from chelation to enzyme binding, which would 
explain the drop off in activity seen in the phytate PCRs above a certain Mg2+ level (Figure 
5.2 b,c and d).   The makeup of the different phytate-Mg2+ species in solution is known to be 
affected by variables such as pH and the presence of other ions in solution (Cheryan et al., 
1983; Crea et al., 2006).  The results of the investigation reported in this chapter indicate the 
complexity of the phytate-Mg2+ interaction and have important implications for phytates’ 
role in PCR inhibition.  
 Following Mg2+ titration PCRs, the potential mechanism of phytate PCR inhibition 
in the form of phytate-enzyme binding was investigated. Crystallisation screens were carried 
out in the presence of phytate in an attempt to dock the molecule into the enzyme KlenTaq, 
prior to X-ray diffraction.  Although the structure of KlenTaq has been published (Korolev 
et al., 1995), it has never been crystallised in the presence of an inhibitor to date.  Flat 
rectangular crystals were successfully produced in phytate containing buffer and X-ray 
diffraction data were collected and analysed.  The KlenTaq structure was resolved to 2.5Å 
but no phytate was found bound to the enzyme.   
 There are a number of reasons why phytate may not have been visible in the 
structural data.  The first is that phytate does not bind the Taq DNA pol polymerase domain 
(KlenTaq) and therefore does not inhibit PCR by competing with the template for binding to 
the enzyme. The second explanation is that phytate may not bind very strongly to the 
enzyme as it has no high affinity binding site.  In this case, phytate may have been bound in 
a number of different places on the enzyme but not always in the same orientation.  
Structural data would not have picked up the ‘low occupancy’ of phytate if it bound in 
numerous places on the enzyme at a low frequency.  The third possibility is that all available 
phytate formed a chelate with the Mg2+ (Cheryan et al., 1983; Crea et al., 2006) present in 
the crystallisation buffer and was therefore not accessible for enzyme binding.  As discussed 
previously, the formation of phytate-Mg2+ complexes is extremely complicated and is 
affected by a number of variables. Further studies involving the ‘soaking’ of crystals in 
different phytate concentrations to increase the chances of phytate, or solution chelates of 
Mg2+-phytate, docking to the enzyme should be performed in order to give a definitive 
answer as to whether phytate does or does not bind the Taq DNA pol polymerase domain 
(Klentaq).  
 This chapter also described an investigation into the ability of heparin-resistance 
conferring mutations to also confer phytate resistance.   Using site-directed mutatgenesis, 
two mutants were successfully produced which contained mutations previously found to 
confer heparin-resistance.  The two mutants were purified and characterised in polymerase 
assays.  The Ghadessy mutant (K540R, D578G, N583S, M747R), based on a heparin-
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resistant Taq DNA pol variant produced by Ghadessy (2001), incorporated 4 amino acid 
changes into the polymerase domain.  These 4 mutations were chosen, out of 6 in the 
original mutant, as they fell in the polymerase domain, which was the main focus of directed 
evolution in this project; they were also thought to confer most of the heparin-resistance as 
they were clustered in the DNA binding region of the polymerase (Ghadessy et al., 2001).  
Polymerase assays over a range of phytate concentrations revealed that the Ghadessy mutant 
had a significant 2.6-fold increase in phytate- resistance compared to the wild-type (Figure 
5.7).  This was interesting as, despite being evolved for heparin-resistance, the Ghadessy 
mutant also exhibited phytate-resistance. The results of the polymerase assay were supported 
by a phytate PCR (with 1.5mM Mg2+) in which the Ghadessy mutant was able to amplify at 
concentrations of 2250µM phytate compared to the wild-type which was inhibited at 
concentrations above 750µM (Figure 5.8).  
 Although a small but significant increase in phytate-resistance was seen with the 
Ghadessy mutant, it was not as significant as the 130-fold increase in heparin resistance that 
Ghadessy and colleagues (2001) managed to produce over 3 rounds of evolution with their 
mutant (Table 3.2).  This suggests that phytate probably does not bind the enzyme 
specifically at the heparin binding site within the DNA binding pocket.  The observed 
increase in phytate resistance may be due to an increased metal binding affinity which 
evolved in part with the heparin resistance. In some cases heparin has been observed to 
chelate metal ions (Shin et al., 2006; Whitfield and Sarkar, 1992) and it may be this 
mechanism that is shared by heparin and phytate, although to different extents, that has 
caused evolved heparin-resistance mutations to confer phytate resistance.  Recent work by 
Kermekchiev et al.(2009) revealed that a single amino acid change in Taq DNA pol can 
confer resistance to inhibition by both blood and soil, which may indicate a common 
mechanism between certain inhibitors found in soil and blood.   
 This experiment provides some evidence that the heparin evolution of the Ghadessy 
mutant has increased ion binding affinity to some extent.  The results of the Ghadessy 
phytate PCR (Figure 5.8) show that the mutant was able to produce amplification in levels of 
up to 2250µM phytate with only 1.5mM Mg2+.  However, in the initial Mg-titration 
experiments (Figure 5.2), when only 1.5mM Mg2+ was added to the PCR, the wild-type 
enzyme was inhibited at 1000µM phytate due to a lack of available Mg2+.   The fact that the 
Ghadessy mutant can produce amplification at such high relative levels of phytate implies 
that the enzymes binding affinity for Mg2+ has increased above the affinity of phytate-Mg2+ 
and the mutant is therefore able to overcome the chelating potential of phytate.   
 The second site-directed mutant was created using a combination of 3 amino acid 
changes selected from the heparin mutants in Chapter 3.  The triple heparin mutant (V529A, 
T588S, R630L) was tested in a polymerase assay over a range of phytate and heparin 
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concentrations to see if (a) the heparin mutations conferred phytate resistance and (b) the 
combined effect of the selected heparin mutations had enhanced the heparin-resistance of the 
enzyme in comparison to the original heparin mutants (Chapter 3).  Polymerase assays over 
a range of phytate concentrations revealed that there was a slight difference in the sensitivity 
to phytate of the heparin site-directed mutant compared to the wild-type (Figure 5.7).  The 
difference in sensitivity to phytate was not statistically significant, however, and this was 
supported by results of phytate PCRs.  The heparin mutant was able to amplify in up to 
1000µM phytate whereas the wild-type was only able to produce amplification in 
concentrations up to 750µM phytate (Figure 5.8).   These results demonstrate that in this 
case the selected heparin-resistance conferring mutations did not confer any significant 
phytate resistance.   
 The heparin mutant was then tested in polymerase assays over a range of heparin 
concentrations.  The assays revealed that the mutant had a 2-fold increase in heparin 
resistance compared to the wild-type.  Although an increase in resistance was observed, it 
was not as significant as the 4-fold increase in resistance achieved with mutant Heparin 22 in 
Chapter 3.  These results indicated that the particular set of amino acid changes selected for 
the site-directed heparin mutant did not increase the heparin-resistance of the mutant beyond 
that which had already been achieved by evolution in Chapter 3.  These results also suggest 
that the mutation P550S, or the combination of P550S and T588S, was key to conferring 
heparin resistance in heparin 22 since P550S was not selected for the site-directed mutant; 
this led to a smaller increase in heparin-resistance being observed in the site-directed mutant 
compared to the directed evolution Hep 22 mutant.   As it is extremely difficult to predict the 
effects of amino acid changes, the results of this site-directed experiment were not entirely 
surprising.  
 The work in this chapter provides some evidence that phytate most likely causes 
PCR inhibition through the chelation of essential Mg2+ ions.  Mg-titration PCRs showed that 
the negative effects of phytate inhibition of PCR can be overcome by the addition of extra 
Mg2+ to the PCR; they also served to illustrate the true complexity of the Mg2+-phytate 
interaction.  KlenTaq-phytate docking studies did not provide any evidence that phytate or 
its Mg2+ chelation species bind directly to the enzyme, at least not with high affinity or with 
high specificity.  Finally, site-directed mutagenesis studies showed that heparin-resistance 
evolved mutations can in some part also confer phytate resistance, which may be a result of 
increased Mg2+ binding affinity overcoming the chelating potential of both heparin and 
phytate.  Further studies would be needed to clarify and fully understand the mode of action 
of phytate inhibition. 
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Chapter Six – Perspectives and Future Work 
 
Overview 
 This project reports the establishment of a high-throughput system for the directed 
evolution of DNA polymerase variants by compartmentalised self-replication (CSR) 
(Chapter 2).  The system was successfully employed to evolve Taq DNA polymerase 
variants with enhanced resistance to heparin (Chapter 3) and phytate (Chapter 4) over one or 
two rounds of CSR, respectively.  Further work (Chapter 5) established the importance of 
the relative Mg2+ and phytate levels in PCR and their effect on PCR inhibition. Site-directed 
mutagenesis studies also revealed some crossover between mutations that confer heparin and 
phytate resistance.  An overview of the properties of a selection of novel variants produced 
and studied in this project is presented in Table 6.1. 
 
 
 
 
AA Mutations 
(Taq umbering) 
Specific 
Activity 
(U/mg) 
IC50 Heparin 
(U/ml) 
IC50 Phytate 
(µM) 
 Wild-type n/a 19,850 0.012 360 
H
ep
a
ri
n
 
Hep22 P550S, T588S 14,870 0.050  
Ghadessy 
SDM
 12
 
K540R, D578G, 
N583S, M747R 
18,050 n/d13 950 
Hep SDM 
V529A, T588S, 
R630L 
30,290 0.026 420 
P
h
y
ta
te
 Phy2(30) 
P685S, M761V, 
A814T 
23,620 n/d 700 
Phy2(45) 
K340I, E694D, 
M761V, A814T 
21,180 n/d 750 
 
 Whilst this project reported some success in evolving novel variants and 
understanding the mode of phytate inhibition, there are a number of different ways in which 
                                                 
12 Based on a heparin-resistant Taq variant produced by Ghadessy et al., 2001. 
13 Not determined. 
Table 6.1 – Properties of novel Taq DA polymerase variants evolved in this project. 
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this work could be extended.  Some potential future work based on the results reported in 
this project will now be discussed.  
 
Exploring the Applied Use of ovel Taq DA polymerase Variants 
 The main aim of this project was to produce a DNA polymerase variant with 
increased resistance to phytate with the intention being that the enzyme could then be used 
in fecal-based PCRs, thus eliminating the need for pre-treatment of the sample to remove 
inhibitory phytate.  The experiments performed in this project used a commercial source of 
phytate in all characterisation assays; however, it would be interesting to see how robust the 
phytate-resistant variants evolved in this project are when used in clinical samples.  Studies 
into the potential application of phytate-resistant variants would first require an exploration 
of the phytate levels present in natural samples that are subjected to diagnostic testing.  The 
level of phytate in faecal samples is hard to predict as it is dependent on both diet and the 
digestion process (Joung et al., 2007; He and Honeycutt, 2001).  Other aspects such as the 
dilution of the sample and the nature of the diagnostic test being performed should also be 
considered when testing novel Taq DNA polymerase variants.  
 The findings in Chapter 5 revealed that if the phytate and Mg2+ levels are at certain 
relative concentrations in a PCR then inhibition can be overcome. These results should be 
explored further and tested in an applied system, as it is possible that the simple addition of 
Mg2+ to an appropriate level is sufficient to overcome the problem of phytate inhibition of 
PCR.  This would mean that extensive further attempts to engineer enzyme variants with 
phytate resistance would not be warranted from an applied perspective. On the other hand, if 
the novel variants produced through directed evolution by CSR were able to completely 
overcome the problem of PCR inhibition in an applied system, then further rounds of 
directed evolution may still prove valuable. 
 
Directed Evolution Studies  
 The work presented in Chapters 3 and 4 demonstrates that the technique of directed 
evolution by CSR can be used to evolve Taq DNA polymerase variants with increased 
resistance to inhibitors.   However, the number of rounds of directed evolution that were 
performed were low, which restricted the overall outcome of the experiment.  If further 
rounds of directed evolution by CSR were performed, each round of evolution may 
contribute an additional increase in resistance leading to a final Taq DNA polymerase 
variant with substantially increased resistance compared to the wild-type enzyme. 
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 The CSR heparin screen performed in Chapter 3, produced a mutant with a 
substantial 4-fold increase in heparin resistance in a single round of CSR, which was similar 
to the 8-fold increase in resistance seen by Ghadessy et al. (2001) after one round of directed 
evolution.  However, Ghadessy et al. (2001) went on to perform multiple rounds of CSR 
with a final outcome of an improved variant with 130-fold increased resistance after 3 
rounds of CSR.   These results suggest that continuing work with the heparin-resistant 
mutant produced in Chapter 3, and performing further rounds of mutagenesis followed by 
CSR screening or StEP recombination, would be beneficial.  Continuing the directed 
evolution of the heparin-resistant mutant would provide insight into whether the mutations 
gained in this study overlap with the mutations that conferred heparin resistance in the 
Ghadessy et al. (2001) final Taq DNA polymerase variant or whether it is possible to 
produce heparin resistance through entirely different mutation combinations.   
 The mutations found in heparin-resistant variants in this study and subsequent work 
involving further rounds of CSR could provide enhanced resistance in addition to providing 
further evidence for heparin’s mode of action.  Follow-up work could involve saturation 
mutagenesis of key residues or further recombination techniques such as StEP.  Selected 
mutations could also potentially result in variants with resistance to other inhibitors that have 
a shared binding site.   
 The CSR phytate screen performed in Chapter 4 could also be extended by further 
rounds of directed evolution but the situation with phytate PCR inhibition is more 
complicated than that of heparin.  Phytate’s mode of action is not known although the work 
completed in Chapter 5 suggests that the main mode of PCR inhibition by phytate is through 
the chelation of essential Mg2+ ions.  This implies that in order to achieve an increase in 
phytate- resistance by CSR, the metal binding affinity of the enzyme must be increased to 
overcome the effects of phytate.  Overall, the CSR phytate investigation led to a lower 
relative increase in resistance than that of the heparin screen, which may suggest it is more 
challenging to evolve phytate resistance or increase enzyme metal binding affinity.  Further 
rounds of CSR would provide some evidence as to whether or not it is possible to evolve 
phytate resistance significantly beyond the level achieved in this study.  The number of 
rounds of directed evolution conducted varies with each experiment but in general an 
average of at least 3-5 rounds of evolution are performed to achieve a significantly enhanced 
variant (Bolt et al., 2008; Johannes et al., 2005).  If further rounds of CSR were successful, 
then the subsequent study of phytate-conferring mutations would be key to providing further 
insight into phytate’s mode of PCR inhibition.  Furthermore, the ability of heparin-
conferring mutations to also confer phytate resistance (as in Chapter 5) and vice versa could 
be explored. 
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Biophysical Approaches to Investigate Phytate Interactions 
 The work presented in Chapter 5 began to elucidate the mode of action of phytate in 
PCR inhibition.  Although it appears that phytate mainly inhibits PCR through the chelation 
of essential Mg2+ ions, inhibition by binding to the enzyme still cannot be ruled out.  The 
initial crystallisation of Klentaq in the presence of phytate indicated that phytate did not bind 
the enzyme; however, the evidence was not conclusive. This initial experiment provides a 
useful starting point for further attempts at phytate docking with the enzyme, which could 
involve growing crystals under various combinations of Mg2+ and phytate or soaking 
crystals in different levels of phytate.  As performed in this study, X-ray crystallography 
could then be used to detect potential phytate or phytate-Mg2+ chelate binding sites in the 
Taq DNA pol polymerase domain.  Docking studies would provide additional evidence as to 
whether phytate does or does not bind the enzyme with high affinity or specificity. 
 Other approaches to investigate phytate’s interaction with DNA polymerase could 
also be used to attempt to establish the mode of phytate inhibition in PCR.  The technique of 
isothermal titration calorimetry (ITC) is one possible method for measuring biological 
interactions through the detection of heat changes.  The heat that is either generated or 
absorbed upon binding of a protein-ligand complex is measured to determine binding 
constants, reaction stoichiometry, and the enthalpy and entropy of the interaction (Perozzo et 
al., 2004).    ITC has previously been used to study the thermodynamics of the binding of 
Taq DNA polymerase with primed template DNA (Datta and LiCata, 2003).  Surface 
Plasmon Resonance (SPR) is another method for measuring biological interactions.  SPR 
measures small changes caused by the interaction of a protein-ligand complex, which allows 
the determination of binding constants.  The target molecule is immobilised on a solid 
surface, which is then treated with a ligand in a mobile phase. If binding occurs then there is 
a change in the intensity of reflected light, which is used to analyse the interaction (van Der 
Merwe, 2001). 
 Understanding the interaction of phytate and its Mg2+ chelates with DNA 
polymerase, if there is one, would also be key to determining phytate’s mode of action and 
may provide valuable information that can be applied to other inhibitors.  It would also fuel 
rational and semi-rational mutagenesis attempts to further engineer phytate resistance in 
DNA polymerases. Further knowledge of the formation of complexes between Mg2+ and 
phytate may also contribute to understanding phytate’s inhibition of PCR through chelation. 
 All the above methods would be key to development of an efficient phytate-resistant 
Taq DNA polymerase variant, which could be used in clinical or veterinary diagnostic tests 
with PCR-inhibitory samples. 
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APPEDIX A 
 
 
Translation of the DA sequence of Sac7-TaqPolymerase: 
 
 
1 atggtgaaagtgaaatttaaatacaaaggtgaagagaaagaagttgacacttctaaaatt 
1  M  V  K  V  K  F  K  Y  K  G  E  E  K  E  V  D  T  S  K  I 
 
61 aaaaaagtgtggcgtgtgggtaaaatggtttctttcacctatgatgataacggcaaaacc 
21  K  K  V  W  R  V  G  K  M  V  S  F  T  Y  D  D  N  G  K  T 
 
121 ggtcgcggtgcggtgtctgagaaagacgcgccgaaagaactgctggatatgctggcgcgt 
41  G  R  G  A  V  S  E  K  D  A  P  K  E  L  L  D  M  L  A  R 
 
181 gcggaacgcgagaaaaaaggtggtgttaccatgaattcggggatgctgcccctctttgag 
61  A  E  R  E  K  K  G  G  V  T  M  N  S  G  M  L  P  L  F  E 
 
241 cccaagggccgggtcctcctggtggacggccaccacctggcctaccgcaccttccacgcc 
81  P  K  G  R  V  L  L  V  D  G  H  H  L  A  Y  R  T  F  H  A 
 
301 ctgaagggcctcaccaccagccggggggagccggtgcaggcggtctacggcttcgccaag 
101  L  K  G  L  T  T  S  R  G  E  P  V  Q  A  V  Y  G  F  A  K 
 
361 agcctcctcaaggccctcaaggaggacggggacgcggtgatcgtggtctttgacgccaag 
121  S  L  L  K  A  L  K  E  D  G  D  A  V  I  V  V  F  D  A  K 
 
421 gccccctccttccgccacgaggcctacggggggtacaaggcgggccgggcccccacgccg 
141  A  P  S  F  R  H  E  A  Y  G  G  Y  K  A  G  R  A  P  T  P 
 
481 gaggactttccccggcaactcgccctcatcaaggagctggtggacctcctggggctggcg 
161  E  D  F  P  R  Q  L  A  L  I  K  E  L  V  D  L  L  G  L  A 
 
541 cgcctcgaggtcccgggctacgaggcggacgacgtcctggccagcctggccaagaaggcg 
181  R  L  E  V  P  G  Y  E  A  D  D  V  L  A  S  L  A  K  K  A 
 
601 gaaaaggagggctacgaggtccgcatcctcaccgccgacaaagacctttaccagctcctt 
201  E  K  E  G  Y  E  V  R  I  L  T  A  D  K  D  L  Y  Q  L  L 
 
661 tccgaccgcatccacgtcctccaccccgaggggtacctcatcaccccggcctggctttgg 
221  S  D  R  I  H  V  L  H  P  E  G  Y  L  I  T  P  A  W  L  W 
 
721 gaaaagtacggcctgaggcccgaccagtgggccgactaccgggccctgaccggggacgag 
241  E  K  Y  G  L  R  P  D  Q  W  A  D  Y  R  A  L  T  G  D  E 
 
781 tccgacaaccttcccggggtcaagggcatcggggagaagacggcgaggaagcttctggag 
261  S  D  N  L  P  G  V  K  G  I  G  E  K  T  A  R  K  L  L  E 
 
841 gagtgggggagcctggaagccctcctcaagaacctggaccggctgaagcccgccatccgg 
281  E  W  G  S  L  E  A  L  L  K  N  L  D  R  L  K  P  A  I  R 
 
901 gagaagatcctggcccacatggacgatctgaagctctcctgggacctggccaaggtgcgc 
301  E  K  I  L  A  H  M  D  D  L  K  L  S  W  D  L  A  K  V  R 
 
961 accgacctgcccctggaggtggacttcgccaaaaggcgggagcccgaccgggagaggctt 
321  T  D  L  P  L  E  V  D  F  A  K  R  R  E  P  D  R  E  R  L 
1021 agggcctttctggagagatctgagtttggcagcctcctccacgagttcggccttctggaa 
341  R  A  F  L  E  R  S  E  F  G  S  L  L  H  E  F  G  L  L  E 
 
1081 agccccaaggccctggaggaggccccctggcccccgccggaaggggccttcgtgggcttt 
361  S  P  K  A  L  E  E  A  P  W  P  P  P  E  G  A  F  V  G  F 
 
1141 gtgctttcccgcaaggagcccatgtgggccgatcttctggccctggccgccgccaggggg 
381  V  L  S  R  K  E  P  M  W  A  D  L  L  A  L  A  A  A  R  G 
 
1201 ggccgggtccaccgggcccccgagccttataaagccctcagggacctgaaggaggcgcgg 
401  G  R  V  H  R  A  P  E  P  Y  K  A  L  R  D  L  K  E  A  R 
 
1261 gggcttctcgccaaagacctgagcgttctggccctgagggaaggccttggcctcccgccc 
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421  G  L  L  A  K  D  L  S  V  L  A  L  R  E  G  L  G  L  P  P 
 
1321 ggcgacgaccccatgctcctcgcctacctcctggacccttccaacaccacccccgagggg 
441  G  D  D  P  M  L  L  A  Y  L  L  D  P  S  N  T  T  P  E  G 
 
1381 gtggcccggcgctacggcggggagtggacggaggaggcgggggagcgggccgccctttcc 
461  V  A  R  R  Y  G  G  E  W  T  E  E  A  G  E  R  A  A  L  S 
                    ← Palm 
1441 gagaggctcttcgccaacctgtgggggaggcttgagggggaggagaggctcctttggctt 
481  E  R  L  F  A  N  L  W  G  R  L  E  G  E  E  R  L  L  W  L 
                                                                                                          Palm → 
1501 taccgggaggtggagaggcccctttccgctgtcctggcccacatggaggccacgggggtg 
501  Y  R  E  V  E  R  P  L  S  A  V  L  A  H  M  E  A  T  G  V 
                  ← Thumb 
1561 cgcctggacgtggcctatctcagggccttgtccctggaggtggccgaggagatcgcccgc 
521  R  L  D  V  A  Y  L  R  A  L  S  L  E  V  A  E  E  I  A  R 
 
1621 ctcgaggccgaggtcttccgcctggccggccaccccttcaacctcaactcccgggaccag 
541  L  E  A  E  V  F  R  L  A  G  H  P  F  N  L  N  S  R  D  Q 
 
1681 ctggaaagggtcctctttgacgagctagggcttcccgccatcggcaagacggagaagacc 
561  L  E  R  V  L  F  D  E  L  G  L  P  A  I  G  K  T  E  K  T 
 
1741 ggcaagcgctccaccagcgccgccgtcctggaggccctccgcgaggcccaccccatcgtg 
581  G  K  R  S  T  S  A  A  V  L  E  A  L  R  E  A  H  P  I  V 
 
1801 gagaagatcctgcagtaccgggagctcaccaagctgaagagcacctacattgaccccttg 
601  E  K  I  L  Q  Y  R  E  L  T  K  L  K  S  T  Y  I  D  P  L 
                                Thumb → ← Palm 
1861 ccggacctcatccaccccaggacgggccgcctccacacccgcttcaaccagacggccacg 
621  P  D  L  I  H  P  R  T  G  R  L  H  T  R  F  N  Q  T  A  T 
                                                                                        Palm → ← Thumb 
1921 gccacgggcaggctaagtagctccgatcccaacctccagaacatccccgtccgcaccccg 
641  A  T  G  R  L  S  S  S  D  P  N  L  Q  N  I  P  V  R  T  P 
Thumb → ← Palm 
1981 cttgggcagaggatccgccgggccttcatcgccgaggaggggtggctattggtggccctg 
661  L  G  Q  R  I  R  R  A  F  I  A  E  E  G  W  L  L  V  A  L 
                    Palm → ← Fingers 
2041 gactatagccagatagagctcagggtgctggcccacctctccggcgacgagaacctgatc 
681  D  Y  S  Q  I  E  L  R  V  L  A  H  L  S  G  D  E  N  L  I 
 
2101 cgggtcttccaggaggggcgggacatccacacggagaccgccagctggatgttcggcgtc 
701  R  V  F  Q  E  G  R  D  I  H  T  E  T  A  S  W  M  F  G  V 
 
2161 ccccgggaggccgtggaccccctgatgcgccgggcggccaagaccatcaacttcggggtc 
721  P  R  E  A  V  D  P  L  M  R  R  A  A  K  T  I  N  F  G  V 
 
2221 ctctacggcatgtcggcccaccgcctctcccaggagctagccatcccttacgaggaggcc 
741  L  Y  G  M  S  A  H  R  L  S  Q  E  L  A  I  P  Y  E  E  A 
 
2281 caggccttcattgagcgctactttcagagcttccccaaggtgcgggcctggattgagaag 
761  Q  A  F  I  E  R  Y  F  Q  S  F  P  K  V  R  A  W  I  E  K 
 
2341 accctggaggagggcaggaggcgggggtacgtggagaccctcttcggccgccgccgctac 
781  T  L  E  E  G  R  R  R  G  Y  V  E  T  L  F  G  R  R  R  Y 
 
2401 gtgccagacctagaggcccgggtgaagagcgtgcgggaggcggccgagcgcatggccttc 
801  V  P  D  L  E  A  R  V  K  S  V  R  E  A  A  E  R  M  A  F 
 
2461 aacatgcccgtccagggcaccgccgccgacctcatgaagctggctatggtgaagctcttc 
821  N  M  P  V  Q  G  T  A  A  D  L  M  K  L  A  M  V  K  L  F 
                    Fingers → ← Palm 
2521 cccaggctggaggaaatgggggccaggatgctccttcaggtccacgacgagctggtcctc 
841  P  R  L  E  E  M  G  A  R  M  L  L  Q  V  H  D  E  L  V  L 
 
 
 
 
 
2581 gaggccccaaaagagagggcggaggccgtggcccggctggccaaggaggtcatggagggg 
144 
 
861  E  A  P  K  E  R  A  E  A  V  A  R  L  A  K  E  V  M  E  G 
 
2641 gtgtatcccctggccgtgcccctggaggtggaggtggggataggggaggactggctctcc 
881  V  Y  P  L  A  V  P  L  E  V  E  V  G  I  G  E  D  W  L  S 
                     Palm → 
        2701 gccaaggagtgatagatcctctagagtcgac 
         901  A  K  E  *  *  I  L  *  S  R  X 
 
Residues that interact with the DA template or dTPs (green) and the catalytic triad (yellow) 
are indicated.  Finger, thumb and palm sub-domains of the polymerase domain are labelled. 
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M13 Rev 1968
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Swa I 2018
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Asc I 2538
PflF I 2571
Aat II 2575
Acc65 I 2692
Asp718 2692
Kpn I 2696
BstX I 3092
Psi I 3229Ale I 3555
NgoM I 3645
Nae I 3647
Fse I 3649
BamH I 3991
Nhe I 4256
Xba I 4720
Sal I 4726
Sph I 4742
M13 Uni 4796
AsiS I 6060
Sgf I 6060
Cla I 6365
Nru I 6401
BstAP I 6762
BstX I 6881
BstX I 7010
Mlu I 7079
Bcl I 7093
BstX I 7133
BstE II 7260
EcoR V 7529
Hpa I 7585
pTTQ18NAK-Sac7Taqpol
8162 bp
APPEDIX B 
 
pTTQ18AK-Sac7TaqPol plasmid construct 
(GeneSys, Camberley, UK) 
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APPEDIX C 
Taq DNA polymerase sequence alignment 
 
TaqPol           ------------------------------------------------------------ 
Sac7-Taqpol    1 MVKVKFKYKGEEKEVDTSKIKKVWRVGKMVSFTYDDNGKTGRGAVSEKDAPKELLDMLAR 
Klentaq          ------------------------------------------------------------ 
 
TaqPol           ----------MNSGMLPLFEPKGRVLLVDGHHLAYRTFHALKGLTTSRGEPVQAVYGFAK 
Sac7-Taqpol   61 AEREKKGGVTMNSGMLPLFEPKGRVLLVDGHHLAYRTFHALKGLTTSRGEPVQAVYGFAK 
Klentaq          ------------------------------------------------------------ 
 
TaqPol        51 SLLKALKEDGDAVIVVFDAKAPSFRHEAYGGYKAGRAPTPEDFPRQLALIKELVDLLGLA 
Sac7-Taqpol  121 SLLKALKEDGDAVIVVFDAKAPSFRHEAYGGYKAGRAPTPEDFPRQLALIKELVDLLGLA 
Klentaq          ------------------------------------------------------------ 
 
TaqPol       111 RLEVPGYEADDVLASLAKKAEKEGYEVRILTADKDLYQLLSDRIHVLHPEGYLITPAWLW 
Sac7-Taqpol  181 RLEVPGYEADDVLASLAKKAEKEGYEVRILTADKDLYQLLSDRIHVLHPEGYLITPAWLW 
Klentaq          ------------------------------------------------------------ 
 
TaqPol      171  EKYGLRPDQWADYRALTGDESDNLPGVKGIGEKTARKLLEEWGSLEALLKNLDRLKPAIR 
Sac7-Taqpol  241 EKYGLRPDQWADYRALTGDESDNLPGVKGIGEKTARKLLEEWGSLEALLKNLDRLKPAIR 
Klentaq          ------------------------------------------------------------ 
 
TaqPol       231 EKILAHMDDLKLSWDLAKVRTDLPLEVDFAKRREPDRERLRAFLERLEFGSLLHEFGLLE 
Sac7-Taqpol  301 EKILAHMDDLKLSWDLAKVRTDLPLEVDFAKRREPDRERLRAFLERLEFGSLLHEFGLLE 
Klentaq          ------------------------------------------------MG-LLHEFGLLE 
                                                                 :* ********* 
 
TaqPol       291 SPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEAR 
Sac7-Taqpol  361 SPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEAR 
Klentaq       12 SPKALEEAPWPPPEGAFVGFVLSRKEPMWADLLALAAARGGRVHRAPEPYKALRDLKEAR 
                 ************************************************************ 
 
TaqPol       351 GLLAKDLSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAGERAALS 
Sac7-Taqpol  421 GLLAKDLSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAGERAALS 
Klentaq       72 GLLAKDLSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEGVARRYGGEWTEEAGERAALS 
                 ************************************************************ 
 
TaqPol       411 ERLFANLWGRLEGEERLLWLYREVERPLSAVLAHMEATGVRLDVAYLRALSLEVAEEIAR 
Sac7-Taqpol  481 ERLFANLWGRLEGEERLLWLYREVERPLSAVLAHMEATGVRLDVAYLRALSLEVAEEIAR 
Klentaq      132 ERLFANLWGRLEGEERLLWLYREVERPLSAVLAHMEATGVRLDVAYLRALSLEVAEEIAR 
                 ************************************************************ 
 
TaqPol       471 LEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKTGKRSTSAAVLEALREAHPIV 
Sac7-Taqpol  541 LEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKTGKRSTSAAVLEALREAHPIV 
Klentaq      192 LEAEVFRLAGHPFNLNSRDQLERVLFDELGLPAIGKTEKTGKRSTSAAVLEALREAHPIV 
                 ************************************************************ 
 
TaqPol       531 EKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTP 
Sac7-Taqpol  601 EKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTP 
Klentaq      252 EKILQYRELTKLKSTYIDPLPDLIHPRTGRLHTRFNQTATATGRLSSSDPNLQNIPVRTP 
                 ************************************************************ 
 
TaqPol       591 LGQRIRRAFIAEEGWLLVALDYSQIELRVLAHLSGDENLIRVFQEGRDIHTETASWMFGV 
Sac7-Taqpol  661 LGQRIRRAFIAEEGWLLVALDYSQIELRVLAHLSGDENLIRVFQEGRDIHTETASWMFGV 
Klentaq      312 LGQRIRRAFIAEEGWLLVALDYSQIELRVLAHLSGDENLIRVFQEGRDIHTETASWMFGV 
                 ************************************************************ 
 
TaqPol       651 PREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQSFPKVRAWIEK 
Sac7-Taqpol  721 PREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQSFPKVRAWIEK 
Klentaq      372 PREAVDPLMRRAAKTINFGVLYGMSAHRLSQELAIPYEEAQAFIERYFQSFPKVRAWIEK 
                 ************************************************************ 
 
TaqPol       711 TLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAADLMKLAMVKLF 
Sac7-Taqpol  781 TLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAADLMKLAMVKLF 
Klentaq      432 TLEEGRRRGYVETLFGRRRYVPDLEARVKSVREAAERMAFNMPVQGTAADLMKLAMVKLF 
                 ************************************************************ 
 
TaqPol       771 PRLEEMGARMLLQVHDELVLEAPKERAEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLS 
Sac7-Taqpol  841 PRLEEMGARMLLQVHDELVLEAPKERAEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLS 
Klentaq      492 PRLEEMGARMLLQVHDELVLEAPKERAEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLS 
                 ************************************************************ 
 
TaqPol       831 AKEILSRX 
Sac7-Taqpol  901 AKEILSRX 
Klentaq      552 AKEX---- 
                 ***    
 
Sequence alignment of Sac7-TaqPolymerase, Taq DNA polymerase, and Klentaq (the large 
fragment of Taq, which comprises the polymerase domain). * - single, fully conserved 
residue,: - conservation of strong groups,. - conservation of weak groups. 
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Appendix D 
 
1kb DA ladder 
(New England Biolabs, Hitchin, UK) 
 
 
